0001564590-21-038648 | 10-K | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	May 31, 2021	Jul. 22, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	May 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	TLRY
Entity Registrant Name	TILRAY, INC.
Entity Central Index Key	0001731348
Current Fiscal Year End Date	--05-31
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		449,220,809
Entity Public Float	$ 675.6
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Entity File Number	001-38594
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4310622
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Entity Address, Address Line One	655 Madison Avenue
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10065
City Area Code	844
Local Phone Number	845-7291
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Part III incorporates certain information by reference from the definitive proxy statement to be filed by the registrant in connection with the 2021 Annual Meeting of Stockholders (the “Proxy Statement”) with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the year ended May 31, 2021, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10‑K to be filed within such 120-day period.

Consolidated Statements of Financial Position - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Current assets
Cash and cash equivalents	$ 488,466	$ 360,646
Accounts receivable, net	87,309	37,931
Inventory	256,429	139,781
Prepaids and other current assets	48,920	32,660
Convertible notes receivable	2,485	10,609
Total current assets	883,609	581,627
Capital assets	650,698	420,706
Right-of-use assets	18,267	5,356
Intangible assets	1,605,918	263,318
Goodwill	2,832,794	447,330
Interest in equity investees	8,106
Long-term investments	17,685	19,595
Other assets	8,285
Total assets	6,025,362	1,737,932
Current liabilities
Bank indebtedness	8,717	389
Accounts payable and accrued liabilities	212,813	112,411
Contingent consideration	60,657
Warrant liability	78,168
Current portion of lease liabilities	4,264	954
Current portion of long-term debt	36,622	6,141
Total current liabilities	401,241	119,895
Long - term liabilities
Lease liabilities	53,946	4,227
Long-term debt	167,486	94,028
Convertible debentures	667,624	196,405
Deferred tax liability	265,845	48,446
Other liabilities	3,907
Total liabilities	1,560,049	463,001
Commitments and contingencies (refer to Note 30)
Shareholders' equity
Common stock	46	24
Additional paid-in capital	4,792,406	1,366,736
Accumulated other comprehensive income (loss)	152,668	(5,434)
Deficit	(486,050)	(113,352)
Total Tilray shareholders' equity	4,459,070	1,247,974
Non-controlling interests	6,243	26,957
Total shareholders' equity	4,465,313	1,274,931
Total liabilities and shareholders' equity	$ 6,025,362	$ 1,737,932

Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Income Statement [Abstract]
Net revenue	$ 513,085	$ 405,326	$ 179,303
Cost of goods sold	389,903	309,273	135,792
Gross profit	123,182	96,053	43,511
Operating expenses:
General and administrative	111,575	93,789	75,841
Selling	26,576	18,975	3,752
Amortization	35,221	15,138	9,550
Marketing and promotion	17,539	15,266	17,400
Research and development	830	1,916	1,052
Impairment		50,679	57,259
Transaction costs	63,612	4,299	17,588
Total operating expenses	255,353	200,062	182,442
Operating loss	(132,171)	(104,009)	(138,931)
Finance income (expense), net	(27,977)	(19,371)	5,259
Non-operating (expense) income, net	(184,838)	14,195	95,534
(Loss) income before income taxes	(344,986)	(109,185)	(38,138)
Income taxes (recovery)	(8,972)	(8,352)	(2,045)
Net (loss) income	(336,014)	(100,833)	(36,093)
Total net income (loss) attributable to:
Shareholders of Tilray Inc.	(367,421)	(102,540)	(25,037)
Non-controlling interests	31,407	1,707	(11,056)
Other comprehensive (loss) income, net of tax
Foreign currency translation (loss) gain	156,649	(858)	(90)
Unrealized loss on convertible notes receivables	(3,824)	(5,476)	(2,570)
Total other comprehensive (loss) income, net of tax	152,825	(6,334)	(2,660)
Comprehensive (loss) income	(183,189)	(107,167)	(38,753)
Total comprehensive income (loss) attributable to:
Shareholders of Tilray Inc.	(214,596)	(108,874)	(27,697)
Non-controlling interests	$ 31,407	$ 1,707	$ (11,056)
Weighted average number of common shares - basic	269,549,852	216,158,217	203,460,138
Weighted average number of common shares - diluted	269,549,852	216,158,217	203,460,138
Earnings (Loss) per share - basic	$ (1.25)	$ (0.47)	$ (0.18)
Earnings (Loss) per share - diluted	$ (1.25)	$ (0.47)	$ (0.18)

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	June 2018 Bought Deal	January 2020 Bought Deal	Broken Coast	LATAM	Sweet Water	Common Stock	Common Stock June 2018 Bought Deal	Common Stock January 2020 Bought Deal	Common Stock Broken Coast	Common Stock LATAM	Common Stock Sweet Water	Additional Paid-In Capital	Additional Paid-In Capital June 2018 Bought Deal	Additional Paid-In Capital January 2020 Bought Deal	Additional Paid-In Capital Broken Coast	Additional Paid-In Capital LATAM	Additional Paid-In Capital Sweet Water	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Deficit)	Retained Earnings (Deficit) Nuuvera Malta	Non-controlling Interests	Non-controlling Interests LATAM	Non-controlling Interests Nuuvera Malta
Beginning Balance at May. 31, 2018	$ 813,715						$ 18						$ 795,134						$ 2,954	$ 1,781		$ 13,828
Beginning Balance, Shares at May. 31, 2018							176,143,413
Shares issued for acquisition		$ 185,969		$ 225	$ 229,012			$ 2			$ 1			$ 185,967		$ 225	$ 207,122						$ 21,889
Shares issued for acquisition, shares								18,300,341		16,731	13,139,992
Share issuance - warrants exercised	1,303												1,303
Share issuance - warrants exercised, shares							461,236
Share issuance - options exercised	3,854												3,854
Share issuance - options exercised, shares							2,205,945
Share issuance - DSUs exercised, shares							86,324
Income tax recovery on share issuance cost	2,591												2,591
Share-based payments	29,028												29,028
Elimination of CTA on disposal																			606	(606)
Non-controlling interests	7,138																					7,138
Comprehensive income (loss) for the period	(38,753)																		(2,660)	(25,037)		(11,056)
Ending Balance at May. 31, 2019	1,234,082						$ 21						1,225,224						900	(23,862)		31,799
Ending Balance, Shares at May. 31, 2019							210,353,982
Shares issued for acquisition			$ 74,395						$ 1						$ 74,394
Shares issued for acquisition, shares									11,771,068
Share issuance - debt settlement	58,234						$ 2						58,232
Share issuance - debt settlement, shares							15,806,989
Share issuance - warrants exercised	858												858
Share issuance - warrants exercised, shares							642,296
Share issuance - options exercised	3,060												3,060
Share issuance - options exercised, shares							1,084,288
Share issuance - RSUs exercised, shares							559,456
Share issuance - DSUs exercised, shares							333,606
Cancelled shares													(459)							459
Cancelled shares, shares							(419,050)
Expired options													(11,924)							11,924
Expired warrants													(728)							728
Share-based payments	18,079												18,079
Nuuvera Malta acquisition																					$ (61)			$ 61
Dividends paid to non-controlling interests	(6,610)																					(6,610)
Comprehensive income (loss) for the period	(107,167)																		(6,334)	(102,540)		1,707
Ending Balance at May. 31, 2020	1,274,931						$ 24						1,366,736						(5,434)	(113,352)		26,957
Ending Balance, Shares at May. 31, 2020							240,132,635
Shares issued for acquisition						$ 65,889						$ 1						$ 65,888
Shares issued for acquisition, shares												8,232,810
Share issuance - legal settlement	10,454												10,454
Share issuance - legal settlement, shares							1,893,858
Share issuance - equity financing	103,537						$ 2						103,535
Share issuance - equity financing, shares							14,610,496
Share issuance - contract settlement	(18,895)						$ 1						21,370									(40,266)
Share issuance - contract settlement, shares							1,165,861
Share issuance - Arrangement	3,204,906						$ 18						3,204,888
Share issuance - Arrangement, shares							179,635,973
Share issuance - options exercised	144												144
Share issuance - options exercised, shares							318,299
Share issuance - RSUs exercised, shares							450,709
Share-based payments	19,391												19,391
Settlement of convertible notes receivable	5,277																		5,277	(5,277)
Dividends paid to non-controlling interests	(11,855)																					(11,855)
Comprehensive income (loss) for the period	(183,189)																		152,825	(367,421)		31,407
Ending Balance at May. 31, 2021	$ 4,465,313						$ 46						$ 4,792,406						$ 152,668	$ (486,050)		$ 6,243
Ending Balance, Shares at May. 31, 2021							446,440,641

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Cash used in operating activities:
Net (loss) income for the year	$ (336,014)	$ (100,833)	$ (36,093)
Adjustments for:
Deferred income tax recovery	(24,873)	(13,305)	(5,833)
Unrealized foreign exchange loss (gain)	49,342	(451)	(194)
Amortization	67,832	35,669	17,210
Loss (gain) on sale of capital assets	(1,523)	8,075	(42)
Impairment		50,679	57,202
Loss on promissory notes receivable		9,698
Transaction costs associated with business acquisitions	59,917		11,660
Other non-cash items	3,025	(90)	242
Stock-based compensation	17,351	18,079	21,951
Loss (gain) on long-term investments & equity investments	1,624	24,295	(59,051)
Loss (gain) on convertible debentures	169,537	(53,611)	(36,630)
Change in non-cash working capital	(50,935)	(78,832)	(12,471)
Net cash used in operating activities	(44,717)	(100,627)	(42,049)
Cash used in investing activities:
Proceeds from disposal of marketable securities		14,816	18,667
Investment in capital and intangible assets	(38,874)	(98,786)	(155,751)
Proceeds from disposal of capital and intangible assets	6,608	1,411	42
Promissory notes advances	(2,419)		(14,746)
Repayment of convertible notes receivable	5,752	19,396	6,466
Investment in long-term investments and equity investees		(451)	(54,724)
Proceeds from disposal of long-term investments and equity investees	8,430	19,570	83,343
Net cash acquired (paid) on business acquisitions	66,608	(25,902)	(17,814)
Net cash used in investing activities	46,105	(69,946)	(134,517)
Cash provided by (used in) financing activities:
Share capital issued, net of cash issuance costs	102,550	74,395	185,969
Proceeds from warrants and options exercised	144	3,918	5,157
Proceeds from convertible debentures			343,607
Repayment of convertible debentures		(812)
Proceeds from long-term debt	102,798	60,944	21,053
Repayment of long-term debt	(64,559)	(8,114)	(8,601)
Repayment of lease liabilities	(1,058)	(126)
Increase in bank indebtedness	8,328	401
Amounts paid to non-controlling interest	(23,895)
Net cash used in financing activities	124,308	130,606	547,185
Effect of foreign exchange on cash and cash equivalents	2,124	(6,572)	(9,570)
Net increase (decrease) in cash and cash equivalents	127,820	(46,539)	361,049
Cash and cash equivalents, beginning of period	360,646	407,185	46,136
Cash and cash equivalents, end of period	488,466	360,646	407,185
Supplementary disclosure of cash flow information
Income taxes	$ 5,623	$ 2,649	$ 4,878

Description of business

12 Months Ended

May 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of business

1.	Description of business

Tilray, Inc., a Delaware corporation, and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, “us” or the “Successor”) is a global medical cannabis research, cultivation, processing and distribution organization, and is one of the leading suppliers of adult-use cannabis in Canada. The Company also markets and distributes food products from hemp seed, offering a broad range of natural and organic hemp-based food products and ingredients that are sold through retailers and websites globally.

On April 30, 2021 Tilray acquired all of the issued and outstanding common shares of Aphria Inc. (“Aphria”), an international organization with a focus on building a global cannabis-lifestyle consumer packaged goods company and involved in the manufacturing and distribution of beer and beer derivative products in the United States, and in the distribution of (non-Cannabis) pharmaceutical products in Germany, pursuant to a plan of arrangement (the “Arrangement”) under the Ontario Business Corporations Act.

Under the terms of the Arrangement, stockholders of Aphria received 0.8381 (the “Exchange Ratio”) of a share of Tilray common stock for each Aphria share held. Tilray stockholders continued to hold their Tilray common stock, which remains outstanding. The Exchange Ratio resulted in Aphria stockholders and Tilray stockholders owning 61.2% and 38.8%, respectively, of the post-closing outstanding Tilray common stock (on a fully diluted basis), resulting in the reverse acquisition of Tilray under the acquisition method, whereby Aphria is deemed to be the acquiring entity from an accounting perspective. Following the completion of the Arrangement, Tilray is the consolidated parent of Aphria and the resulting company operates under the Tilray corporate name.

Basis of preparation

12 Months Ended

May 31, 2021

Basis Of Preparation [Abstract]

Basis of preparation

2.	Basis of preparation

The policies applied in these consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”).

Based on the determination that Aphria was the accounting acquirer in the Arrangement, Aphria’s historical financial statements became the historical financial statements of the Company. The acquired assets and liabilities of Tilray are included in the Company’s consolidated balance sheets as of April 30, 2021 and the results of its operations and cash flows are included in the Company’s consolidated statement of income (loss) and comprehensive income (loss) and cash flows for periods beginning after April 30, 2021. In conjunction with the reverse acquisition, the Company elected to adopt Aphria’s fiscal year end of June 1 to May 31.

Prior to April 30, 2021 Aphria was a foreign private issuer reporting its financial statements under International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Boards. These consolidated financial statements, for all periods, are presented in accordance with GAAP.

These consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies. For the fiscal year ended May 31, 2021 the Company reported a consolidated net loss of $336,014 and a consolidated net loss of $100,833 and $36,093 for the years ending May 31, 2020 and May 31, 2019, respectively.

For the years ended May 31, 2021, 2020 and 2019, the Company had cash flows used in operating activities of $44,717, $100,627 and $42,049, respectively. As of May 31, 2021 and 2020, the Company had working capital of $482,368 and $ 461,732 respectively.

Current management forecasts and related assumptions support the view that the Company can adequately manage the operational needs of the business with the current cash on hand for the next twelve months from the date of issuance of these financial statements.

These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the Company’s financial position and results of operations.

Foreign currency

These consolidated financial statements are presented in U.S. dollars (“USD”), which is the Company’s reporting currency; however, the functional currency of the entities in these financial statements are their respective local currencies, including Canadian dollar, USD, Euro, Australian dollar, and Great Britain pound.

Foreign currency transactions are remeasured to the respective functional currencies of the Company’s entities at the exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are remeasured to the functional currency at the foreign exchange rate applicable at the statement of financial position date. Non-monetary items carried at historical cost denominated in foreign currencies are remeasured to the functional currency at the date of the transactions. Non-monetary items carried at fair value denominated in foreign currencies are remeasured to the functional currency at the date when the fair value was determined. Realized and unrealized exchange gains and losses are recognized through profit and loss.

On consolidation, the assets and liabilities of foreign operations reported in their functional currencies are translated into USD, the Group’s presentation currency, at period-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into USD using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income (loss) and accumulated in equity.

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. The following is a list of the Company’s operating subsidiaries:

Subsidiaries	Jurisdiction of incorporation	Ownership interest
Natura Naturals Inc.	Canada	100%
Tilray, Inc.	United States	100%
Manitoba Harvest USA LLC	United States	100%
Tilray Canada, Ltd.	Canada	100%
Dorada Ventures, Ltd.	Canada	100%
FHF Holdings Ltd.	Canada	100%
High Park Farms Ltd.	Canada	100%
Tilray Deutschland GmbH	Germany	100%
Pardal Holdings, Lda.	Portugal	100%
Tilray Portugal Unipessoal, Lda.	Portugal	100%
Tilray Australia New Zealand Pty. Ltd.	Australia	100%
Tilray Ventures Ltd.	Ireland	100%
Manitoba Harvest Japan K.K.	Japan	100%
High Park Holdings, Ltd.	Canada	100%
Fresh Hemp Foods Ltd.	Canada	100%
Natura Naturals Holdings Inc.	Canada	100%
National Cannabinoid Clinics Pty Ltd.	Australia	100%
Tilray Latin America SpA	Chile	100%
Tilray Portugal II, Lda.	Portugal	100%
High Park Gardens Inc.	Canada	100%
1197879 B.C. Ltd	Canada	100%
High Park Shops Inc.	Canada	100%
Privateer Evolution, LLC	United States	100%
Tilray France SAS	France	100%
High Park Holdings B.V.	Netherlands	100%
High Park Botanicals B.V.	Netherlands	100%
Broken Coast Cannabis Ltd.	British Columbia, Canada	100%
SweetWater Brewing Company, LLC	United States	100%
SweetWater Colorado Brewing Co.	United States	100%
ARA – Avanti Rx Analytics Inc.	Ontario, Canada	100%
FL Group S.r.l.	Italy	100%
ABP, S.A.	Argentina	100%
Aphria Germany GmbH	Germany	100%
Aphria RX GmbH	Germany	100%
CC Pharma GmbH	Germany	100%
CC Pharma Research and Development GmbH	Germany	100%
Aphria Wellbeing GmbH	Germany	100%
CC Pharma Luxemburg GmbH	Luxemburg	100%
ASG Pharma Ltd.	Malta	100%
ColCanna S.A.S.	Colombia	90%
CC Pharma Nordic ApS	Denmark	75%
1974568 Ontario Ltd.	Ontario, Canada	51%

Intragroup balances, and any unrealized gains and losses or income and expenses arising from transactions with jointly controlled entities are eliminated to the extent of the Company’s interest in the entity.

A Variable Interest Entity (“VIE”) is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support, is structured such that equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights, or do not substantively participate in the gains and losses of the entity. Upon inception of a contractual agreement, the Company performs an assessment to determine whether the arrangement contains a variable interest in a legal entity and whether that legal entity is a VIE. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE entity that could potentially be significant to the VIE. Where the Company concludes it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE. When the Company is not the primary beneficiary, the VIE is accounted for using the equity method and is included in equity method investments on the balance sheets. At May 31, 2021, 2020, and 2019, the Company had no consolidated VIEs. Refer to Note 13 Interest in equity investees for the Company’s VIEs accounted for using the equity method.

The Company regularly reviews and reconsiders previous conclusions regarding whether it is the primary beneficiary of a VIE. The Company also reviews and reconsiders previous conclusions regarding whether the Company holds a variable interest in a potential VIE, the status of an entity as a VIE, and whether the Company is required to consolidate such a VIE in the financial statements when a change occurs.

The Company treats transactions that do not result in a loss of control as equity transactions and generally no gain or loss is recognized. A change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognized in a separate reserve within equity attributable to the owners of the Company.

Equity method investments

In accordance with ASC 323, Investments – Equity Method and Joint Ventures, investments in entities over which the Company does not have a controlling financial interest but has significant influence are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recognized initially at cost, which includes transaction costs. After initial recognition, the consolidated financial statements include the Company’s share of undistributed earnings or losses, and impairment, if any, until the date on which significant influence ceases.

If the Company’s share of losses in an equity investment equals or exceeds its interest in the entity, including any net advances, the group does not recognize further losses, unless it has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee.

Unrealized gains on transactions between the Company and its equity-method investees are eliminated only to the extent of the Company’s interest in these entities. Unrealized losses are also eliminated, except to the extent that the underlying asset is impaired.

Significant accounting policies

12 Months Ended

May 31, 2021

Accounting Policies [Abstract]

Significant accounting policies

3.	Significant accounting policies

The significant accounting policies used by the Company are as follows:

Cash and cash equivalents

Cash and cash equivalents are comprised of cash and highly liquid investments that are both readily convertible into known amounts of cash with original maturities of three months or less. Cash and cash equivalents include amounts held in United States dollar, Canadian dollar, Euro, Australian dollar, Great Britain pound, Colombian peso, Argentine peso, and corporate bonds, commercial paper, treasury bills and money market funds.

Accounts receivable

The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in its accounts receivable portfolio as of the reporting dates based on the projection of expected credit losses. The Company applies the aging method to estimate the allowance for expected credit losses. The aging method is applied to accounts receivables at the business unit level to reflect shared risk characteristics, such as receivable type, customer type and geographical location. The aging method assigns accounts receivables to a level of delinquency and applies loss rates to each class based on historical loss experience. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the current classes and the expected future loss. This assessment incorporates all available information relevant to considering the collectability of its current classes, including considering economic and business conditions, default trends, changes in its class composition, among other internal and external factors. The expected credit loss estimates are adjusted for current conditions and reasonable supportable forecasts.

As part of the Company’s analysis of expected credit losses, it may analyze contracts on an individual basis in situations where such accounts receivables exhibit unique risk characteristics and are not expected to experience similar losses to the rest of their class.

Inventory

Inventory consists of our cannabis, wellness, beverage, and distribution inventory, as follows:

Cannabis inventory consists of our plants, dried cannabis, cannabis trim, cannabis derivatives such as oils, and vape products. Cannabis inventory costs include pre-harvest, post-harvest, shipment and fulfillment, as well as costs related to accessories. Pre-harvest costs include labor and direct materials to grow cannabis, which includes water, electricity, nutrients, integrated pest management, growing supplies and allocated overhead. Post-harvest costs include costs associated with drying, trimming, blending, extracting, purifying, quality testing and allocated overhead. Shipment and fulfillment costs include the costs of packaging, labelling, courier services, and allocated overhead.

Wellness inventory cost includes hemp seeds, packaging and co-packing. Seed costs include commodity cost paid to farmers, genetic seed cost to provide and manage contracted farmers, hulling and processing costs, including labor and overhead. Packaging costs include packaging materials, labor and overhead to run machinery. Co-packing cost are generally for products not manufactured by the Company directly and would include all costs to produce the products.

Beverage inventory cost includes materials we incur to make and ship beer beverages. These costs include brewing materials, such as barley, hops and various grains. Packaging materials such as glass bottles, aluminum cans, cardboard and paperboard are also included in the cost of our beverage inventory. Additionally, our cost of goods sold include both direct and indirect labor, shipping and handling including freight costs, utilities, maintenance costs, warehousing costs, purchasing and receiving costs, amortization, promotional packaging, and other manufacturing overheads

Distribution inventory includes costs related to procurement of pharmaceutical products for re-sale in entities’ respective markets.

Inventory is valued at the lower of cost and net realizable value, determined using weighted average cost. All direct and indirect costs related to inventory are capitalized as they are incurred, and they are subsequently recorded in cost of goods sold on the statements of loss and comprehensive loss at the time inventory is sold. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material to the Company’s statements of financial position, statements of loss and comprehensive loss and statements of cash flows.

Capital assets

Capital assets are recorded at cost, net of accumulated amortization and impairment, if any. Amortization for the properties included in our capital assets is calculated using the following terms and methods:

Asset type	Depreciation method	Depreciation term (estimated useful life)
Land	Not depreciated	No term
Production facility	Straight-line	20 – 30 years
Equipment	Straight-line	3 – 25 years
Leasehold improvements	Straight-line	Lesser of estimated useful life or lease term
Construction in progress	Not depreciated	No term
Finance lease right-of-use assets	Straight-line	Lesser of the lease term and the useful life of the leased asset

The estimated residual values and useful lives are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

When assets are retired or disposed of, the cost and accumulated amortization are removed from the respective accounts and any related gain or loss is recognized. Maintenance and repairs are charged to expenses as incurred. Significant expenditures, which extend the useful lives of assets or increase productivity, are capitalized. When significant parts of one of our capital assets have different useful lives, they are accounted for as separate items or components of capital assets.

Construction in progress includes construction progress payments, deposits, engineering costs and other costs directly related to the construction of the facilities. Expenditures are capitalized during the construction period and construction in progress is transferred to the relevant class of capital assets when the assets are available for use, at which point in time the amortization of the asset commences.

Intangible assets

Intangible assets include intangible assets acquired as part of business combinations, asset acquisitions and other business transactions. The Company records intangible assets at cost, net of accumulated amortization and accumulated impairment losses, if any. Cost is measured based on the fair values of cash consideration paid and equity interests issued. The cost of an intangible asset acquired is its acquisition date fair value.

Amortization of definite life intangible assets is calculated on a straight -line basis over the estimated useful lives of the assets using the following terms:

Asset type	Amortization term
Customer relationships and distribution channel	14 – 16 years
Licences, permits & applications	90 months – indefinite
Brands, intellectual property and trademarks	15 months – 25 years
Non-compete agreements	Over term of non-compete
Know how	5 years

When there is no foreseeable limit on the period of time over which an intangible asset is expected to contribute to the cash flows of the Company, an intangible asset is determined to have an indefinite-lived. Indefinite-lived intangible assets are not amortized but tested for impairment annually or more frequently when indicators of impairment exist. If the carrying value of an individual indefinite-lived intangible asset exceeds its fair value, such individual indefinite-lived intangible asset is impaired by the amount of the excess.

The estimated useful lives are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

Impairment of long-lived assets

The Company reviews long-lived assets, including capital assets and definite life intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are grouped and tested at the lowest level for which identifiable independent cash flows are available (“asset group”). An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value may be determined using a market approach or income approach. The reversal of impairment losses is prohibited.

Business combinations and goodwill

The Company accounts for business combinations using the acquisition method in accordance with Accounting Standards Codification, ASC 805, Business Combinations which requires recognition of assets acquired and liabilities assumed, including contingent assets and liabilities, at their respective fair values on the date of acquisition.

Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or liability is remeasured at subsequent reporting dates, with the corresponding gain or loss recognized in profit or loss.

Non-controlling interests in the acquiree are measured at fair value on acquisition date. Acquisition-related costs are recognized as expenses in the periods in which the costs are incurred and the services are received (except for the costs to issue debt or equity securities which are recognized according to specific requirements).

Purchase price allocations may be preliminary and, during the measurement period not to exceed one year from the date of acquisition, changes in assumptions and estimates that result in adjustments to the fair value of assets acquired and liabilities assumed are recorded in the period the adjustments are determined.

Goodwill represents the excess of the consideration transferred for the acquisition of subsidiaries over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. Following initial recognition, goodwill is measured at cost less any accumulated impairment losses.

Impairment of goodwill and indefinite-lived intangible assets

Goodwill is allocated to the reporting unit in which the business that created the goodwill resides. A reporting unit is an operating segment, or a business unit one level below that operating segment, for which discrete financial information is prepared and regularly reviewed by segment management. We operate in five operating segments which are our reporting units, and goodwill is allocated at the operating segment level. The Company reviews goodwill and indefinite-lived intangible assets annually for impairment in the fourth quarter, or more frequently, if events or circumstances indicate that the carrying amount of an asset may not be recoverable.

Leases

The Company determines if an arrangement is a lease at inception. The Company has operating and finance leases for facilities, office spaces, production equipment and vehicles. Operating leases are included in right‐of‐use (“ROU”) assets and finance lease ROU assets are included in capital assets in the statements of financial position. The lease liabilities are included in lease liabilities (current and non-current) in the statements of financial position.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are classified as a finance lease or an operating lease. A finance lease is a lease in which:

•

ownership of the property transfers to the lessee by the end of the lease term;

•

the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise;

•

the lease is for a major part of the remaining economic life of the underlying asset;

•

the present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already included in the lease payments equals or exceeds substantially all of the fair value; or

•

the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.

The Company classifies a lease as an operating lease when it does not meet any one of these criteria.

The ROU asset is initially measured at cost, which is primarily comprised of the initial amount of the lease liability, plus initial direct costs and lease payments at or before the commencement date, less any lease incentives received. All ROU assets are reviewed periodically for impairment.

The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate. The incremental borrowing rate is defined as the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

Lease payments included in the measurement of the lease liability comprise:

•

fixed lease payments (including in-substance fixed payments), less any lease incentives;

•

variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date;

•

the amount expected to be payable by the lessee under residual value guarantees;

•

the exercise of purchase options, if the lessee is reasonably certain to exercise the options; and

•

payments of penalties for early termination of a lease unless the Company is reasonably certain not to terminate early.

For finance leases, lease expenses are the sum of interest on the lease obligations and amortization of the ROU assets. Finance lease ROU assets are amortized based on the lesser of the lease term and the useful life of the leased asset according to the capital asset accounting policy. If ownership of the ROU assets transfers to the Company at the end of the lease term or if the Company is reasonably certain to exercise a purchase option, amortization is calculated using the estimated useful life of the leased asset.

For operating leases, the lease expenses are generally recognized on a straight-line basis over the lease term and recorded to general and administrative expenses in the statements of loss and comprehensive loss.

The Company has elected to apply the practical expedient, for each class of underlying asset, to not separate non-lease components from the associated lease components of the lessee’s contract and account for both components as a single lease component.

The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (defined as leases with a lease term of 12 months or less that do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise). Short-term leases include real estate and vehicles and are not significant in comparison to the Company’s overall lease portfolio. For these leases, the Company recognizes the leases as an operating expense on a straight-line basis over the term of the lease.

Convertible notes receivable

Convertible notes receivables include various investments in which the Company has the right to convert the indenture into common stock shares of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders’ equity until realized. The Company assesses its convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, credit quality of debt instrument issuers, and the duration and extent to which the fair value is less than cost. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of loss and comprehensive loss and a new cost basis for the investment is established. The Company also evaluates whether there is a plan to sell the security or it is more likely than not that the Company will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).

Long-term investments

Long-term investments include investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence and are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in non-operating income (loss).

Equity method investments

Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of losses reported in loss from equity method investments on the statements of loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within interest in equity investees on the statements of financial position.

Convertible debentures

The Company accounts for its convertible debentures in accordance with ASC 470-20 Debt with Conversion and Other Options, which requires the liability and equity components of convertible debt instruments that may be settled in cash upon conversion, including partial cash settlement, to be separately accounted for in a manner that reflects the issuer’s nonconvertible debt borrowing rate. The initial proceeds from the sale of convertible notes are allocated between a liability component and an equity component in a manner that reflects interest expense at the rate of similar nonconvertible debt that could have been issued at such time. The equity component represents the excess initial proceeds received over the fair value of the liability component of the notes as of the date of issuance. The resulting debt discount is amortized over the period during which the convertible notes are expected to be outstanding as additional non-cash interest expenses.

Upon repurchase of convertible debt instruments, ASC 470-20 requires the issuer to allocate total settlement consideration, inclusive of transaction costs, amongst the liability and equity components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component, including unamortized debt issuance costs, would be recognized as gain (loss) on extinguishment of debt in the statements of loss and comprehensive loss. The remaining settlement consideration allocated to the equity component would be recognized as a reduction of additional paid-in capital in the statements of financial position.

For convertible debentures with an embedded conversion feature that did not meet the equity scope exception from derivative accounting pursuant to ASC 815-15, the Company elected the fair value option under ASC 825 Fair Value Measurements. When the fair value option is elected, the convertible debenture is initially recognized at fair value on the statements of financial position and all subsequent changes in fair value, excluding the impact of the change in fair value related to instrument-specific credit risk are recorded in non-operating income (loss). The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income (loss). Transaction costs directly attributable to the issuance of the convertible debenture is immediately expensed in the statements of loss and comprehensive loss.

Warrants

Warrants are accounted for in accordance with applicable accounting guidance provided in ASC 815 Derivatives and Hedging – Contracts in Entity's Own Equity, as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. Warrants classified as liabilities are recorded at fair value and are remeasured at each reporting date until settlement. Changes in fair value is recognized as a component of change in fair value of warrant liability in the statements of loss and comprehensive loss. Transaction costs allocated to warrants that are presented as a liability were immediately expensed in the statements of loss and comprehensive loss. Warrants classified as equity instruments are initially recognized at fair value and are not subsequently remeasured.

Fair value measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of accounts receivable, prepaids and other current assets, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity. The Company calculates the estimated fair value of financial instruments, including convertible notes receivable, long-term investments, warrant liability, contingent consideration, and convertible debentures, using quoted market prices when available. When quoted market prices are not available, fair value is determined based on valuation techniques using the best information available and may include quoted market prices, market comparables, and discounted cash flow projections.

Income taxes

Income taxes are recognized in the consolidated statements of loss and comprehensive loss and are comprised of current and deferred taxes. Current tax is recognized in connection with income for tax purposes, unrealized tax benefits and the recovery of tax paid in a prior period and measured using enacted tax rates and laws applicable to the taxation period during which the income for tax purposes arose. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management makes an assessment of the likelihood that a deferred tax asset will be realized, and a valuation allowance is provided to the extent that it is more likely than not that all or a portion of a deferred tax asset will not be realized.

The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. A change in the recognition or measurement of an unrealized tax benefit is reflected in the period during which the change occurs.

Revenue

Revenue is recognized when the control of the promised goods, through performance obligation, is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations.

Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of operations and recognized as a current liability within accounts payable and other current liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority.

In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates.

In determining the transaction price for the sale of goods, the Company considers the effects of variable consideration and the existence of significant financing components, if any.

Some contracts for the sale of goods may provide customers with a right of return, volume discount, bonuses for volume/quality achievement, or sales allowance. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. These items give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because this method best predicts the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer’s consideration. The estimate is updated at each reporting period date.

The Company may receive short-term advances from its customers. Using the practical expedient in ASC 606, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the Company transfers a promised good to a customer and when the customer pays for that good or service will be one year or less. The Company has not, nor expects to receive long-term advances from customers.

Cost of goods sold

Cost of goods sold represents costs directly related to manufacturing and distribution of the Company’s products. Primary costs include raw materials, packaging, direct labor, overhead, shipping and handling, the amortization of manufacturing equipment and production facilities and tariffs. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and property taxes. Cost of goods sold also includes inventory valuation adjustments. The Company recognizes the cost of goods sold as the associated revenues are recognized.

General and administrative

General and administrative expenses are comprised primarily of (i) personnel related costs such as salaries, benefits, annual employee bonus expense and stock-based ‘compensation costs for personnel in corporate, finance, legal, and other administrative positions; (ii) legal, accounting, consulting and other professional fees; and (iii) corporate insurance and other facilities costs associated with our corporate and administrative locations.

Selling

Selling expenses are comprised direct selling costs which primarily consist of (i) commissions paid to our third-party workforce, (ii) patient acquisition and maintenance fees, (iii) Health Canada’s cannabis fees and (iv) freight.

Marketing and promotion

Marketing and promotion expenses are comprised primarily of marketing and advertising expenses.

Research and development

Research and development costs are expensed as incurred. Research and development are comprised primarily of costs for personnel, clinical study costs, contracted research, consulting services, materials and supplies, milestones, an allocation of our occupancy costs and other expenses incurred to sustain our overall research and development programs.

Stock-based compensation

The Company has an omnibus plan which includes issuances of stock options, restricted stock units (“RSUs”) and stock appreciation rights (“SARs”) in place. The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option pricing model. The fair value of RSUs is based on the share price as at date of grant and no SARs were issued to date. The share-based compensation expense is based on the fair value of the stock-based awards at the grant date and the expense is recognized over the related service period following a straight-line vesting expense schedule. The Company estimates forfeitures at the time of grant and revises these estimates in subsequent periods if actual forfeitures differ from those estimates. Any revisions are recognized in the consolidated statements of loss and comprehensive loss such that the cumulative expense reflects the revised estimate.

For performance-based stock options and RSUs, the Company records compensation expense over the estimated service period adjusted for a probability factor of achieving the performance-based milestones. At each reporting date, the Company assesses the probability factor and records compensation expense accordingly, net of estimated forfeitures.

Earnings (loss) per share

Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments.

In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive.

Critical accounting estimates and judgments

The preparation of the Company’s financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, revenues and expenses. These estimates and judgements are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.

Financial statement areas that require significant judgement are as follows:

Leases – The Company applies judgement in determining whether a contract contains a lease and if a lease is classified as an operating lease or a finance lease. The Company determines the lease term as the non-cancellable term of the lease, which may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. That is, it considers all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate (e.g., construction of significant leasehold improvements or significant customization to the leased asset).

Long-term investments and convertible notes receivable – The determination of fair value of the Company’s long-term investments and convertible notes receivable at other than initial cost is subject to certain limitations. Financial information for private companies in which the Company has investments may not be available and, even if available, that information may be limited and/or unreliable.

Use of the valuation approach described below may involve uncertainties and determinations based on the Company’s judgment and any value estimated from these techniques may not be realized or realizable.

Company-specific information is considered when determining whether the fair value of a long-term investment or convertible notes receivable should be adjusted upward or downward at the end of each reporting period. In addition to company-specific information, the Company will consider trends in general market conditions and the share performance of comparable publicly traded companies when valuing long-term investments and convertible notes receivable.

The fair value of long-term investments and convertible notes receivable may need to be adjusted if:

•

There has been a significant subsequent equity financing provided by outside investors at a valuation different than the current value of the investee company, in which case the fair value of the investment is set to the value at which that financing took place;

•

There have been significant corporate, political, or operating events affecting the investee company that, in management’s opinion, have a material impact on the investee company’s prospects and therefore its fair value. In these circumstances, the adjustment to the fair value of the investment will be based on management’s judgment and any value estimated may not be realized or realizable;

•

The investee company is placed into receivership or bankruptcy;

•

Based on financial information received from the investee company, it is apparent to the Company that the investee company is unlikely to be able to continue as a going concern;

•

Important positive or negative management changes by the investee company that the Company’s management believes will have a positive or negative impact on the investee company’s ability to achieve its objectives and build value for shareholders.

Adjustment to the fair value of a long-term investment and convertible notes receivable will be based upon management’s judgment and any value estimated may not be realized or realizable. The resulting values for non-publicly traded investments may differ from values that would be realized if a ready market existed.

Estimated useful lives, impairment considerations and amortization of capital and intangible assets – Amortization of capital and intangible assets is dependent upon estimates of useful lives based on management’s judgment.

Goodwill and indefinite-lived intangible asset impairment testing require management to make estimates in the impairment testing model. On at least an annual basis, the Company tests whether goodwill and indefinite-lived intangible assets are impaired. Impairment of definite long-lived assets is influenced by judgment in defining a reporting unit and determining the indicators of impairment, and estimates used to measure impairment losses

The reporting unit’s fair value is determined using discounted future cash flow models, which incorporate assumptions regarding future events, specifically future cash flows, growth rates and discount rates. The uncertainties of coronavirus’ (“COVID-19”) impact on the future cash flow estimates are further described in Note 10 Business acquisitions and goodwill.

Stock-based compensation – The fair value of stock-based compensation expenses are estimated using the Black-Scholes option pricing model and rely on a number of assumptions including the fair value of common shares on the grant date, risk-free rate, volatility rate, annual dividend yield, the expected term, and the estimated rate of forfeiture of options granted. Volatility is estimated by using the historical volatility of the Company.

Business combinations – Judgement is used in determining a) whether an acquisition is a business combination or an asset acquisition. We use judgement in applying the acquisition method of accounting for business combinations and estimates to value identifiable assets and liabilities at the acquisition date. Estimates are used to determine cash flow projections, including the period of future benefit, and future growth and discount rates, among other factors. The values allocated to the acquired assets and liabilities assumed affect the amount of goodwill recorded on acquisition. Fair value of assets acquired and liabilities assumed is typically estimated using an income approach, which is based on the present value of future discounted cash flows. Significant estimates in the discounted cash flow model include the discount rate, rate of future revenue growth and profitability of the acquired business and working capital effects. The discount rate considers the relevant risk associated with the business-specific characteristics and the uncertainty related to the ability to achieve projected cash flows. These estimates and the resulting valuations require significant judgment. Management engages third party experts to assist in the valuation of material acquisitions.

Convertible debentures – The fair value of Convertible Debentures where the Company had elected the fair value option are determined using the Black-Scholes option pricing model. Assumptions and estimates are made in determining an appropriate conversion price, volatility, dividend yield, and the fair value of common stock. There is judgement in assessing what portion of the gain or loss, if any, relates to the change in the instrument-specific credit risk.

Warrant liability – The fair value of the warrant liability is measured using a Black Scholes pricing model. Assumptions and estimates are made in determining an appropriate risk-free interest rate, volatility, term, dividend yield, discount due to exercise restrictions, and the fair value of common stock. Any significant adjustments to the unobservable inputs would have a direct impact on the fair value of the warrant liability.

New accounting pronouncements not yet adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The standard is effective for annual reporting periods beginning after December 15, 2021 and including interim periods within those fiscal years, which means that it will be effective for the Company in the first quarter of our year beginning June 1, 2021. The Company is currently evaluating the effect of adopting this ASU on the Company’s financial Statements. We do not expect the adoption of ASU 2019-12 to have a material impact on our consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for the Company beginning June 1, 2021. The Company is currently evaluating the effect of adopting this ASU.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. ASU 2020-06 is effective for the Company beginning June 1, 2022. This update may be applied retrospectively or on a modified retrospective basis with the cumulative effect recognized as an adjustment to the opening balance of retained earnings on the date of adoption. The Company is currently evaluating the effect of adopting this ASU.

Prepaids and other current assets

12 Months Ended

May 31, 2021

Prepaid Expense And Other Assets Current [Abstract]

Prepaids and other current assets

4.	Prepaids and other current assets

Prepaids and other current assets are comprised of:

	May 31, 2021		May 31, 2020
Prepaid assets	$	31,012		13,760
Sales tax receivable		9,331		8,464
Prepaid corporate taxes		—		4,670
Other		8,577		5,766
	$	48,920	$	32,660

Included within prepaid assets are insurance, deposits, advanced payments on contracts, and other prepayments that will result in future benefit.

Inventory

12 Months Ended

May 31, 2021

Inventory Disclosure [Abstract]

Inventory

Inventory is comprised of:

	May 31, 2021		May 31, 2020
Plants	$	23,083	$	12,288
Dried cannabis		118,269		59,045
Cannabis trim		2,931		2,796
Cannabis derivatives		24,158		19,496
Cannabis vapes		3,791		4,124
Packaging and other inventory items		31,462		16,398
Wellness inventory		15,171		—
Beverage alcohol inventory		5,402		—
Distribution inventory		32,162		25,634
Total inventory	$	256,429	$	139,781

Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. During the year ended May 31, 2021, the Company recorded charges for inventory and inventory-related write downs as a component of cost of sales. Cannabis products were written down by $19,919 for the year ended May 31, 2021 and there were no write downs for the years ended May 31, 2020 and 2019.

Related party transactions

12 Months Ended

May 31, 2021

Related party transactions

6.	Related party transactions

In the normal course of business, the Company enters into related party transactions with certain entities under common control and joint ventures as detailed below.

Leafly Holdings, Inc. (“Leafly”)

The Company has an agreement with Leafly providing for data licensing activities. During the year ended May 31, 2021, 2020, and 2019 operational expenses were nil, respectively was recorded within general and administrative expenses in the statements of loss and comprehensive loss.

Docklight LLC (“Docklight”) royalty and management services

The Company pays Docklight a royalty fee pursuant to a brand licensing agreement which provides the Company with exclusive rights in Canada for the use of certain adult-use brands. During the year ended May 31, 2021, 2020 and 2019 royalty fees of were $125, nil, and nil, respectively were recorded within general and administrative expenses in the statements of loss and comprehensive loss.

Fluent and Cannfections

The Company has joint venture arrangements with a 50% ownership and voting interest in each of Fluent and Cannfections. Refer to Note 13 for details over transactions with these entities for the year ended May 31, 2021, 2020 and 2019.

Capital assets

12 Months Ended

May 31, 2021

Property Plant And Equipment [Abstract]

Capital assets

7.	Capital assets

Capital asset consisted of the following:

	Land			Production facility			Equipment			Leasehold improvements			ROU assets under finance lease			Construction in process			Total capital assets
Cost:
At May 31, 2019	$	24,047		$	168,614		$	57,755		$	896		$	—		$	126,338		$	377,650
Additions		—			3,342			15,691			925			—			75,557			95,515
Transfers		54			27,968			81,112			11,996			—			(121,130	)		—
Disposals		—			—			(5,339	)		—			—			(4,147	)		(9,486	)
Impairment		(11	)		(2,561	)		(34	)		(89	)		—			(1,602	)		(4,297	)
Effect of foreign exchange		(2	)		(505	)		(2,117	)		(345	)		—			1,476			(1,493	)
At May 31, 2020		24,088			196,858			147,068			13,383			—			76,492			457,889
Business acquisition		5,538			55,916			35,045			1,560			35,519			46,151			179,729
Additions		261			3,236			6,284			525			—			25,773			36,079
Transfers		—			63,159			11,189			—			—			(74,348	)		—
Disposals		(5,237	)		—			(513	)		(192	)		—			—			(5,942	)
ROU Amortization		—			—			—			—			(827	)		—			(827	)
Effect of foreign exchange		3,899			27,341			16,335			1,783			34			11,254			60,646
At May 31, 2021	$	28,549		$	346,510		$	215,408		$	17,059		$	34,726		$	85,322		$	727,574
Accumulated amortization:
At May 31, 2019	$	—		$	5,556		$	6,469		$	137		$	—		$	—		$	12,162
Amortization		—			10,134			14,551			336			—			—			25,021
At May 31, 2020		—			15,690			21,020			473			—			—			37,183
Amortization		—			14,007			24,996			690			—			—			39,693
At May 31, 2021	$	—		$	29,697		$	46,016		$	1,163		$	—		$	—		$	76,876
Net book value:
At May 31, 2019	$	24,047		$	163,058		$	51,286		$	759		$	—		$	126,338		$	365,488
At May 31, 2020	$	24,088		$	181,168		$	126,048		$	12,910		$	—		$	76,492		$	420,706
At May 31, 2021	$	28,549		$	316,813		$	169,392		$	15,896		$	34,726		$	85,322		$	650,698

Leases

12 Months Ended

May 31, 2021

Leases [Abstract]

Leases

The Company has operating and finance leases for facilities, office spaces, production equipment and vehicles.

Leases have varying terms with remaining lease terms of up to approximately 20 years. Certain of our lease arrangements provide us with the option to extend or to terminate the lease early.

The table below presents the lease-related assets and liabilities recorded on the balance sheet.

	Classification on Balance Sheet	May 31, 2021		May 31, 2020
Assets
Operating lease, right-of- use assets	Right of use assets	$	18,267	$	5,356
Finance lease, right-of-use assets	Capital assets		34,726		—
Total right-of-use asset		$	52,993	$	5,356
Liabilities
Current:
Operating lease liability	Accrued lease obligations - current	$	3,613	$	954
Finance lease liability	Accrued lease obligations - current		651		—
Non-current:
Operating lease liability	Accrued lease obligations - non-current		18,465		4,227
Finance lease liability	Accrued lease obligations - non-current		35,481		—
Total lease liabilities		$	58,210	$	5,181

The table below presents certain information related to the lease costs for finance and operating leases.

	May 31, 2021		May 31, 2020
Finance lease cost:
Amortization of right-of-use assets	$	806	$	—
Interest on lease liabilities		765		—
Operating lease cost		1,374		1,128
Total lease cost	$	2,945	$	1,128

The Company does not have short term lease expense or sublease income for the year ending May 31, 2021.

The table below presents supplemental cash flow information related to leases.

	May 31, 2021		May 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	1,466	$	994
Operating cash flows from finance leases		774		—
Financing cash flows from finance leases		231		—

The following table presents the future undiscounted payment associated with lease liabilities as of May 31, 2021:

	Year ending May 31,
	Operating leases			Finance leases
2022		7,824			2,404
2023		4,272			7,183
2024		3,925			2,061
2025		3,023			2,122
2026		2,964			2,186
Thereafter		4,102			39,586
Total minimum lease payments	$	26,110		$	55,542
Less: amounts of leases related to interest payments		(419	)		(18,759	)
Present value of minimum lease payments		25,691			36,783
Less: current accrued lease obligation		(3,613	)		(651	)
Obligation recognized	$	22,078		$	36,132

Intangible assets

12 Months Ended

May 31, 2021

Intangible Assets Net Excluding Goodwill [Abstract]

Intangible assets

9.	Intangible assets

Intangible assets are comprised of the following items:

	Customer relationships & distribution channel			Licenses, permits & applications			Non- compete agreements			Intellectual property, trademarks, know how & brands			Total intangible assets
Cost
At May 31, 2019	$	23,957		$	200,102		$	2,415		$	72,122		$	298,596
Additions		84			2,158			—			3,608		$	5,850
Impairment		—			(14,445	)		—			—		$	(14,445	)
Effect of foreign exchange		(269	)		393			(10	)		(1,918	)	$	(1,804	)
At May 31, 2020		23,772			188,208			2,405			73,812		$	288,197
Business acquisition		214,000			202,716			10,000			912,080		$	1,338,796
Effect of foreign exchange		2,038			24,006			48			5,025		$	31,117
At May 31, 2021	$	239,810		$	414,930		$	12,453		$	990,917		$	1,658,110
Accumulated amortization
At May 31, 2019	$	4,354		$	623		$	1,081		$	8,172		$	14,230
Amortization		4,506			131			1,006			5,006		$	10,649
At May 31, 2020		8,860			754			2,087			13,178		$	24,879
Amortization		9,442			413			2,212			15,246		$	27,313
At May 31, 2021	$	18,302		$	1,167		$	4,299		$	28,424		$	52,192
Net book value
At May 31, 2019	$	19,603		$	199,479		$	1,334		$	63,950		$	284,366
At May 31, 2020	$	14,912		$	187,454		$	318		$	60,634		$	263,318
At May 31, 2021	$	221,508		$	413,763		$	8,154		$	962,493		$	1,605,918

Included in Licences, permits & applications is $412,000 of indefinite-lived intangible assets (2020 - $186,000).

Estimated amortization expense for each of the five succeeding fiscal years and thereafter is as follows:

	Years ending May 31,
2022	$	72,172
2023		68,409
2024		65,946
2025		65,533
2026		65,533
Thereafter		855,801
	$	1,193,394

Business Acquisitions

12 Months Ended

May 31, 2021

Business Combinations [Abstract]

Business Acquisitions

10.	Business Acquisitions

Reverse Acquisition

On December 15, 2020, Tilray entered into an Arrangement Agreement (as amended, the “Arrangement Agreement” with Aphria Inc. (“Aphria”), or the “Aphria-Tilray business combination”, pursuant to which Tilray acquired all of the issued and outstanding common shares of Aphria pursuant to a plan of arrangement (the “Plan of Arrangement”) under the Ontario Business Corporations Act (the “Arrangement”) with the primary objective to increase its scalable operational footprint, expand its portfolio of diverse medical and adult-use cannabis brands and products, expand its multi-continent distribution network, and gain a robust capital structure to fund a global expansion strategy. The transaction closed on April 30, 2021 (“Closing Date”).

The fair value of the purchase price is, as follows:

	April 30, 2021
Number of Tilray common shares outstanding at acquisition date		179,635,973
Conversion ratio		0.8381
Tilray common shares issued at closing		214,337,159
Market share price of Aphria converted stock units	$	14.62
Fair value of Tilray common stock transferred to Aphria shareholders		3,133,609
Consideration related to stock-based compensation ⁽¹⁾		71,297
Total fair value of consideration transferred	$	3,204,906

⁽¹⁾

On acquisition date there was consideration in the form of 1,207,010 restricted stock units and 4,782,132 stock options that had been issued before the acquisition date to employees and non-employees of Tilray. The pre-combination fair value of these awards is $17,646 and $53,650, respectively. The consideration will be reassessed and adjusted to fair value each quarter through General and Administration Expense in the Statement of Loss and Comprehensive Loss.

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value of the net assets acquired may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes preliminary estimated fair value of the assets acquired and the liabilities assumed at the effective acquisition date.

	April 30, 2021
Assets
Cash and cash equivalents	$	375,673
Accounts receivable		28,054
Inventory		76,547
Prepaids and other current assets		8,960
Capital assets		136,637
Right-of-use assets, operating leases		12,606
Definite-lived intangible assets (estimated useful life)
Distribution channel (15 years)		404,000
Customer relationships (15 years)		59,000
Know how (5 years)		115,000
Brands (10 to 25 years)		301,000
Indefinite-lived intangible assets
Licenses		200,000
Goodwill		2,221,613
Other assets		22,879
Total assets		3,961,969
Liabilities
Accounts payable		62,292
Accrued expenses and other current liabilities		85,120
Accrued lease obligations		21,962
Warrant liability		79,402
Deferred tax liability		236,391
Convertible notes		267,862
Other liabilities		4,034
Total liabilities		757,063
Net assets acquired	$	3,204,906

In connection with the reverse acquisition, the Company incurred transaction costs of $42,000. The goodwill of $2,221,613 is primarily related to factors such as synergies and market share and reportable under the Company’s Cannabis and Wellness segment is as follows on a preliminary basis:

		Cannabis				Wellness				Total
Goodwill related to Tilray			2,144,143				77,470				2,221,613

Goodwill is not deductible for tax purposes. The financial results of Tilray are included in the Company’s financial statements since acquisition date. The Consolidated Statements of Loss and Comprehensive Loss include net revenue of $13,018 and net income of $645.

Supplemental pro forma information (unaudited)

The unaudited pro forma information for the periods set forth below gives effect to the reverse acquisition as if the reverse acquisition had occurred as of June 1, 2019. This pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the transactions been consummated as of that time.

	Years ended May 31,
	2021			2020
Revenue	$	692,270		$	624,950
Net loss	$	(795,251	)	$	(649,276	)
Net loss per share - basic and diluted	$	(1.77	)	$	(1.71	)

The above pro forma revenue and net loss include adjustments directly attributable to the business combination and related primarily non-recurring transaction costs of $37,000, increase in intangible assets amortization expense of $28,000 and decrease in interest expense associated with Tilray’s convertible senior notes of 5,000

Acquisition of SW Brewing Company, LLC

On November 25, 2020, the Company, through its wholly-owned subsidiary Four Twenty Corporation, completed the purchase of all the shares of SW Brewing Company, LLC which is the holding company of 100% of the common shares of SweetWater. The purchase price consisted of cash consideration of $255,543, share consideration of 8,232,810 shares, and additional cash consideration of up to $66,000 contingent on SweetWater achieving specified EBITDA targets. The fair value of the shares on the date the Company closed the acquisition was $65,889, the fair value of the contingent consideration on the date the Company closed the acquisition was $58,959.

	Amount
Consideration
Cash	$	255,543
Shares		65,889
Contingent consideration		58,959
Total consideration		380,391
Net assets acquired
Current assets
Cash and cash equivalents		6,988
Accounts receivable		3,810
Prepaids and other current assets		528
Inventory		4,815
Long-term assets
Capital assets		43,093
Customer relationships		155,000
Intellectual property, trademarks & brands		92,000
Non-compete agreements		10,000
Goodwill		100,202
Total assets		416,436
Current liabilities
Accounts payable and accrued liabilities		5,289
Current portion of lease liabilities		434
Long-term liabilities
Lease liabilities		30,322
Total liabilities		36,045
Total net assets acquired	$	380,391

The contingent consideration from the acquisition of SweetWater is a fair value measurement and as such is carried at fair value. The fair value has been determined by discounting future expected cash outflows at a discount rate of 5%. The inputs into the future expected cash outflows are level 3 on the fair value hierarchy and are subject to volatility and uncertainty, which could significantly affect the fair value of the contingent consideration in future periods. As at May 31, 2021, the fair value of the contingent consideration was $60,657, expected to be paid in December 2023. The goodwill of $102,202 is primarily related to factors such as synergies and market opportunities and reportable under the Company’s Beverage Alcohol segment.

Supplemental pro forma information (unaudited)

The unaudited pro forma information for the periods set forth below gives effect to the acquisition of SW Brewing Company, LLC as if the transaction had occurred as of June 1, 2019. This pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the transactions been consummated as of that time.

	Years ended May 31,
	2021			2020
Revenue	$	542,000		$	470,000
Net loss	$	(328,000	)	$	(80,000	)
Net loss per share - basic and diluted	$	(0.73	)	$	(0.37	)

Goodwill

12 Months Ended

May 31, 2021

Goodwill Disclosure [Abstract]

Goodwill

11.

Goodwill

The goodwill recognized is as a result of expected synergies from combining operations through business acquisitions and none of the goodwill is deductible for income tax purposes.

Goodwill is comprised of:

	Segment	May 31, 2021		May 31, 2020
Broken Coast Cannabis Ltd.	Cannabis business		105,963		105,963
Nuuvera Corp.	Business under development		273,606		273,606
LATAM Holdings Inc.	Business under development		63,239		63,239
CC Pharma GmbH	Distribution business		4,458		4,458
SweetWater	Beverage alcohol business		100,202		—
Tilray	Cannabis business		2,144,143		—
Tilray	Wellness business		77,470		—
Effect of foreign exchange			63,713		64
		$	2,832,794	$	447,330

During the year ended May 31, 2021, the Company completed its annual goodwill impairment assessment of the fair value of the Company’s reporting units compared to their carrying amount. For the year ended May 31, 2021 there were no impairment charges recognized. For the year ended May 31, 2020, the Company recorded the following impairment charges:

$3,581 (C$4,800) on CannInvest Africa Ltd. and Verve Dynamics Incorporated (Pty) Ltd., the Company used a discount rate of 38.5%;

$3,730 (C$5,000) on ABP, S.A., the Company used a discount rate of 23.3%;

$14,301 (C$19,171) on Marigold Projects Jamaica Limited (“Marigold”), the Company used a discount rate of 38.5%; and

$29,067 (C$35,000) on ColCanna S.A.S., the Company used a discount rate of 40.0%.

Convertible notes receivable

12 Months Ended

May 31, 2021

Convertible Notes Receivable [Abstract]

Convertible notes receivable

12.	Convertible notes receivable

During the year ended May 31, 2021, the Company did not purchase any convertible notes (2020 - $nil). The unrealized loss on convertible notes receivable recognized in other comprehensive income amounts to $3,824 and $5,476 for the years ended May 31, 2021 and 2020 respectively.

During the year ended May 31, 2021, and 2020 the Company received total proceeds of $1,251,and $nil respectively from sales of available-for-sale securities and gain (loss) of $5,277, and $nil respectively was reclassified out of accumulated other comprehensive income into earnings.

The fair value was determined using the Black-Scholes option pricing model using the following assumptions: the risk-free rate of 1.25%; expected life of the convertible note; volatility of 70% based on comparable companies; forfeiture rate of nil; dividend yield of nil; and, the exercise price of the respective conversion feature.

Convertible notes receivable is comprised of the following investments:

	May 31, 2021			May 31, 2020
HydRx Farms Ltd. (d/b/a Scientus Pharma)	$	—		$	4,352
10330698 Canada Ltd. (d/b/a Starbuds)		828			3,429
High Tide Inc.		1,657			2,828
Total convertible notes receivable		2,485			10,609
Deduct - current portion		(2,485	)		(10,609	)
Total convertible notes receivable, non current portion	$	—		$	—

HydRx Farms Ltd. (d/b/a Scientus Pharma)

On August 14, 2017, Aphria purchased C$11,500 in secured convertible debentures of Scientus Pharma (“SP”). The convertible debentures bore interest at 8%, paid semi-annually, matured in two years and included the right to convert the debentures into common shares of SP at C$2.75 per common share at any time before maturity. During the year ended May 31, 2021, the Company settled the note receivable for $4,032 (C$5,000).

10330698 Canada Ltd. (d/b/a Starbuds)

On December 28, 2018, Aphria purchased C$5,000 in secured convertible debentures of Starbuds. The convertible debentures bear interest at 8.5% per annum accruing daily due until maturity on December 28, 2020. The debentures are secured against the assets of Starbuds. The debentures and any accrued and unpaid interest are convertible into common shares for C$0.50 per common share and matured on December 28, 2020. Starbuds is currently in default under the convertible debentures.

As at May 31, 2021, the fair value of the Company’s secured convertible debentures was $828 (C$1,000) (May 31, 2020 - $3,429 (C$4,728)), which includes $385 (C$465) (May 31, 2020 - $157 (C$216)) of accrued interest. The remaining change resulted in a fair value gain (loss) recognized in other comprehensive income.

High Tide Inc.

On April 10, 2019, Aphria purchased C$4,500 in unsecured convertible debentures of High Tide Inc. (“High Tide”). The convertible debentures bear interest at 10% per annum, payable annually up front in common shares of High Tide based on the 10-day volume weighted average price (the “Debentures”). The Debentures matured on April 10, 2021. In addition to the Debentures, the Company received 6,000,000 warrants in High Tide as part of the purchase of the unsecured convertible debentures (Note 13). Upon maturity, the Company agreed to extend the maturity date on C$2,000 of the convertible notes. The extended notes bear interest at 9% per annum and are due on April 21, 2023.

Interest in equity investees

12 Months Ended

May 31, 2021

Investments Debt And Equity Securities [Abstract]

Interest in equity investees

13.	Interest in equity investees

The Company acquired the following equity method investments as a results of the Arrangement on April 30, 2021:

Plain Vanilla Research Limited Partnership (“Fluent”)

A joint venture with Anheuser-Busch InBev (“AB InBev”) to research and develop non- alcohol beverages containing cannabis. Under the terms of the arrangement, the Company and AB InBev each have 50% ownership and 50% voting interest in the Plain Vanilla Research Limited Partnership (“Fluent”), headquartered in Canada. The Company has determined that Fluent is a VIE, but the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance. Accordingly, the Company does not consolidate the financial statements of Fluent and accounts for this investment using the equity method of accounting. At May 31, 2021 the maximum exposure to loss is limited to the Company’s equity investment in the joint venture.

Cannfections Group Inc. (“Cannfections”)

A joint venture with Cannfections Group Inc. (“Cannfections”) to develop and manufacture confectionary cannabis products. Under the terms of the arrangement, the Company and Cannfections each have 50% ownership and 50% voting interest. During the year ended May 31, 2021 the Company made no contributions to the joint venture.

The Company’s ownership interests in its equity method investments as of May 31, 2021 is as follows:

	Approximate ownership %	Carrying value May 31, 2021		Loss from equity method investments year ended May 31, 2021
Investment in Fluent	50%	$	3,906	$	(416	)
Investment in Cannfections	50%		4,200		(42	)
Total equity method investments		$	8,106	$	(458	)

Long-term investments

12 Months Ended

May 31, 2021

Investments All Other Investments [Abstract]

Long-term investments

14.	Long-term investments

Long-term investments are comprised of the following items:

	Fair value May 31, 2021		Fair value May 31, 2020
Equity investments measured at fair value		12,185		19,595
Equity investments under measurement alternative		5,500		—
Total other investments		17,685		19,595

The Company’s equity investments at fair value consist of publicly traded shares, equity interest in non-traded companies and warrants held by the Company. The Company’s equity investments under measurement alternative include equity investments without readily determinable fair values. For the year ended May 31, 2021 the Company received proceeds of $8,430 on the sale of investments (2020-$19,570, 2019-$83,343) and recognized $1,567 in unrealized losses due to the change in fair value of investments (2020-$23,057, 2019-$8,122).

Income taxes and deferred income taxes

12 Months Ended

May 31, 2021

Income Tax Disclosure [Abstract]

Income taxes and deferred income taxes

15.	Income taxes and deferred income taxes

Loss before income taxes includes the following components:

	For the year ended May 31,
	2021			2020			2019
United States	$	(7,814	)		—			—
Canada		(323,964	)		(88,930	)		(30,733	)
Other countries		(13,208	)		(20,255	)		(7,405	)
	$	(344,986	)		(109,185	)		(38,138	)

The (recoveries) expense for income taxes consists of:

	For the year ended May 31,
	2021			2020			2019
Current:
United States	$	—			—			—
Canada		15,227			5,294			3,296
Other countries		697			375			407
	$	15,924			5,669			3,703

Deferred:
United States	$	1,517			—			—
Canada		(30,111	)		(9,226	)		(3,281	)
Other countries		3,698			(4,795	)		(2,467	)
	$	(24,896	)		(14,021	)		(5,748	)
Income tax benefits, net	$	(8,972	)		(8,352	)		(2,045	)

A reconciliation of income taxes at the statutory rate with the reported taxes is as follows:

	For the year ended May 31,
	2021			2020			2019
Loss before net income taxes:	$	(344,986	)		(109,185	)		(38,138	)
Income tax benefits at statutory rate		(72,408	)		(22,929	)		(8,009	)
Tax impact of foreign operations		(19,016	)		(6,310	)		(2,504	)
Foreign exchange and other		1,011			(63	)		(491	)
Non-deductible expenses		(1,347	)		2,474			5,731
Non-deductible (taxable) losses		45,230			2,152			(11,724	)
Changes in enacted rates		135			—			—
Change in fair value of warrant liability		(259	)		—			—
Stock based and other compensation		2,902			4,105			14,655
Change in valuation allowance		46,007			1,066			297
Non deductible dividend		(755	)		—			—
Non deductible impairment		—			11,153			—
Effect of transaction		(10,472	)		—			—

Income tax benefits, net	$	(8,972	)		(8,352	)		(2,045	)

The following table summarizes the components of deferred tax:

	May 31,
	2021			2020			2019
Deferred assets
Operating loss carryforwards - United States	$	57,320			—			—
Operating loss carryforwards - Canada		152,382			20,512			9,535
Operating loss carryforwards - Other Countries		7,801			9,037			5,079
Capital loss carryforwards		1,350			1,854			7,028
Intangible assets		86,541			—			—
Property and equipment		17,107			—			—
Currently nondeductible interest		9,491			—			—
Partnership interests		34,108			—			—
Deferred financing costs		4,237			5,022			—
Investment tax credits and related pool balance		526			—			—
Other		26,716			1,704			1,101
Total Deferred tax assets		397,579			38,129			22,743
Less valuation allowance		(265,940	)		(4,583	)		(4,583	)
Net deferred tax assets		131,639			33,546			18,160
Deferred tax liabilities
Property and equipment		(15,997	)		(8,356	)		(1,995	)
Intangible assets		(376,228	)		(69,580	)		(73,454	)
Convertible Senior Notes Due 2023		(4,977	)		(4,056	)		(4,739	)
Total deferred tax liabilities		(397,202	)		(81,992	)		(80,188	)
Net deferred tax liability	$	(265,563	)		(48,446	)		(62,028	)

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law in the U.S. The CARES Act, among other things, permits U.S. net operating loss ("NOL") carryovers and carrybacks to offset 100% of U.S. taxable income for taxable years beginning before 2021. The CARES Act also contains modifications on the limitation of business interest for tax years beginning in 2019 and 2020. The modifications to Section 163(j) increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income. The CARES Act results in increasing the allowable interest expense and NOL carryover deductions in 2020.

The Tax Cuts and Jobs Act (2017 Tax Act) was enacted on December 22, 2017 and reduced the U.S. statutory federal corporate tax rate from 35% to 21%. The Tax Act also contains additional provisions that are effective for the company in 2018, including a new tax on Global Intangible Low-Taxed Income (“GILTI”). Under GAAP, we are allowed to make an accounting policy choice to either (i) treat taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the "period cost method"); or (ii) factor in such amounts into the measurement of our deferred taxes (the "deferred method"). The Company has made a policy decision to record GILTI tax as a current-period expense when incurred.

Deferred income taxes have not been recorded on the basis differences for investments in consolidated subsidiaries as these basis differences are indefinitely reinvested or will reverse in a non-taxable manner. Quantification of the deferred income tax liability, if any, associated with indefinitely reinvested basis differences is not practicable. Deferred income taxes have been recorded on the basis differences for investments in nonconsolidated entities.

At May 31, 2021, the Company had United States net operating loss carry-forwards of approximately $224,795 that can be carried forward indefinitely and generally limited in annual use to 80% of the current year taxable income starting 2021. The Company has Canadian net operating loss carry-forwards of approximately $510,456 that can be carried forward 20 years and begin to expire in 2028. Management believes that it is more-likely-than-not that the benefit from certain United States and foreign net operating loss carry-forwards will not be realized. In recognition of this risk, the Company has provided a valuation allowance on the deferred tax assets relating to these carry-forwards. The net change in the total valuation allowance was an increase of $261,357 and $0 for the years ended May 31, 2021 and 2020, respectively.

The Company recognizes the financial statement impact of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest impact that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The total amount of gross unrecognized tax benefits (“GUTB”) was $0, $0, and $0 as of May 31, 2021, 2020 and 2019 respectively. There is a reasonable possibility that the Company’s unrecognized tax benefits will change within twelve months due to audit settlements or the expiration of statute of limitations, but the Company does not expect the change to be material to the financial statements.

The Company recognizes interest and, if applicable, penalties for any uncertain tax positions. Interest and penalties are recorded as a component of income tax expenses. In the years ended May 31, 2021, 2020 and 2019, the Company recorded approximately $0, $0 and $0, respectively, of interest and penalty expenses related to uncertain tax positions. As of May 31, 2021, and 2020, the Company had a cumulative balance of accrued interest and penalties on unrecognized tax positions of $0 and $0, respectively.

The Company and its subsidiaries are subject to United States federal income tax as well as the income tax of multiple state and foreign jurisdictions. The Company is not currently under audit in any jurisdiction for any period. Major jurisdictions where there are wholly owned subsidiaries of Tilray, Inc. which require income tax filings include the Canada, Portugal, Germany, and Australia. The earliest periods open for review by local taxing authorities are fiscal years 2016 for Canada, 2017 for Portugal, 2016 for Germany, 2017 for Australia, and 2018 for United States.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Bank indebtedness

12 Months Ended

May 31, 2021

Bank Indebtedness [Abstract]

Bank indebtedness

16.	Bank indebtedness

The Company secured an operating line of credit in the amount of C$1,000 which bears interest at the lender’s prime rate plus 75 basis points. As at May 31, 2021, the Company has not drawn on the line of credit. The operating line of credit is secured by a first charge on the property at 265 Talbot St. West, Leamington, Ontario and a first ranking position on a general security agreement.

The Company’s subsidiary, CC Pharma, has two operating lines of credit for €5,000 and €3,500 each, which bear interest at Euro Over Night Index Average plus 1.79% and Euro Interbank Offered Rate plus 3.682% respectively.

As at May 31, 2021, a total of €7,000 ($8,717) was drawn down from the available credit of €8,500. The operating lines of credit are secured by a first charge on the inventory held by CC Pharma.

The Company’s subsidiary, Four Twenty Corporation (“420”), has a revolving credit facility of $20,000 which bears interest at EURIBOR plus an applicable margin. As at May 31, 2021, the Company has not drawn any amount on the revolving line of credit. The revolving credit facility is secured by all of 420 and SweetWater’s assets and includes a corporate guarantee by the Company.

Accounts payable and accrued liabilities

12 Months Ended

May 31, 2021

Payables And Accruals [Abstract]

Accounts payable and accrued liabilities

17.	Accounts payable and accrued liabilities

Accounts payable and accrued liabilities comprised of:

	May 31,		May 31,
	2021		2020
Trade payables	$	57,706	$	41,159
Accrued liabilities		112,594		48,105
Accrued payroll and employment related taxes		19,390		—
Income taxes payable		14,764		4,651
Accrued interest		148		—
Accrued legal settlement		—		18,496
Other accruals		8,211		—
	$	212,813	$	112,411

As part of the reverse acquisition, (refer to Note 10 Business acquisitions and goodwill), the Company acquired a trademark and license agreement with Authentic Brands Group (“ABG”) for the use of the Prince trademark (“ABG Prince Agreement”). Under the ABG Prince Agreement, the Company pays a royalty on actual product sales in addition to a guaranteed minimum royalty payment of $375 on a quarterly basis until the maturity date of December 31, 2025.

Long-term debt

12 Months Ended

May 31, 2021

Long Term Debt [Abstract]

Long-term debt

18.	Long-term debt

The following table sets forth the net carrying amount of long-term debt instruments:

	May 31,			May 31,
	2021			2020
Credit facility - C$80,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2022	$	62,964		$	58,026
Term loan - C$25,000 - Canadian 5-year bond interest rate plus 2.73% with a minimum 4.50%, 5-year term, with a 15-year amortization, repayable in blended monthly payments, due in July 2023		14,335			13,231
Term loan - C$25,000 - 3.95%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly instalments of $188 including interest, due in April 2022		17,117			15,939
Term loan - C$1,250 - 3.99%, 5-year term, with a 10-year amortization, repayable in equal monthly instalments of $13 including interest, due in July 2021		587			602
Mortgage payable - C$3,750 - 3.95%, 5-year term, with a 20-year amortization, repayable in equal monthly instalments of $23 including interest, due in July 2021		2,562			2,349
Vendor take-back mortgage - C$2,850 - 6.75%, 5-year term, repayable in equal monthly instalments of $56 including interest, due in June 2021		92			508
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate + 1.79%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		3,356			4,163
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate + 2.68%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		3,356			4,163
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate + 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in April 2025		1,831			1,665
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate + 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in June 2025		1,831			—
Term loan - $100,000 - EUROBIR rate plus an applicable margin, 3-year term, repayable in quarterly instalments beginning March 31, 2021 of $7,500 in its first twelve months and $10,000 in each of the next two years, due in March 2024		98,138			—
		206,169			100,646
Deduct - unamortized financing fees		(2,061	)		(477	)
- principal portion included in current liabilities		(36,622	)		(6,141	)
	$	167,486		$	94,028

The credit facility of C$80,000 ($66,278) was entered into on November 29, 2019 by 51% owned subsidiary Aphria Diamond and is secured by a first charge on the property at 620 County Road 14, Leamington, Ontario, owned by Aphria Diamond, and a guarantee from Aphria Inc.

The term loan of C$25,000 ($20,712) was entered into on July 27, 2018 and is secured by a first charge on the property at 223, 231, 239, 265, 269, 271 and 275 Talbot Street West, Leamington Ontario, a first position on a general security agreement, and an assignment of fire insurance to the lender. The effective interest rate during the year was 4.68%.

The term loan of C$25,000 ($20,712) was entered into on May 9, 2017 and is secured by a first charge on the property at 265 Talbot Street West, Leamington Ontario, a first position on a general security agreement, and an assignment of fire insurance to the lender.

The term loan of C$1,250 ($1,036) and mortgage payable of C$3,750 ($3,108) were entered into on July 22, 2016 and are secured by a first charge on the property at 265 Talbot Street West, Leamington, Ontario and a first position on a general security agreement.

The vendor take-back mortgage payable of C$2,850 ($2,361) was entered into on June 30, 2016 in conjunction with the acquisition of the property at 265 Talbot Street West. The mortgage is secured by a second charge on the property at 265 Talbot Street West, Leamington, Ontario. The mortgage was repaid in full and the security deemed released in June 2021.

During the year ended May 31, 2021, the Company entered into a term loan for €1,500 ($2,210) through wholly owned subsidiary CC Pharma. The term loans for €9,500 ($13,955) are held through wholly-owned subsidiary CC Pharma. These term loans are secured against the distribution inventory held by CC Pharma.

During the year ended May 31, 2021, the Company, entered into a secured credit agreement for term loan of $100,000 through wholly owned subsidiary Four Twenty Corporation (“420”). The Company drew the full amount of the term loan. 420 provided all of its and SweetWater’s assets as security for the loan and Aphria Inc. provided a corporate guarantee.

As at May 31, 2021, the Company was in compliance with all the long-term debt covenants.

Convertible debentures

12 Months Ended

May 31, 2021

Debt Instruments [Abstract]

Convertible debentures

19.	Convertible debentures

The following table sets forth the net carrying amount of the convertible debentures:

	May 31,		May 31,
	2021		2020
5.25% Convertible Notes ("APHA 24")	$	399,444	$	196,405
5.00% Convertible Notes ("TLRY 23")		268,180		—
Total convertible debentures	$	667,624	$	196,405

APHA 24

	May 31,		May 31,
	2021		2020
Opening balance	$	196,405	$	305,626
Debt settlement		—		(66,127	)
Fair value adjustment		203,039		(43,094	)
	$	399,444	$	196,405

The unsecured convertible debentures were entered into in April 2019, in the principal amount of $350,000, are due in five years from issuance. The APHA 24 bears interest at a rate of 5.25% per annum, payable semi-annually in arrears on June 1 and December 1 of each year. The APHA 24 matures on June 1, 2024, unless earlier converted. The APHA 24 is an unsecured obligation and ranks senior in right of payment to all indebtedness that is expressly subordinated in right of payment to it. The APHA 24 will rank equal in right of payment with all liabilities that are not subordinated. The APHA 24 is effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness.

Holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time between December 1, 2023 to the maturity date. The initial conversion rate for the APHA 24 will be 89.31162364 shares of common stock, par value $0.0001 per share, of Tilray, Inc. per $1,000 principal amount

of Notes, which will be settled in cash, common shares of Aphria or a combination thereof, at Tilray’s election. This is equivalent to an initial conversion price of approximately $11.20 per common share, subject to adjustments in certain events. In addition, holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time preceding December 1, 2023, if:

(a)

the last reported sales price of the common shares for at least 20 trading days during a period of 30 consecutive trading days immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

(b)

during the five-business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1 principal amount of the APHA 24 for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company’s common shares and the conversion rate on each such trading day;

(c)

the Company calls any or all of the APHA 24 for redemption or;

(d)

upon occurrence of specified corporate event.

The Company may not redeem the APHA 24 prior to June 6, 2022, except upon the occurrence of certain changes in tax laws. On or after June 6, 2022, the Company may redeem for cash all or part of the Notes, at its option, if the last reported sale price of the Company’s common shares has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on and including trading day immediately preceding the date on which the Company provides notice of redemption. The redemption of the APHA 24 will be equal to 100% of the principal amount plus accrued and unpaid interest to, but excluding, the redemption date.

The Company elected the fair value option under ASC 825 Fair Value Measurements for the APHA 24. The APHA 24 was initially recognized at fair value on the balance sheet. All subsequent changes in fair value, excluding the impact of the change in fair value related to instrument-specific credit risk are recorded in non-operating income. The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income (loss).

The overall change in fair value of the APHA 24 during the year ended May 31, 2021 was an increase of $170,453 with a foreign exchange impact of $32,586 (2020 – decrease of $43,094 and $nil), which included contractual interest of $13,600 (2020 - $17,979). As at May 31, 2021, there was $259,400 principal outstanding (2020 - $259,400).

TLRY 23

	May 31,
	2021
Opening balance	$	—
Principal amount issued		277,856
Unamortized discount		(9,676	)
Net carrying amount	$	268,180

As part of the reverse acquisition (refer to Note 10 Business acquisitions and goodwill), the Company acquired convertible notes with a fair value of $277,857.

The TLRY 23 bears interest at a rate of 5.00% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. Additional interest may accrue on the TLRY 23 in specified circumstances. The TLRY 23 will mature on October 1, 2023, unless earlier repurchased, redeemed or converted. There are no principal payments required over the five-year term of the TLRY 23, except in the case of redemption or events of defaults.

The TLRY 23 is the Company’s general unsecured obligations and ranks senior in right of payment to all of the Company’s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of the Company’s unsecured indebtedness that is not so subordinated; effectively junior in right of payment

to any of Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of the Company’s current or future subsidiaries.

The Indenture includes customary covenants and sets forth certain events of default after which the convertible notes may be declared immediately due and payable, including certain types of bankruptcy or insolvency involving the Company. To the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after such event of default, consist exclusively of the right to receive additional interest on the notes. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election (the “cash conversion option”). The initial conversion rate for the convertible notes is 5.9735 shares of common stock per one thousand dollar principal amount of notes, which is equivalent to an initial conversion price of approximately $167.41 per share of common stock, which represents approximately 1,659,737 shares of common stock, based on the $277,856 aggregate principal amount of convertible notes outstanding as of May 31, 2021 (2020 - $nil). Throughout the term of the TLRY 23, the conversion rate may be adjusted upon the occurrence of certain events.

Prior to the close of business on the business day immediately preceding April 1, 2023, the TLRY 23 will be convertible only under the specified circumstances. On or after April 1, 2023 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their TLRY 23, in multiples of $1 principal amount, at the option of the holder regardless of the aforementioned circumstances.

The Company may from time to time seek to retire or purchase its TLRY 23, in open market purchases, privately negotiated transactions or otherwise. Such purchases or exchanges, if any, will depend on prevailing market conditions, the company's liquidity requirements, contractual restrictions and other factors. The amounts involved in any such transactions, individually or in the aggregate, may be material.

As of May 31, 2021, the TLRY 23 is not yet convertible. The convertible notes will become convertible upon the satisfaction of the above circumstances. The remaining unamortized debt discount related to the convertible notes as of May 31, 2021 will be accreted over the remaining term of the TLRY 23, which is approximately 28 months.

As at May 31, 2021, the Company was in compliance with all the covenants set forth under the Indenture.

During the year ended May 31, 2021, the Company recognized total interest expense of $1,585 (2020 – $nil), which included contractual interest coupon of $1,158 (2020 - $nil) and amortization of the discount of $427 (2020 - $nil).

Warrants

12 Months Ended

May 31, 2021

Warrants And Rights Note Disclosure [Abstract]

Warrants

20.

Warrants

The warrant details of the Company are as follows:

Weighted

Expiry

Number of

average

Type of warrant

Classification

date

warrants

price

Warrant

Equity

September 26, 2021

166,000

3.14

Warrant

Equity

January 30, 2022

5,828,651

9.26

Warrant

Liability

March 17, 2025

6,209,000

5.95

12,203,651

7.41

As part of the Arrangement, Aphria’s 2016 Warrants (the 200,000 warrants issued by Aphria expiring September 26, 2021) were exchanged for 166,000 Replacement Warrants (warrants to purchase Tilray shares pursuant to the Plan of Arrangement), expiring September 26, 2021.

As part of the Arrangement, Aphria’s all 2020 Warrants (the 7,022,472 warrants issued by Aphria expiring January 30, 2022), ceased to represent a warrant to acquire Aphria shares and instead represent a right to receive 5,828,651 Tilray shares in accordance with their term.

As part of the Arrangement, all outstanding Tilray Warrants which expire on March 17, 2025 remain outstanding without change to any of their terms. The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. There were no triggering events during the year ended May 31, 2021. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to affect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of common stock due to be issued multiplied by any trading price of the common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.

	May 31, 2021				May 31, 2020
			Weighted					Weighted
	Number of		average		Number of			average
	warrants		price		warrants			price
Outstanding, beginning of the year		5,994,651	$	8.91		1,903,024		$	12.01
Exercised during the year		—		—		(636,089	)		1.47
Issued during the year		6,209,000		5.95		5,828,652			9.08
Cancelled during the year		—		—		—			—
Expired during the year		—		—		(1,100,936	)		19.46
Outstanding, end of the year		12,203,651	$	7.41		5,994,651		$	8.91

The Company estimated the fair value of the warrant liability at May 31, 2021 at $12.59 per warrant using the Black Scholes pricing model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		0.90	%
Expected volatility		70	%
Expected term	4.3 years
Expected dividend yield		—	%
Strike price	$	5.95
Fair value of common stock	$	16.67

Expected volatility is based on both historical and implied volatility of the Company’s common stock.

Stock-based compensation

12 Months Ended

May 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based compensation

21.	Stock-based compensation

For the year ended May 31, 2021, the total stock-based compensation expense was $17,351 (2020 - $18,079 and 2019 - $21,951). The Company operates multiple stock-based award plans as follows:

Tilray 2018 Equity Incentive Plan and Original Plan

The 2018 Equity Incentive Plan (EIP) authorizes the award of stock options, restricted stock units (“RSUs”) and stock appreciation rights (“SARs”) to employees, including officers, non-employee directors and consultants and the employees and consultants of our affiliates. Shares subject to awards granted under the EIP that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under the EIP. Additionally, shares become available for future grant under the EIP if they were issued under the EIP and if the Company repurchases them or they are forfeited. This includes shares used to pay the

exercise price of an award or to satisfy the tax withholding obligations related to an award. The maximum number of shares of common stock subject to stock awards granted under the EIP or otherwise during any one calendar year to any non-employee director, taken together with any cash fees paid by the Company to such non-employee director during such calendar year for service on the Board of Directors, will not exceed five hundred thousand dollars in total value, calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes, or, with respect to the calendar year in which a nonemployee director is first appointed or elected to our Board of Directors, one million dollars.

Stock options represent the right to purchase shares of our common stock on the date of exercise at a stated exercise price. The exercise price of a stock option generally must be at least equal to the fair market value of our shares of common stock on the date of grant. The Company’s compensation committee may provide for stock options to be exercised only as they vest or to be immediately exercisable with any shares issued on exercise being subject to the Company’s right of repurchase that lapses as the shares vest. The maximum term of stock options granted under the EIP is ten years.

RSUs represent a right to receive common stock or their cash equivalent for each RSU that vests, which vesting may be based on time or achievement of performance conditions. Unless otherwise determined by our compensation committee at the time of grant, vesting will cease on the date the participant no longer provides services to the Company and unvested shares will be forfeited. If an RSU has not been forfeited, then on the date specified in the RSUs, the Company will deliver to the holder a number of whole shares of common stock, cash or a combination of shares of our common stock and cash. Additionally, dividend equivalents may be credited in respect of shares covered by the RSUs. Any additional shares covered by the RSU credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying RSU agreement to which they relate. The RSUs generally vest over a 3-or-4 year period. The fair value of RSUs are based on the share price as at date of grant.

SARs provide for a payment, or payments, in cash or shares of common stock to the holder based upon the difference between the fair market value of shares of our common stock on the date of exercise and the stated exercise price. The maximum term of SARs granted under the EIP is ten years. No SARs were issued to date.

The EIP permits the grant of performance-based stock and cash awards. The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates or business segments and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. The length of any performance period, the performance goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been attained will be conclusively determined by the Board of Directors.

As of April 30, 2021, 9,806,851 shares of common stock had been reserved for issuance under the EIP. The number of shares of common stock reserved for issuance under the 2018 EIP will automatically increase on January 1 of each calendar year, for a period of not more than ten years, starting on January 1, 2019 and ending on and including January 1, 2027, in an amount equal to 4% of the total number of shares of our common stock outstanding on December 31 of the prior calendar year, or a lesser number of shares determined by our Board of Directors. The shares reserved include only the outstanding shares related to stock options and RSUs and excludes stock options outstanding under the Original Plan.

Certain employees and other service providers of the Company participate in the equity-based compensation plan of Privateer Holdings, Inc (the “Original Plan”) under the terms and valuation method detailed below. The expected life of the stock options represented the period of time stock options were expected to be outstanding and was estimated considering vesting terms and employees’ historical exercise and post-vesting employment termination behavior. Expected volatility was based on historical volatilities of public companies operating in a similar industry to Privateer Holdings. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant. The expected dividend yield was determined based on the stock option’s exercise price and expected annual dividend rate at the time of grant.

No stock options were granted under the EIP during the year ended May 31, 2021. For the year ended May 31, 2020 and 2019, the fair value of each stock option granted is estimated on grant date using the Black-Scholes option pricing model using the following assumptions: risk-free rate for 2020 – 2.10% and 2019 – 2.92% on the date of grant; expected life for 2020 – 8.97 years and 2019 – 5.79 years; volatility for 2020 – 61.33% and 2019 – 58.54% based on comparable companies; dividend yield for 2020 and 2019 of $nil; and, the exercise price of the respective option. The expected life of the award is estimated using the simplified method since the Company does not have adequate historical exercise data to estimate the expected term.

Stock-based activity under the EIP and Original Plan for the year ended May 31, 2021 is as follows:

EIP Time-based stock option activity
	Stock Options			Weighted- average exercise price		Weighted- average remaining contractual term (years)		Aggregate intrinsic value
Balance May 1,		3,182,547		$	14.19		1.7	$	30,331,823
Granted		—			—		—		—
Exercised		(1,665	)		7.76		—		—
Forfeited		(188	)		7.76		—		—
Cancelled		(468	)		65.20		—		—
Balance May 31,		3,180,226		$	14.19		1.3	$	25,171,187

Original plan time-based stock option activity
	Stock Options			Weighted- average exercise price		Weighted- average remaining contractual term (years)		Aggregate intrinsic value
Balance May 1,		946,948			3.99		2		13,777,571
Exercised		(29,403	)		4.71		—		—
Forfeited		—			—		—		—
Cancelled		—			—		—		—
Balance May 31,		917,545		$	3.97		1.7	$	11,885,699

Time-based RSU activity
	Time-based RSUs			Weighted-average grant-date fair value per share		Weighted-average remaining contractual term (years)		Aggregate intrinsic value
Balance May 1,		1,285,134		$	15.70		—		—
Granted		198,521			7.76		—		—
Vested		(112,508	)		12.99		—		—
Forfeited		(165,904	)		11.97		—		—
Cancelled		—			—		—		—
Balance May 31,		1,205,243		$	15.16		—	$	20,091,286

Predecessor Plan - Aphria

Prior to the reverse acquisition (Note 10), Aphria had established the Aphria Omnibus Incentive Plan (the “Predecessor Plan”). Following stockholder approval of the EIP, no new awards have been granted under the Predecessor Plan. In connection with the reverse acquisition Aphria stock options, Aphria RSUs and DSUs issued under the Predecessor Plan were exchanged for options, RSUs under the EIP. As a result of the modification, all grantees were affected, and the Company recognized nil incremental compensation cost.

The fair value of each stock option granted under the Predecessor Plan is estimated on grant date using the Black-Scholes option pricing model using the following assumptions: risk-free rate of 0.39% (2020 – 1.20 – 1.56% and 2019 – 1.66 – 2.38%) on the date of grant; expected life of 5 years (2020 - 5 years and 2019 – 3 - 5 years); volatility of 70% (2020 and 2019 – 70%) based on comparable companies; forfeiture rate of 35% (2020 – 20% and 2019 – 0%); dividend yield of $nil (2020 and 2019 – $nil); and, the exercise price of the respective option. The expected life of the award is estimated using the simplified method since the Company does not have adequate historical exercise data to estimate the expected term.

Stock option, RSU and DSU activity for the Company under the Predecessor Plan is as follows:

Time-based stock option activity

	May 31, 2021
						Weighted		Weighted
				Weighted		average		average
				average		grant		remaining		Aggregate
	Number of			exercise		date fair		contractual		Intrinsic
	options			price		value		term (years)		Amount
Outstanding, beginning of the year		4,484,051		$	12.04	$	6.24		2.9		(32,781	)
Exercised during the year		(1,073,986	)		8.70	$	4.38	N/A		N/A
Granted during the year		41,500			5.88	$	2.18	N/A		N/A
Forfeited during the year		(884,320	)		14.06	$	7.46	N/A		N/A
Expired during the year		(68,060	)		18.72	$	8.80	N/A		N/A
Outstanding, end of the year		2,499,185		$	12.48	$	6.51		2.4		10,472
Vested and exercisable, end of the year		1,846,090		$	13.53	$	7.16		2.2		5,797

During the year ended May 31, 2021, the Company issued 41,500 stock options at an exercise price of $5.88 per share, exercisable for 5 years to officers of the Company. The weighted-average grant date fair values of time-based stock options granted during the year ended May 31, 2021 was $2.18 per share (2020 - $3.54 and 2019 - $7.32). The total intrinsic values of these stock options exercised during the year ended May 31, 2021 was $4,679,758 (2020 - $4,869,447 and 2019 - $28,025,979). The total fair value of time-based stock options vested during the year ended May 31, 2021 was $3,054,257 (2020 - $9,592,767 and 2019 - $14,983,131).

As of May 31, 2021, the total remaining unrecognized compensation expenses related to non-vested time-based stock options amounted to $3,058,733 (2020 - $8,209,817 and 2019 - $17,110,533), which will be amortized over the weighted-average remaining requisite service period of approximately 1.06 years (2020 – 1.53 years and 2019 – 1.52 years).

Performance-based stock option activity

	May 31, 2021
						Weighted		Weighted
				Weighted		average		average
				average		grant		remaining		Aggregate
	Number of			exercise		date fair		contractual		Intrinsic
	options			price		value		term (years)		Amount
Outstanding, beginning of the year		398,400		$	8.11	$	3.80	0.6			(1,347	)
Exercised during the year		(166,000	)	$	5.15	$	2.38	N/A		N/A
Granted during the year		—			—		—	N/A		N/A
Forfeited during the year		(232,400	)	$	10.23	$	4.81	N/A		N/A
Expired during the year		—			—		—	N/A		N/A
Outstanding, end of the year		—			—		—		—		—
Vested and exercisable, end of the year		—			—		—		—		—

The weighted-average grant date fair values of performance-based stock options granted during the year ended May 31, 2021 was $N/A per share (2020 - $N/A and 2019 - $N/A). The total intrinsic values of these stock options exercised during the year ended May 31, 2021 was $746,743 (2020 - $326,033 and 2019 - $1,864,100). The total fair value of performance-based stock options vested during the year ended May 31, 2021 was $395,138 (2020 - $222,721 and 2019 - $461,188).

As of May 31, 2021, the total remaining unrecognized compensation expenses related to non-vested performance-based stock options amounted to $N/A (2020 - $1,074,701 and 2019 - $1,206,415), which will be amortized over the weighted-average remaining requisite service period of approximately N/A years (2020 – 0.58 years and 2019 – 0.76 years).

Time-based and Performance-based RSU activity

As of May 31, 2021, the total remaining unrecognized compensation expenses related to non-vested time-based RSUs amounted to $16,273,457 (2020 - $10,240,001 and 2019 - $1,392,478), which will be amortized over the weighted-average remaining requisite service period of approximately 1.03 years (2020 – 1.44 years and 2019 – 0.54 years). The total intrinsic values of the time-based RSUs exercised during the year ended May 31, 2021 was $10,905,991 (2020 - $5,123,883 and 2019 - $775,962). The total fair value of time-based RSUs vested during the year ended May 31, 2021 was $8,777,963 (2020 - $4,507,883 and 2019 - $2,044,952).

	May 31, 2021
				Weighted						Weighted
				average						average
				grant -						grant -
				date fair			Performance-			date fair
	Time- based			value per			based			value per
	RSUs			share			RSUs			share
Non-vested, beginning of the year		1,588,743		$	7.71			19,335		$	6.01
Granted during the year		2,370,862		$	6.24			—			—
Vested during the year		(1,006,222	)	$	(6.83	)		—			—
Forfeited during the year		(158,411	)	$	(6.68	)		(19,335	)	$	(6.01	)
Non-vested, end of the year		2,794,972		$	6.88			—			—

Accumulated other comprehensive loss

12 Months Ended

May 31, 2021

Equity [Abstract]

Accumulated other comprehensive loss

22.	Accumulated other comprehensive loss

Accumulated other comprehensive loss includes the following components:

	Foreign currency translation (loss) gain			Unrealized loss on convertible notes receivables			Total
Balance May 31, 2018	$	110		$	2,844		$	2,954
Other comprehensive income (loss)		(90	)		(2,570	)		(2,660	)
Elimination of CTA on disposal of equity investee		606			—			606
Balance May 31, 2019		626			274			900
Other comprehensive income (loss)		(858	)		(5,476	)		(6,334	)
Balance May 31, 2020		(232	)		(5,202	)		(5,434	)
Settlement of convertible notes receivable		—			5,277			5,277
Other comprehensive income (loss)		156,649			(3,824	)		152,825
Balance May 31, 2021	$	156,417		$	(3,749	)	$	152,668

Non-controlling interests

12 Months Ended

May 31, 2021

Text Block [Abstract]

Non-controlling interests

23.	Non-controlling interests

The following tables summarise the information relating to the Company’s subsidiaries, CC Pharma Nordic ApS, Aphria Diamond, Marigold Projects Jamaica Limited (“Marigold”), and ColCanna S.A.S. before intercompany eliminations.

Non-controlling interests as at May 31, 2021:

	CC Pharma			Aphria					ColCanna			May 31,
	Nordic ApS			Diamond			Marigold		S.A.S.			2021
Current assets	$	919		$	19,531		$	—	$	315		$	20,765
Non-current assets		103			153,696			—		146,587			300,386
Current liabilities		(956	)		(28,511	)		—		(62	)		(29,529	)
Non-current liabilities		(406	)		(69,332	)		—		(6,606	)		(76,344	)
Net assets		(340	)		75,384			—		140,234			215,278

Non-controlling interests as at May 31, 2020:

	Aphria					ColCanna			May 31,
	Diamond			Marigold		S.A.S.			2020
Current assets	$	25,957		$	—	$	547		$	26,504
Non-current assets		156,251			—		83,857			240,108
Current liabilities		(11,337	)		—		(274	)		(11,611	)
Non-current liabilities		(128,031	)		—		(24,471	)		(152,502	)
Net assets		42,840			—		59,659			102,499

Non-controlling interests for the year ended May 31, 2021:

	CC Pharma			Aphria					ColCanna			May 31,
	Nordic ApS			Diamond			Marigold		S.A.S.			2021
Revenue	$	827		$	131,381		$	—	$	—		$	132,208
Total expenses (recovery)		(958	)		(67,030	)		—		(923	)		(68,911	)
Net (loss) income		(131	)		64,351			—		(923	)		63,297
Other comprehensive (loss) income		—			—			—		—		$	—
Net comprehensive income		(131	)		64,351			—		(923	)		63,297

Non-controlling interests for the year ended May 31, 2020:

	Aphria					ColCanna		May 31,
	Diamond			Marigold		S.A.S.		2020
Revenue	$	24,142		$	40	$	—	$	24,182
Total expenses (recovery)		(25,141	)		4,995		19,447		(699	)
Net (loss) income		(999	)		5,035		19,447		23,483
Other comprehensive (loss) income		—			—		—	$	—
Net comprehensive loss		(999	)		5,035		19,447		23,483

Non-controlling interests for the year ended May 31, 2019:

	Aphria Diamond			CannInvest Africa Ltd.			Verve Dynamics			Nuuvera Malta Ltd.			Marigold			ColCanna S.A.S.			May 31, 2019
Revenue	$	—		$	—		$	—		$	174		$	—		$	—		$	174
Total expenses (recovery)		(21,273	)	$	(8	)	$	(634	)		(791	)		(572	)		(942	)		(24,220	)
Net (loss) income		(21,273	)		(8	)		(634	)		(617	)		(572	)		(942	)		(24,046	)
Other comprehensive (loss) income		—			—			—			—			—			—
Net comprehensive loss		(21,273	)		(8	)		(634	)		(617	)		(572	)		(942	)		(24,046	)

Net revenue

12 Months Ended

May 31, 2021

Revenues [Abstract]

Net revenue

24.	Net revenue

Net revenue is comprised of:

	For the year ended May 31,
	2021			2020			2019
Cannabis revenue	$	264,334			153,477			67,592
Cannabis excise taxes		(62,942	)		(23,581	)		(7,716	)
Net cannabis revenue		201,392			129,896			59,876
Beverage alcohol revenue		29,661			—			—
Beverage alcohol excise taxes		(1,062	)		—			—
Net beverage alcohol revenue		28,599			—			—
Distribution revenue		277,300			275,430			119,427
Wellness revenue		5,794			—			—
	$	513,085		$	405,326		$	179,303

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Cost of goods sold

12 Months Ended

May 31, 2021

Cost Of Goods And Services Sold [Abstract]

Cost of goods sold

25.	Cost of goods sold

Cost of goods sold is comprised of:

	For the year ended May 31,
	2021		2020		2019
Cannabis costs	$	130,511		68,551		31,341
Beverage alcohol costs		12,687		—		—
Distribution costs		242,472		240,722		104,451
Wellness costs		4,233		—		—
	$	389,903	$	309,273	$	135,792

General and administrative expenses

12 Months Ended

May 31, 2021

General And Administrative Expense [Abstract]

General and administrative expenses

26.	General and administrative expenses

General and administrative expenses are comprised of the following items:

	For the year ended May 31,
	2021		2020		2019
Executive compensation	$	8,645	$	6,777	$	4,402
Consulting fees		6,633		9,272		4,928
Office and general		19,503		12,351		12,486
Professional fees		5,146		4,918		8,916
Salaries and wages		37,126		28,252		14,842
Stock-based compensation		17,351		18,079		21,951
Insurance		12,257		9,370		4,050
Travel and accommodation		2,711		2,798		2,356
Rent		2,203		1,972		1,910
	$	111,575	$	93,789	$	75,841

Finance income (expense), net

12 Months Ended

May 31, 2021

Finance Income Expense Net [Abstract]

Finance income (expense), net

27.	Finance income (expense), net

Finance income (expense), net is comprised of:

	For the year ended May 31,
	2021			2020			2019
Interest income	$	2,926		$	6,273		$	11,138
Interest expense		(30,903	)		(25,644	)		(5,879	)
	$	(27,977	)	$	(19,371	)	$	5,259

Non-operating (expense) income

12 Months Ended

May 31, 2021

Nonoperating Income Expense [Abstract]

Non-operating (expense) income

28.	Non-operating (expense) income

Non-operating (expense) income is comprised of:

	For the year ended May 31,
	2021			2020			2019
Foreign exchange (loss) gain	$	(22,347	)	$	6,145		$	692
Loss on marketable securities		—			(252	)		(135	)
Gain (loss) on sale of capital assets		1,523			(8,075	)		42
(Loss) gain from equity investees		(458	)		—			44,191
Deferred gain on sale of intellectual property		—			—			257
Loss on promissory notes receivable		—			(9,698	)		—
(Loss) gain on long-term investments		(2,352	)		(24,295	)		14,860
Unrealized (loss) gain on convertible debentures		(170,453	)		44,322			36,630
Realized gain on settlement of convertible debentures		—			9,289			—
Legal settlement		—			(3,241	)		—
Unrealized loss on financial liabilities		—			—			(1,003	)
Change in fair value of warrant liability		1,234			—			—
Other non-operating items, net		8,015			—			—
	$	(184,838	)	$	14,195		$	95,534

Change in non-cash working capital

12 Months Ended

May 31, 2021

Change In Non Cash Working Capital [Abstract]

Change in non-cash working capital

29.	Change in non-cash working capital

Change in non-cash working capital is comprised of:

	For the year ended May 31,
	2021			2020			2019
Decrease (increase) in:
Accounts receivable	$	(23,512	)	$	(25,593	)	$	9,421
Prepaids and other current assets		(6,772	)		(10,899	)		4,322
Inventory		(35,286	)		(89,660	)		(26,069	)
Increase (decrease) in:
Accounts payable and accrued liabilities		14,501			47,335			(8,984	)
Deferred revenue		134			(15	)		8,839
	$	(50,935	)	$	(78,832	)	$	(12,471	)

Commitments and contingencies

12 Months Ended

May 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and contingencies

30.	Commitments and contingencies

Purchase and other commitments

The Company has payments on long-term debt (refer to Note 18 Long-term debt), convertible notes (refer to Note 19 Convertible Debentures), ABG finance liability (refer to Note 17 Accounts payable and accrued liabilities) material purchase commitments and construction commitments as follows:

	Total		2022		2023		2024		2025		2026		Thereafter
Long-term debt repayment	$	204,108		36,623		69,925		95,181		1,438		941		—
Convertible notes, principal and interest		571,989		13,893		13,893		284,803		259,400		—		—
ABG finance liability		6,000		1,500		1,500		1,500		1,500		—		—
Material purchase obligations		26,097		21,141		4,009		854		93		—		—
Construction commitments		1,814		1,814		—		—		—		—		—
Total	$	810,008	$	74,971	$	89,327	$	382,338	$	262,431	$	941	$	—

Legal proceedings

From time to time, the Company and/or its subsidiaries may become defendants in legal actions arising out of the ordinary course and conduct of its business. As of May 31, 2021, in the opinion of management, no claims meet the criteria to record a loss contingency.

Financial risk management and financial instruments

12 Months Ended

May 31, 2021

Financial Risk Management And Financial Instruments [Abstract]

Financial risk management and financial instruments

31.	Financial risk management and financial instruments

Financial instruments

The Company has classified its financial instruments as described in Note 3 Significant accounting policies.

The carrying values of accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

The Company’s long-term debt of $20,358 (2020 - $19,398) is subject to fixed interest rates. The Company’s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for Government of Canada securities of similar duration. In each period thereafter, the incremental premium is held constant while the Government of Canada security is based on the then current market value to derive the discount rate.

Fair value hierarchy

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. Cash and cash equivalents are Level 1. The hierarchy is summarized as follows:

Level 1

Quoted prices (unadjusted) in active markets for identical assets and liabilities

Level 2

Inputs that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices) from observable market data

Level 3

Inputs for assets and liabilities not based upon observable market data

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of May 31, 2021 and 2020 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

								May 31,
	Level 1		Level 2		Level 3			2021
Financial assets
Cash and cash equivalents	$	488,466	$	—	$	—		$	488,466
Convertible notes receivable		—		2,485		—			2,485
Long-term investments		9,251		2,934		—			12,185
Financial liabilities
Warrant liability		—		—		(78,168	)		(78,168	)
Contingent consideration		—		—		(60,657	)		(60,657	)
APHA 24 Convertible debenture		—		—		(399,444	)		(399,444	)
Total recurring fair value measurements	$	497,717	$	5,419	$	(538,269	)	$	(35,133	)

								May 31,
	Level 1		Level 2		Level 3			2020
Financial assets
Cash and cash equivalents	$	360,646	$	—	$	—		$	360,646
Convertible notes receivable		—		10,609		—			10,609
Long-term investments		11,244		8,351		—			19,595
Financial liabilities
APHA 24 Convertible debenture		—		—		(196,405	)		(196,405	)
Total recurring fair value measures	$	371,890	$	18,960	$	(196,405	)	$	194,445

The Company’s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration, and warrant liability.

Convertible notes receivable and long-term investments recorded at fair value: The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash flows and is classified as Level 2.

Warrant liability: The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

APHA 24: This instrument is held at fair value. The estimated fair value is determined using the Black Scholes option pricing model and is classified as Level 3.

Contingent consideration: The contingent consideration from the acquisition of SweetWater is determined by discounting future expected cash outflows at a discount rate of 5%. The inputs into the future expected cash outflows are classified as Level 3.

The opening balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled to the closing balances as follows:

	APHA 24
	Convertible			Warrant			Contingent
	debenture			liability			consideration			Total
Closing balance May 31, 2020	$	(196,405	)	$	—		$	—		$	(196,405	)
Additions		—			(79,402	)		(58,959	)		(138,361	)
Disposals		—			—			—			—
Unrealized gain (loss) on fair value		(203,039	)		1,234			(1,698	)		(203,503	)
Closing balance May 31, 2021	$	(399,444	)	$	(78,168	)	$	(60,657	)	$	(538,269	)

The unrealized gain (loss) on fair value for the Convertible Debenture and the warrant liability is recognized in non-operating income (loss) using the following inputs:

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 3 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 4 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%

Items measured at fair value on a non-recurring basis

The Company's prepayments and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Financial risk management

The Company has exposure to the following risks from its use of financial instruments: credit; liquidity; currency rate; interest rate price; equity price risk; and capital management risk.

(a)

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The maximum credit exposure at May 31, 2021, is the carrying amount of cash and cash equivalents, accounts receivable, prepaids and other current assets, promissory notes receivable and convertible notes receivable. All cash and cash equivalents are placed with major financial institutions in Canada, Australia, Portugal, Germany, Colombia, Argentina and the United States. To date, the Company has not experienced any losses on its cash deposits. Accounts receivable are unsecured, and the Company does not require collateral from its customers.

The Company evaluates the collectability of its accounts receivable and maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in the existing accounts receivable portfolio as of the reporting dates based on the estimate of expected net credit losses.

Trade receivables included an allowance for doubtful accounts of $4,571 at May 31, 2021 (2020-$2,313), and is comprised of the following aged receivables:

	Total		0-30 days			31-60 days			61-90 days			90+ days
Trade receivables	$	87,309		70,997			8,253			1,051			7,008
				82	%		9	%		1	%		8	%

Due to the uncertainties associated with COVID-19, the Company may be unable to accurately predict the creditworthiness of its counterparties and their ability to meet their obligations. This may result in unforeseen additional credit losses.

(b)

Liquidity risk

As at May 31, 2021, the Company’s financial liabilities consist of bank indebtedness and accounts payable and accrued liabilities, which have contractual maturity dates within one-year, long-term debt, and convertible debentures which have contractual maturities over the next five years.

The Company maintains a debt service charge covenant on certain loans secured by its Aphria One facilities that is measured at year-end only. The Company maintains debt service charge and leverage covenants on certain loans secured by its Aphria Diamond facilities and 420 that are measured quarterly. The Company believes that it has sufficient operating room with respect to its financial covenants for the next fiscal year and does not anticipate being in breach of any of its financial covenants.

The Company manages its liquidity risk by reviewing its capital requirements on an ongoing basis. Based on the Company’s working capital position at May 31, 2021, management regards liquidity risk to be low.

(c)

Currency rate risk

As at May 31, 2021, a portion of the Company’s financial assets and liabilities held in Canadian dollars and Euros consist of cash and cash equivalents, convertible notes receivable, and long-term investments. The Company’s objective in managing its foreign currency risk is to minimize its net exposure to foreign currency cash flows by transacting, to the greatest extent possible, with third parties in the functional currency. The Company is exposed to currency rate risk in other comprehensive income, relating to foreign subsidiaries which operate in a foreign currency. The Company does not currently use foreign exchange contracts to hedge its exposure of its foreign currency cash flows as management has determined that this risk is not significant at this point in time.

(d)

Interest rate price risk

The Company’s exposure to changes in interest rates relates primarily to the Company’s outstanding debt. The Company manages interest rate risk by restricting the type of investments and varying the terms of maturity and issuers of marketable securities. Varying the terms to maturity reduces the sensitivity of the portfolio to the impact of interest rate fluctuations.

(e)

Equity price risks

As of May 31, 2021, the Company held long-term equity investments at fair value and equity investments under the measurement alternative. These investment in equities were acquired as part of our strategic transactions. Accordingly, the changes in fair values of investment in equities measured at fair value or under the measurement alternative are recognized through gain (loss) on long-term investment in the statements of net loss and comprehensive loss. Based on the fair value of investment in equities held as of May 31, 2021, a hypothetical decrease of 10% in the prices for these companies would reduce the fair values of the investments and result in unrealized loss recorded in gain (loss) on long-term investment by $1,769.

Similarly, based on the fair value of our warrant liability as of May 31, 2021, a hypothetical increase of 10% in the price for our common stock would increase the change in fair value of warrant liability and result in unrealized gain recorded in non-operating income by $9,800.

(f)

Capital management

The Company’s objectives when managing its capital are to safeguard its ability to continue as a going concern, to meet its capital expenditures for its continued operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, issue new debt, or acquire or dispose of assets. The Company is not subject to externally imposed capital requirements.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company’s capital management approach in the year. The Company considers its cash and cash equivalents and marketable securities as capital.

Segment reporting

12 Months Ended

May 31, 2021

Segment Reporting [Abstract]

Segment reporting

32.	Segment reporting

Information reported to the Chief Operating Decision Maker (“CODM”) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in five segments. 1) cannabis operations, which encompasses the production, distribution and sale of both medical and adult-use cannabis, 2) beverage alcohol operations, which encompasses cultivation, distribution and sale of beverage alcohol products, 3) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers, 4) wellness products, which encompasses hemp foods and cannabidiol (“CBD”) products and 5) businesses under development which encompass operations in which the Company has not received final licensing or has not commenced commercial sales from operations. Factors considered in determining the operating segments include the Company’s business activities, the management structure directly accountable to the CODM, availability of discrete financial information and strategic priorities within the organizational structure. Operating segments have not been aggregated and no asset information is provided for the segments because the Company’s CODM does not receive asset information by segment on a regular basis.

Segment net revenue from external customers:

	For the year ended May 31,
	2021		2020		2019
Cannabis business	$	201,392	$	129,896	$	59,876
Distribution business		277,300		275,430		119,427
Beverage alcohol business		28,599		—		—
Wellness business		5,794		—		—
Business under development		—		—		—
Total net revenue	$	513,085	$	405,326	$	179,303

Channels of Cannabis revenue were as follows:

	For the year ended May 31,
	2021			2020			2019
Revenue from medical cannabis products	$	25,539		$	28,685		$	33,017
Revenue from adult-use cannabis products		222,930			112,207			30,236
Revenue from wholesale cannabis products		6,615			12,585			4,339
Revenue from international cannabis products		9,250			—			—
Less excise tax		(62,942	)		(23,581	)		(7,716	)
Total net cannabis revenue	$	201,392		$	129,896		$	59,876

Geographic net revenue:

	For the year ended May 31,
	2021		2020		2019
North America	$	229,120	$	129,663	$	59,629
EMEA		279,062		271,291		116,578
Latin America		4,903		4,372		3,096
Total net revenue	$	513,085	$	405,326	$	179,303

Geographic capital assets:

	May 31, 2021		May 31, 2020
North America		504,575	$	371,823
EMEA		140,838		44,348
Latin America		5,285		4,535
Total capital assets	$	650,698	$	420,706

Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. For the years ended May 31, 2021, 2020, and 2019 there were no major customers representing greater than 10% of our annual revenues.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Quarterly financial data (unaudited)

12 Months Ended

May 31, 2021

Quarterly Financial Information Disclosure [Abstract]

Quarterly financial data (unaudited)

33.	Quarterly financial data (unaudited)

The following table contains selected quarterly data for 2021 and 2020. information should be read in conjunction with the Company’s financial statements and related notes included elsewhere in this report. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

	For the three months ended
	August 31, 2020			November 30, 2020			February 28, 2021			May 31, 2021
Net revenue	$	117,490		$	129,459			123,900			142,236
Gross profit		34,945			35,283			30,456			22,498
Net income (loss)		(21,744	)		(89,249	)		(258,626	)		33,605
Net income (loss) attributable to Tilray shareholders		(32,958	)		(100,811	)		(280,856	)		47,204
Earnings (loss) per share - basic		(0.09	)		(0.37	)		(0.97	)		0.18
Earnings (loss) per share - fully diluted		(0.09	)		(0.37	)		(0.97	)		0.18

	For the three months ended
	August 31, 2019		November 30, 2019			February 29, 2020			May 31, 2020
Net revenue	$	94,078	$	89,967		$	107,739		$	113,542
Gross profit		20,555		21,812			25,879			27,807
Net income (loss)		1,435		(6,265	)		(11,699	)		(84,306	)
Net income (loss) attributable to Tilray shareholders		1,564		(5,996	)		(11,003	)		(87,105	)
Earnings (loss) per share - basic		0.01		(0.03	)		(0.05	)		(0.39	)
Income (loss) per share - fully diluted		0.01		(0.03	)		(0.05	)		(0.39	)

Significant accounting policies (Policies)

12 Months Ended

May 31, 2021

Accounting Policies [Abstract]

Cash and cash equivalents

Accounts receivable

Inventory

Inventory consists of our cannabis, wellness, beverage, and distribution inventory, as follows:

Distribution inventory includes costs related to procurement of pharmaceutical products for re-sale in entities’ respective markets.

Capital assets

Asset type	Depreciation method	Depreciation term (estimated useful life)
Land	Not depreciated	No term
Production facility	Straight-line	20 – 30 years
Equipment	Straight-line	3 – 25 years
Leasehold improvements	Straight-line	Lesser of estimated useful life or lease term
Construction in progress	Not depreciated	No term
Finance lease right-of-use assets	Straight-line	Lesser of the lease term and the useful life of the leased asset

The estimated residual values and useful lives are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

Intangible assets

Amortization of definite life intangible assets is calculated on a straight -line basis over the estimated useful lives of the assets using the following terms:

Asset type	Amortization term
Customer relationships and distribution channel	14 – 16 years
Licences, permits & applications	90 months – indefinite
Brands, intellectual property and trademarks	15 months – 25 years
Non-compete agreements	Over term of non-compete
Know how	5 years

The estimated useful lives are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

Impairment of long-lived assets

Business combinations and goodwill

Impairment of goodwill and indefinite-lived intangible assets

Leases

•

ownership of the property transfers to the lessee by the end of the lease term;

•

the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise;

•

the lease is for a major part of the remaining economic life of the underlying asset;

•

the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.

The Company classifies a lease as an operating lease when it does not meet any one of these criteria.

Lease payments included in the measurement of the lease liability comprise:

•

fixed lease payments (including in-substance fixed payments), less any lease incentives;

•

variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date;

•

the amount expected to be payable by the lessee under residual value guarantees;

•

the exercise of purchase options, if the lessee is reasonably certain to exercise the options; and

•

payments of penalties for early termination of a lease unless the Company is reasonably certain not to terminate early.

Convertible notes receivable

Long-term investments

Equity method investments

Convertible debentures

Warrants

Fair value measurements

Income taxes

Revenue

In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates.

In determining the transaction price for the sale of goods, the Company considers the effects of variable consideration and the existence of significant financing components, if any.

Cost of goods sold

General and administrative

Selling

Marketing and promotions

Marketing and promotion

Marketing and promotion expenses are comprised primarily of marketing and advertising expenses.

Research and development

Stock-based compensation

Earnings (loss) per share

Critical accounting estimates and judgments

Financial statement areas that require significant judgement are as follows:

The fair value of long-term investments and convertible notes receivable may need to be adjusted if:

•

The investee company is placed into receivership or bankruptcy;

•

Based on financial information received from the investee company, it is apparent to the Company that the investee company is unlikely to be able to continue as a going concern;

•

Recent accounting pronouncements adopted/not yet adopted

New accounting pronouncements not yet adopted

Basis of preparation (Tables)

12 Months Ended

May 31, 2021

Basis Of Preparation [Abstract]

List of Company's Operating Subsidiaries

The following is a list of the Company’s operating subsidiaries:

Subsidiaries	Jurisdiction of incorporation	Ownership interest
Natura Naturals Inc.	Canada	100%
Tilray, Inc.	United States	100%
Manitoba Harvest USA LLC	United States	100%
Tilray Canada, Ltd.	Canada	100%
Dorada Ventures, Ltd.	Canada	100%
FHF Holdings Ltd.	Canada	100%
High Park Farms Ltd.	Canada	100%
Tilray Deutschland GmbH	Germany	100%
Pardal Holdings, Lda.	Portugal	100%
Tilray Portugal Unipessoal, Lda.	Portugal	100%
Tilray Australia New Zealand Pty. Ltd.	Australia	100%
Tilray Ventures Ltd.	Ireland	100%
Manitoba Harvest Japan K.K.	Japan	100%
High Park Holdings, Ltd.	Canada	100%
Fresh Hemp Foods Ltd.	Canada	100%
Natura Naturals Holdings Inc.	Canada	100%
National Cannabinoid Clinics Pty Ltd.	Australia	100%
Tilray Latin America SpA	Chile	100%
Tilray Portugal II, Lda.	Portugal	100%
High Park Gardens Inc.	Canada	100%
1197879 B.C. Ltd	Canada	100%
High Park Shops Inc.	Canada	100%
Privateer Evolution, LLC	United States	100%
Tilray France SAS	France	100%
High Park Holdings B.V.	Netherlands	100%
High Park Botanicals B.V.	Netherlands	100%
Broken Coast Cannabis Ltd.	British Columbia, Canada	100%
SweetWater Brewing Company, LLC	United States	100%
SweetWater Colorado Brewing Co.	United States	100%
ARA – Avanti Rx Analytics Inc.	Ontario, Canada	100%
FL Group S.r.l.	Italy	100%
ABP, S.A.	Argentina	100%
Aphria Germany GmbH	Germany	100%
Aphria RX GmbH	Germany	100%
CC Pharma GmbH	Germany	100%
CC Pharma Research and Development GmbH	Germany	100%
Aphria Wellbeing GmbH	Germany	100%
CC Pharma Luxemburg GmbH	Luxemburg	100%
ASG Pharma Ltd.	Malta	100%
ColCanna S.A.S.	Colombia	90%
CC Pharma Nordic ApS	Denmark	75%
1974568 Ontario Ltd.	Ontario, Canada	51%

Significant accounting policies (Tables)

12 Months Ended

May 31, 2021

Accounting Policies [Abstract]

Summary of Depreciation Calculation

Asset type	Depreciation method	Depreciation term (estimated useful life)
Land	Not depreciated	No term
Production facility	Straight-line	20 – 30 years
Equipment	Straight-line	3 – 25 years
Leasehold improvements	Straight-line	Lesser of estimated useful life or lease term
Construction in progress	Not depreciated	No term
Finance lease right-of-use assets	Straight-line	Lesser of the lease term and the useful life of the leased asset

Capital asset consisted of the following:

	Land			Production facility			Equipment			Leasehold improvements			ROU assets under finance lease			Construction in process			Total capital assets
Cost:
At May 31, 2019	$	24,047		$	168,614		$	57,755		$	896		$	—		$	126,338		$	377,650
Additions		—			3,342			15,691			925			—			75,557			95,515
Transfers		54			27,968			81,112			11,996			—			(121,130	)		—
Disposals		—			—			(5,339	)		—			—			(4,147	)		(9,486	)
Impairment		(11	)		(2,561	)		(34	)		(89	)		—			(1,602	)		(4,297	)
Effect of foreign exchange		(2	)		(505	)		(2,117	)		(345	)		—			1,476			(1,493	)
At May 31, 2020		24,088			196,858			147,068			13,383			—			76,492			457,889
Business acquisition		5,538			55,916			35,045			1,560			35,519			46,151			179,729
Additions		261			3,236			6,284			525			—			25,773			36,079
Transfers		—			63,159			11,189			—			—			(74,348	)		—
Disposals		(5,237	)		—			(513	)		(192	)		—			—			(5,942	)
ROU Amortization		—			—			—			—			(827	)		—			(827	)
Effect of foreign exchange		3,899			27,341			16,335			1,783			34			11,254			60,646
At May 31, 2021	$	28,549		$	346,510		$	215,408		$	17,059		$	34,726		$	85,322		$	727,574
Accumulated amortization:
At May 31, 2019	$	—		$	5,556		$	6,469		$	137		$	—		$	—		$	12,162
Amortization		—			10,134			14,551			336			—			—			25,021
At May 31, 2020		—			15,690			21,020			473			—			—			37,183
Amortization		—			14,007			24,996			690			—			—			39,693
At May 31, 2021	$	—		$	29,697		$	46,016		$	1,163		$	—		$	—		$	76,876
Net book value:
At May 31, 2019	$	24,047		$	163,058		$	51,286		$	759		$	—		$	126,338		$	365,488
At May 31, 2020	$	24,088		$	181,168		$	126,048		$	12,910		$	—		$	76,492		$	420,706
At May 31, 2021	$	28,549		$	316,813		$	169,392		$	15,896		$	34,726		$	85,322		$	650,698

Summary of Estimated Useful Lives of Definite Life Intangible Assets

Amortization of definite life intangible assets is calculated on a straight -line basis over the estimated useful lives of the assets using the following terms:

Asset type	Amortization term
Customer relationships and distribution channel	14 – 16 years
Licences, permits & applications	90 months – indefinite
Brands, intellectual property and trademarks	15 months – 25 years
Non-compete agreements	Over term of non-compete
Know how	5 years

Prepaids and other current assets (Tables)

12 Months Ended

May 31, 2021

Prepaid Expense And Other Assets Current [Abstract]

Summary of prepaids and other current assets

Prepaids and other current assets are comprised of:

	May 31, 2021		May 31, 2020
Prepaid assets	$	31,012		13,760
Sales tax receivable		9,331		8,464
Prepaid corporate taxes		—		4,670
Other		8,577		5,766
	$	48,920	$	32,660

Inventory (Tables)

12 Months Ended

May 31, 2021

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory is comprised of:

	May 31, 2021		May 31, 2020
Plants	$	23,083	$	12,288
Dried cannabis		118,269		59,045
Cannabis trim		2,931		2,796
Cannabis derivatives		24,158		19,496
Cannabis vapes		3,791		4,124
Packaging and other inventory items		31,462		16,398
Wellness inventory		15,171		—
Beverage alcohol inventory		5,402		—
Distribution inventory		32,162		25,634
Total inventory	$	256,429	$	139,781

Capital assets (Tables)

12 Months Ended

May 31, 2021

Property Plant And Equipment [Abstract]

Summary of Depreciation Calculation

Asset type	Depreciation method	Depreciation term (estimated useful life)
Land	Not depreciated	No term
Production facility	Straight-line	20 – 30 years
Equipment	Straight-line	3 – 25 years
Leasehold improvements	Straight-line	Lesser of estimated useful life or lease term
Construction in progress	Not depreciated	No term
Finance lease right-of-use assets	Straight-line	Lesser of the lease term and the useful life of the leased asset

Capital asset consisted of the following:

	Land			Production facility			Equipment			Leasehold improvements			ROU assets under finance lease			Construction in process			Total capital assets
Cost:
At May 31, 2019	$	24,047		$	168,614		$	57,755		$	896		$	—		$	126,338		$	377,650
Additions		—			3,342			15,691			925			—			75,557			95,515
Transfers		54			27,968			81,112			11,996			—			(121,130	)		—
Disposals		—			—			(5,339	)		—			—			(4,147	)		(9,486	)
Impairment		(11	)		(2,561	)		(34	)		(89	)		—			(1,602	)		(4,297	)
Effect of foreign exchange		(2	)		(505	)		(2,117	)		(345	)		—			1,476			(1,493	)
At May 31, 2020		24,088			196,858			147,068			13,383			—			76,492			457,889
Business acquisition		5,538			55,916			35,045			1,560			35,519			46,151			179,729
Additions		261			3,236			6,284			525			—			25,773			36,079
Transfers		—			63,159			11,189			—			—			(74,348	)		—
Disposals		(5,237	)		—			(513	)		(192	)		—			—			(5,942	)
ROU Amortization		—			—			—			—			(827	)		—			(827	)
Effect of foreign exchange		3,899			27,341			16,335			1,783			34			11,254			60,646
At May 31, 2021	$	28,549		$	346,510		$	215,408		$	17,059		$	34,726		$	85,322		$	727,574
Accumulated amortization:
At May 31, 2019	$	—		$	5,556		$	6,469		$	137		$	—		$	—		$	12,162
Amortization		—			10,134			14,551			336			—			—			25,021
At May 31, 2020		—			15,690			21,020			473			—			—			37,183
Amortization		—			14,007			24,996			690			—			—			39,693
At May 31, 2021	$	—		$	29,697		$	46,016		$	1,163		$	—		$	—		$	76,876
Net book value:
At May 31, 2019	$	24,047		$	163,058		$	51,286		$	759		$	—		$	126,338		$	365,488
At May 31, 2020	$	24,088		$	181,168		$	126,048		$	12,910		$	—		$	76,492		$	420,706
At May 31, 2021	$	28,549		$	316,813		$	169,392		$	15,896		$	34,726		$	85,322		$	650,698

Leases (Tables)

12 Months Ended

May 31, 2021

Leases [Abstract]

Summary of Lease-related Assets and Liabilities

The table below presents the lease-related assets and liabilities recorded on the balance sheet.

	Classification on Balance Sheet	May 31, 2021		May 31, 2020
Assets
Operating lease, right-of- use assets	Right of use assets	$	18,267	$	5,356
Finance lease, right-of-use assets	Capital assets		34,726		—
Total right-of-use asset		$	52,993	$	5,356
Liabilities
Current:
Operating lease liability	Accrued lease obligations - current	$	3,613	$	954
Finance lease liability	Accrued lease obligations - current		651		—
Non-current:
Operating lease liability	Accrued lease obligations - non-current		18,465		4,227
Finance lease liability	Accrued lease obligations - non-current		35,481		—
Total lease liabilities		$	58,210	$	5,181

Summary of Information Related to Lease Costs for Finance and Operating Leases

The table below presents certain information related to the lease costs for finance and operating leases.

	May 31, 2021		May 31, 2020
Finance lease cost:
Amortization of right-of-use assets	$	806	$	—
Interest on lease liabilities		765		—
Operating lease cost		1,374		1,128
Total lease cost	$	2,945	$	1,128

Summary of Supplemental Cash Flow Information Related to Leases

The table below presents supplemental cash flow information related to leases.

	May 31, 2021		May 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	1,466	$	994
Operating cash flows from finance leases		774		—
Financing cash flows from finance leases		231		—

Summary of Future Undiscounted Payment associated with Lease Liabilities

The following table presents the future undiscounted payment associated with lease liabilities as of May 31, 2021:

	Year ending May 31,
	Operating leases			Finance leases
2022		7,824			2,404
2023		4,272			7,183
2024		3,925			2,061
2025		3,023			2,122
2026		2,964			2,186
Thereafter		4,102			39,586
Total minimum lease payments	$	26,110		$	55,542
Less: amounts of leases related to interest payments		(419	)		(18,759	)
Present value of minimum lease payments		25,691			36,783
Less: current accrued lease obligation		(3,613	)		(651	)
Obligation recognized	$	22,078		$	36,132

Intangible assets (Tables)

12 Months Ended

May 31, 2021

Intangible Assets Net Excluding Goodwill [Abstract]

Schedule of Intangible Assets

Intangible assets are comprised of the following items:

	Customer relationships & distribution channel			Licenses, permits & applications			Non- compete agreements			Intellectual property, trademarks, know how & brands			Total intangible assets
Cost
At May 31, 2019	$	23,957		$	200,102		$	2,415		$	72,122		$	298,596
Additions		84			2,158			—			3,608		$	5,850
Impairment		—			(14,445	)		—			—		$	(14,445	)
Effect of foreign exchange		(269	)		393			(10	)		(1,918	)	$	(1,804	)
At May 31, 2020		23,772			188,208			2,405			73,812		$	288,197
Business acquisition		214,000			202,716			10,000			912,080		$	1,338,796
Effect of foreign exchange		2,038			24,006			48			5,025		$	31,117
At May 31, 2021	$	239,810		$	414,930		$	12,453		$	990,917		$	1,658,110
Accumulated amortization
At May 31, 2019	$	4,354		$	623		$	1,081		$	8,172		$	14,230
Amortization		4,506			131			1,006			5,006		$	10,649
At May 31, 2020		8,860			754			2,087			13,178		$	24,879
Amortization		9,442			413			2,212			15,246		$	27,313
At May 31, 2021	$	18,302		$	1,167		$	4,299		$	28,424		$	52,192
Net book value
At May 31, 2019	$	19,603		$	199,479		$	1,334		$	63,950		$	284,366
At May 31, 2020	$	14,912		$	187,454		$	318		$	60,634		$	263,318
At May 31, 2021	$	221,508		$	413,763		$	8,154		$	962,493		$	1,605,918

Schedule of Estimated Amortization Expense

Estimated amortization expense for each of the five succeeding fiscal years and thereafter is as follows:

	Years ending May 31,
2022	$	72,172
2023		68,409
2024		65,946
2025		65,533
2026		65,533
Thereafter		855,801
	$	1,193,394

Business Acquisitions (Tables)

12 Months Ended

May 31, 2021

Aphria Inc

Business Acquisition [Line Items]

Schedule of Fair Value of Purchase Price

The fair value of the purchase price is, as follows:

	April 30, 2021
Number of Tilray common shares outstanding at acquisition date		179,635,973
Conversion ratio		0.8381
Tilray common shares issued at closing		214,337,159
Market share price of Aphria converted stock units	$	14.62
Fair value of Tilray common stock transferred to Aphria shareholders		3,133,609
Consideration related to stock-based compensation ⁽¹⁾		71,297
Total fair value of consideration transferred	$	3,204,906

⁽¹⁾

Summary of Preliminary Estimated Fair Value of Assets Acquired and Liabilities Assumed at Effective Acquisition Date

The table below summarizes preliminary estimated fair value of the assets acquired and the liabilities assumed at the effective acquisition date.

	April 30, 2021
Assets
Cash and cash equivalents	$	375,673
Accounts receivable		28,054
Inventory		76,547
Prepaids and other current assets		8,960
Capital assets		136,637
Right-of-use assets, operating leases		12,606
Definite-lived intangible assets (estimated useful life)
Distribution channel (15 years)		404,000
Customer relationships (15 years)		59,000
Know how (5 years)		115,000
Brands (10 to 25 years)		301,000
Indefinite-lived intangible assets
Licenses		200,000
Goodwill		2,221,613
Other assets		22,879
Total assets		3,961,969
Liabilities
Accounts payable		62,292
Accrued expenses and other current liabilities		85,120
Accrued lease obligations		21,962
Warrant liability		79,402
Deferred tax liability		236,391
Convertible notes		267,862
Other liabilities		4,034
Total liabilities		757,063
Net assets acquired	$	3,204,906

Schedule of Goodwill

		Cannabis				Wellness				Total
Goodwill related to Tilray			2,144,143				77,470				2,221,613

Schedule of Supplemental Pro Forma Information

	Years ended May 31,
	2021			2020
Revenue	$	692,270		$	624,950
Net loss	$	(795,251	)	$	(649,276	)
Net loss per share - basic and diluted	$	(1.77	)	$	(1.71	)

S W Brewing Company L L C

Business Acquisition [Line Items]

Summary of Preliminary Estimated Fair Value of Assets Acquired and Liabilities Assumed at Effective Acquisition Date

The table below summarizes preliminary estimated fair value of the assets acquired and the liabilities assumed at the effective acquisition date.

	Amount
Consideration
Cash	$	255,543
Shares		65,889
Contingent consideration		58,959
Total consideration		380,391
Net assets acquired
Current assets
Cash and cash equivalents		6,988
Accounts receivable		3,810
Prepaids and other current assets		528
Inventory		4,815
Long-term assets
Capital assets		43,093
Customer relationships		155,000
Intellectual property, trademarks & brands		92,000
Non-compete agreements		10,000
Goodwill		100,202
Total assets		416,436
Current liabilities
Accounts payable and accrued liabilities		5,289
Current portion of lease liabilities		434
Long-term liabilities
Lease liabilities		30,322
Total liabilities		36,045
Total net assets acquired	$	380,391

Schedule of Supplemental Pro Forma Information

	Years ended May 31,
	2021			2020
Revenue	$	542,000		$	470,000
Net loss	$	(328,000	)	$	(80,000	)
Net loss per share - basic and diluted	$	(0.73	)	$	(0.37	)

Goodwill (Tables)

12 Months Ended

May 31, 2021

Goodwill Disclosure [Abstract]

Schedule of Goodwill

Goodwill is comprised of:

	Segment	May 31, 2021		May 31, 2020
Broken Coast Cannabis Ltd.	Cannabis business		105,963		105,963
Nuuvera Corp.	Business under development		273,606		273,606
LATAM Holdings Inc.	Business under development		63,239		63,239
CC Pharma GmbH	Distribution business		4,458		4,458
SweetWater	Beverage alcohol business		100,202		—
Tilray	Cannabis business		2,144,143		—
Tilray	Wellness business		77,470		—
Effect of foreign exchange			63,713		64
		$	2,832,794	$	447,330

Convertible notes receivable (Tables)

12 Months Ended

May 31, 2021

Convertible Notes Receivable [Abstract]

Summary of Convertible Notes Receivable

Convertible notes receivable is comprised of the following investments:

	May 31, 2021			May 31, 2020
HydRx Farms Ltd. (d/b/a Scientus Pharma)	$	—		$	4,352
10330698 Canada Ltd. (d/b/a Starbuds)		828			3,429
High Tide Inc.		1,657			2,828
Total convertible notes receivable		2,485			10,609
Deduct - current portion		(2,485	)		(10,609	)
Total convertible notes receivable, non current portion	$	—		$	—

Interest in equity investees (Tables)

12 Months Ended

May 31, 2021

Investments Debt And Equity Securities [Abstract]

Summary of Ownership Interests in Equity Method Investments

The Company’s ownership interests in its equity method investments as of May 31, 2021 is as follows:

	Approximate ownership %	Carrying value May 31, 2021		Loss from equity method investments year ended May 31, 2021
Investment in Fluent	50%	$	3,906	$	(416	)
Investment in Cannfections	50%		4,200		(42	)
Total equity method investments		$	8,106	$	(458	)

Long-term investments (Tables)

12 Months Ended

May 31, 2021

Investments All Other Investments [Abstract]

Schedule of Long-term Investments

Long-term investments are comprised of the following items:

	Fair value May 31, 2021		Fair value May 31, 2020
Equity investments measured at fair value		12,185		19,595
Equity investments under measurement alternative		5,500		—
Total other investments		17,685		19,595

Income taxes and deferred income taxes (Tables)

12 Months Ended

May 31, 2021

Income Tax Disclosure [Abstract]

Summary of Loss Before Income Taxes

Loss before income taxes includes the following components:

	For the year ended May 31,
	2021			2020			2019
United States	$	(7,814	)		—			—
Canada		(323,964	)		(88,930	)		(30,733	)
Other countries		(13,208	)		(20,255	)		(7,405	)
	$	(344,986	)		(109,185	)		(38,138	)

Summary of (Recoveries) Expense for Income Taxes

The (recoveries) expense for income taxes consists of:

	For the year ended May 31,
	2021			2020			2019
Current:
United States	$	—			—			—
Canada		15,227			5,294			3,296
Other countries		697			375			407
	$	15,924			5,669			3,703

Deferred:
United States	$	1,517			—			—
Canada		(30,111	)		(9,226	)		(3,281	)
Other countries		3,698			(4,795	)		(2,467	)
	$	(24,896	)		(14,021	)		(5,748	)
Income tax benefits, net	$	(8,972	)		(8,352	)		(2,045	)

Summary of Reconciliation of Income Taxes at Statutory Rate with Reported Taxes

A reconciliation of income taxes at the statutory rate with the reported taxes is as follows:

	For the year ended May 31,
	2021			2020			2019
Loss before net income taxes:	$	(344,986	)		(109,185	)		(38,138	)
Income tax benefits at statutory rate		(72,408	)		(22,929	)		(8,009	)
Tax impact of foreign operations		(19,016	)		(6,310	)		(2,504	)
Foreign exchange and other		1,011			(63	)		(491	)
Non-deductible expenses		(1,347	)		2,474			5,731
Non-deductible (taxable) losses		45,230			2,152			(11,724	)
Changes in enacted rates		135			—			—
Change in fair value of warrant liability		(259	)		—			—
Stock based and other compensation		2,902			4,105			14,655
Change in valuation allowance		46,007			1,066			297
Non deductible dividend		(755	)		—			—
Non deductible impairment		—			11,153			—
Effect of transaction		(10,472	)		—			—

Income tax benefits, net	$	(8,972	)		(8,352	)		(2,045	)

Summary of Components of Deferred Tax

The following table summarizes the components of deferred tax:

	May 31,
	2021			2020			2019
Deferred assets
Operating loss carryforwards - United States	$	57,320			—			—
Operating loss carryforwards - Canada		152,382			20,512			9,535
Operating loss carryforwards - Other Countries		7,801			9,037			5,079
Capital loss carryforwards		1,350			1,854			7,028
Intangible assets		86,541			—			—
Property and equipment		17,107			—			—
Currently nondeductible interest		9,491			—			—
Partnership interests		34,108			—			—
Deferred financing costs		4,237			5,022			—
Investment tax credits and related pool balance		526			—			—
Other		26,716			1,704			1,101
Total Deferred tax assets		397,579			38,129			22,743
Less valuation allowance		(265,940	)		(4,583	)		(4,583	)
Net deferred tax assets		131,639			33,546			18,160
Deferred tax liabilities
Property and equipment		(15,997	)		(8,356	)		(1,995	)
Intangible assets		(376,228	)		(69,580	)		(73,454	)
Convertible Senior Notes Due 2023		(4,977	)		(4,056	)		(4,739	)
Total deferred tax liabilities		(397,202	)		(81,992	)		(80,188	)
Net deferred tax liability	$	(265,563	)		(48,446	)		(62,028	)

Accounts payable and accrued liabilities (Tables)

12 Months Ended

May 31, 2021

Payables And Accruals [Abstract]

Summary of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities comprised of:

	May 31,		May 31,
	2021		2020
Trade payables	$	57,706	$	41,159
Accrued liabilities		112,594		48,105
Accrued payroll and employment related taxes		19,390		—
Income taxes payable		14,764		4,651
Accrued interest		148		—
Accrued legal settlement		—		18,496
Other accruals		8,211		—
	$	212,813	$	112,411

Long-term debt (Tables)

12 Months Ended

May 31, 2021

Long Term Debt [Abstract]

Schedule of Net Carrying Amount of Long-term Debt Instruments

The following table sets forth the net carrying amount of long-term debt instruments:

	May 31,			May 31,
	2021			2020
Credit facility - C$80,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2022	$	62,964		$	58,026
Term loan - C$25,000 - Canadian 5-year bond interest rate plus 2.73% with a minimum 4.50%, 5-year term, with a 15-year amortization, repayable in blended monthly payments, due in July 2023		14,335			13,231
Term loan - C$25,000 - 3.95%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly instalments of $188 including interest, due in April 2022		17,117			15,939
Term loan - C$1,250 - 3.99%, 5-year term, with a 10-year amortization, repayable in equal monthly instalments of $13 including interest, due in July 2021		587			602
Mortgage payable - C$3,750 - 3.95%, 5-year term, with a 20-year amortization, repayable in equal monthly instalments of $23 including interest, due in July 2021		2,562			2,349
Vendor take-back mortgage - C$2,850 - 6.75%, 5-year term, repayable in equal monthly instalments of $56 including interest, due in June 2021		92			508
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate + 1.79%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		3,356			4,163
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate + 2.68%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		3,356			4,163
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate + 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in April 2025		1,831			1,665
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate + 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in June 2025		1,831			—
Term loan - $100,000 - EUROBIR rate plus an applicable margin, 3-year term, repayable in quarterly instalments beginning March 31, 2021 of $7,500 in its first twelve months and $10,000 in each of the next two years, due in March 2024		98,138			—
		206,169			100,646
Deduct - unamortized financing fees		(2,061	)		(477	)
- principal portion included in current liabilities		(36,622	)		(6,141	)
	$	167,486		$	94,028

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Convertible debentures (Tables)

12 Months Ended

May 31, 2021

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

Convertible notes receivable is comprised of the following investments:

	May 31, 2021			May 31, 2020
HydRx Farms Ltd. (d/b/a Scientus Pharma)	$	—		$	4,352
10330698 Canada Ltd. (d/b/a Starbuds)		828			3,429
High Tide Inc.		1,657			2,828
Total convertible notes receivable		2,485			10,609
Deduct - current portion		(2,485	)		(10,609	)
Total convertible notes receivable, non current portion	$	—		$	—

Convertible Debentures

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

The following table sets forth the net carrying amount of the convertible debentures:

	May 31,		May 31,
	2021		2020
5.25% Convertible Notes ("APHA 24")	$	399,444	$	196,405
5.00% Convertible Notes ("TLRY 23")		268,180		—
Total convertible debentures	$	667,624	$	196,405

APHA 24

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

APHA 24

	May 31,		May 31,
	2021		2020
Opening balance	$	196,405	$	305,626
Debt settlement		—		(66,127	)
Fair value adjustment		203,039		(43,094	)
	$	399,444	$	196,405

TLRY 23

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

TLRY 23

	May 31,
	2021
Opening balance	$	—
Principal amount issued		277,856
Unamortized discount		(9,676	)
Net carrying amount	$	268,180

Warrants (Tables)

12 Months Ended

May 31, 2021

Warrants And Rights Note Disclosure [Abstract]

Schedule of Warrant Details

The warrant details of the Company are as follows:

Weighted

Expiry

Number of

average

Type of warrant

Classification

date

warrants

price

Warrant

Equity

September 26, 2021

166,000

3.14

Warrant

Equity

January 30, 2022

5,828,651

9.26

Warrant

Liability

March 17, 2025

6,209,000

5.95

12,203,651

7.41

	May 31, 2021				May 31, 2020
			Weighted					Weighted
	Number of		average		Number of			average
	warrants		price		warrants			price
Outstanding, beginning of the year		5,994,651	$	8.91		1,903,024		$	12.01
Exercised during the year		—		—		(636,089	)		1.47
Issued during the year		6,209,000		5.95		5,828,652			9.08
Cancelled during the year		—		—		—			—
Expired during the year		—		—		(1,100,936	)		19.46
Outstanding, end of the year		12,203,651	$	7.41		5,994,651		$	8.91

Schedule of Estimated Fair Value of Warrant Liability

The Company estimated the fair value of the warrant liability at May 31, 2021 at $12.59 per warrant using the Black Scholes pricing model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		0.90	%
Expected volatility		70	%
Expected term	4.3 years
Expected dividend yield		—	%
Strike price	$	5.95
Fair value of common stock	$	16.67

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 3 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 4 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%

Stock-based compensation (Tables)

12 Months Ended

May 31, 2021

Tilray 2018 Equity Incentive Plan and Original Plan | EIP Original Plan and Time-based RSU

Schedule of Stock Option Activity

Stock-based activity under the EIP and Original Plan for the year ended May 31, 2021 is as follows:

EIP Time-based stock option activity
	Stock Options			Weighted- average exercise price		Weighted- average remaining contractual term (years)		Aggregate intrinsic value
Balance May 1,		3,182,547		$	14.19		1.7	$	30,331,823
Granted		—			—		—		—
Exercised		(1,665	)		7.76		—		—
Forfeited		(188	)		7.76		—		—
Cancelled		(468	)		65.20		—		—
Balance May 31,		3,180,226		$	14.19		1.3	$	25,171,187

Original plan time-based stock option activity
	Stock Options			Weighted- average exercise price		Weighted- average remaining contractual term (years)		Aggregate intrinsic value
Balance May 1,		946,948			3.99		2		13,777,571
Exercised		(29,403	)		4.71		—		—
Forfeited		—			—		—		—
Cancelled		—			—		—		—
Balance May 31,		917,545		$	3.97		1.7	$	11,885,699

Time-based RSU activity
	Time-based RSUs			Weighted-average grant-date fair value per share		Weighted-average remaining contractual term (years)		Aggregate intrinsic value
Balance May 1,		1,285,134		$	15.70		—		—
Granted		198,521			7.76		—		—
Vested		(112,508	)		12.99		—		—
Forfeited		(165,904	)		11.97		—		—
Cancelled		—			—		—		—
Balance May 31,		1,205,243		$	15.16		—	$	20,091,286

Predecessor Plan | Time-based Stock Options | Aphria

Schedule of Stock Option Activity

Stock option, RSU and DSU activity for the Company under the Predecessor Plan is as follows:

Time-based stock option activity

	May 31, 2021
						Weighted		Weighted
				Weighted		average		average
				average		grant		remaining		Aggregate
	Number of			exercise		date fair		contractual		Intrinsic
	options			price		value		term (years)		Amount
Outstanding, beginning of the year		4,484,051		$	12.04	$	6.24		2.9		(32,781	)
Exercised during the year		(1,073,986	)		8.70	$	4.38	N/A		N/A
Granted during the year		41,500			5.88	$	2.18	N/A		N/A
Forfeited during the year		(884,320	)		14.06	$	7.46	N/A		N/A
Expired during the year		(68,060	)		18.72	$	8.80	N/A		N/A
Outstanding, end of the year		2,499,185		$	12.48	$	6.51		2.4		10,472
Vested and exercisable, end of the year		1,846,090		$	13.53	$	7.16		2.2		5,797

Predecessor Plan | Performance Based Stock Option | Aphria

Schedule of Stock Option Activity

Performance-based stock option activity

	May 31, 2021
						Weighted		Weighted
				Weighted		average		average
				average		grant		remaining		Aggregate
	Number of			exercise		date fair		contractual		Intrinsic
	options			price		value		term (years)		Amount
Outstanding, beginning of the year		398,400		$	8.11	$	3.80	0.6			(1,347	)
Exercised during the year		(166,000	)	$	5.15	$	2.38	N/A		N/A
Granted during the year		—			—		—	N/A		N/A
Forfeited during the year		(232,400	)	$	10.23	$	4.81	N/A		N/A
Expired during the year		—			—		—	N/A		N/A
Outstanding, end of the year		—			—		—		—		—
Vested and exercisable, end of the year		—			—		—		—		—

Predecessor Plan | Time-based and Performance-based RSU | Aphria

Schedule of Time-based and Performance-based RSU Activity

	May 31, 2021
				Weighted						Weighted
				average						average
				grant -						grant -
				date fair			Performance-			date fair
	Time- based			value per			based			value per
	RSUs			share			RSUs			share
Non-vested, beginning of the year		1,588,743		$	7.71			19,335		$	6.01
Granted during the year		2,370,862		$	6.24			—			—
Vested during the year		(1,006,222	)	$	(6.83	)		—			—
Forfeited during the year		(158,411	)	$	(6.68	)		(19,335	)	$	(6.01	)
Non-vested, end of the year		2,794,972		$	6.88			—			—

Accumulated other comprehensive loss (Tables)

12 Months Ended

May 31, 2021

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss includes the following components:

	Foreign currency translation (loss) gain			Unrealized loss on convertible notes receivables			Total
Balance May 31, 2018	$	110		$	2,844		$	2,954
Other comprehensive income (loss)		(90	)		(2,570	)		(2,660	)
Elimination of CTA on disposal of equity investee		606			—			606
Balance May 31, 2019		626			274			900
Other comprehensive income (loss)		(858	)		(5,476	)		(6,334	)
Balance May 31, 2020		(232	)		(5,202	)		(5,434	)
Settlement of convertible notes receivable		—			5,277			5,277
Other comprehensive income (loss)		156,649			(3,824	)		152,825
Balance May 31, 2021	$	156,417		$	(3,749	)	$	152,668

Non-controlling interests (Tables)

12 Months Ended

May 31, 2021

Text Block [Abstract]

Summary of Information Relating to Company's Subsidiaries

Non-controlling interests as at May 31, 2021:

	CC Pharma			Aphria					ColCanna			May 31,
	Nordic ApS			Diamond			Marigold		S.A.S.			2021
Current assets	$	919		$	19,531		$	—	$	315		$	20,765
Non-current assets		103			153,696			—		146,587			300,386
Current liabilities		(956	)		(28,511	)		—		(62	)		(29,529	)
Non-current liabilities		(406	)		(69,332	)		—		(6,606	)		(76,344	)
Net assets		(340	)		75,384			—		140,234			215,278

Non-controlling interests as at May 31, 2020:

	Aphria					ColCanna			May 31,
	Diamond			Marigold		S.A.S.			2020
Current assets	$	25,957		$	—	$	547		$	26,504
Non-current assets		156,251			—		83,857			240,108
Current liabilities		(11,337	)		—		(274	)		(11,611	)
Non-current liabilities		(128,031	)		—		(24,471	)		(152,502	)
Net assets		42,840			—		59,659			102,499

Non-controlling interests for the year ended May 31, 2021:

	CC Pharma			Aphria					ColCanna			May 31,
	Nordic ApS			Diamond			Marigold		S.A.S.			2021
Revenue	$	827		$	131,381		$	—	$	—		$	132,208
Total expenses (recovery)		(958	)		(67,030	)		—		(923	)		(68,911	)
Net (loss) income		(131	)		64,351			—		(923	)		63,297
Other comprehensive (loss) income		—			—			—		—		$	—
Net comprehensive income		(131	)		64,351			—		(923	)		63,297

Non-controlling interests for the year ended May 31, 2020:

	Aphria					ColCanna		May 31,
	Diamond			Marigold		S.A.S.		2020
Revenue	$	24,142		$	40	$	—	$	24,182
Total expenses (recovery)		(25,141	)		4,995		19,447		(699	)
Net (loss) income		(999	)		5,035		19,447		23,483
Other comprehensive (loss) income		—			—		—	$	—
Net comprehensive loss		(999	)		5,035		19,447		23,483

Non-controlling interests for the year ended May 31, 2019:

	Aphria Diamond			CannInvest Africa Ltd.			Verve Dynamics			Nuuvera Malta Ltd.			Marigold			ColCanna S.A.S.			May 31, 2019
Revenue	$	—		$	—		$	—		$	174		$	—		$	—		$	174
Total expenses (recovery)		(21,273	)	$	(8	)	$	(634	)		(791	)		(572	)		(942	)		(24,220	)
Net (loss) income		(21,273	)		(8	)		(634	)		(617	)		(572	)		(942	)		(24,046	)
Other comprehensive (loss) income		—			—			—			—			—			—
Net comprehensive loss		(21,273	)		(8	)		(634	)		(617	)		(572	)		(942	)		(24,046	)

Net revenue (Tables)

12 Months Ended

May 31, 2021

Revenues [Abstract]

Summary of Net Revenue

Net revenue is comprised of:

	For the year ended May 31,
	2021			2020			2019
Cannabis revenue	$	264,334			153,477			67,592
Cannabis excise taxes		(62,942	)		(23,581	)		(7,716	)
Net cannabis revenue		201,392			129,896			59,876
Beverage alcohol revenue		29,661			—			—
Beverage alcohol excise taxes		(1,062	)		—			—
Net beverage alcohol revenue		28,599			—			—
Distribution revenue		277,300			275,430			119,427
Wellness revenue		5,794			—			—
	$	513,085		$	405,326		$	179,303

Cost of Goods Sold (Tables)

12 Months Ended

May 31, 2021

Cost Of Goods And Services Sold [Abstract]

Summary of Cost of Goods Sold

Cost of goods sold is comprised of:

	For the year ended May 31,
	2021		2020		2019
Cannabis costs	$	130,511		68,551		31,341
Beverage alcohol costs		12,687		—		—
Distribution costs		242,472		240,722		104,451
Wellness costs		4,233		—		—
	$	389,903	$	309,273	$	135,792

General and administrative expenses (Tables)

12 Months Ended

May 31, 2021

General And Administrative Expense [Abstract]

Schedule of General and Administrative Expenses

General and administrative expenses are comprised of the following items:

	For the year ended May 31,
	2021		2020		2019
Executive compensation	$	8,645	$	6,777	$	4,402
Consulting fees		6,633		9,272		4,928
Office and general		19,503		12,351		12,486
Professional fees		5,146		4,918		8,916
Salaries and wages		37,126		28,252		14,842
Stock-based compensation		17,351		18,079		21,951
Insurance		12,257		9,370		4,050
Travel and accommodation		2,711		2,798		2,356
Rent		2,203		1,972		1,910
	$	111,575	$	93,789	$	75,841

Finance income (expense), net (Tables)

12 Months Ended

May 31, 2021

Finance Income Expense Net [Abstract]

Summary of Finance Income (Expense), Net

Finance income (expense), net is comprised of:

	For the year ended May 31,
	2021			2020			2019
Interest income	$	2,926		$	6,273		$	11,138
Interest expense		(30,903	)		(25,644	)		(5,879	)
	$	(27,977	)	$	(19,371	)	$	5,259

Non-operating (expense) income (Tables)

12 Months Ended

May 31, 2021

Nonoperating Income Expense [Abstract]

Schedule of Non-Operating (Expense) Income

Non-operating (expense) income is comprised of:

	For the year ended May 31,
	2021			2020			2019
Foreign exchange (loss) gain	$	(22,347	)	$	6,145		$	692
Loss on marketable securities		—			(252	)		(135	)
Gain (loss) on sale of capital assets		1,523			(8,075	)		42
(Loss) gain from equity investees		(458	)		—			44,191
Deferred gain on sale of intellectual property		—			—			257
Loss on promissory notes receivable		—			(9,698	)		—
(Loss) gain on long-term investments		(2,352	)		(24,295	)		14,860
Unrealized (loss) gain on convertible debentures		(170,453	)		44,322			36,630
Realized gain on settlement of convertible debentures		—			9,289			—
Legal settlement		—			(3,241	)		—
Unrealized loss on financial liabilities		—			—			(1,003	)
Change in fair value of warrant liability		1,234			—			—
Other non-operating items, net		8,015			—			—
	$	(184,838	)	$	14,195		$	95,534

Change in Non-cash Working Capital (Tables)

12 Months Ended

May 31, 2021

Change In Non Cash Working Capital [Abstract]

Summary of Change in Non-cash Working Capital

Change in non-cash working capital is comprised of:

	For the year ended May 31,
	2021			2020			2019
Decrease (increase) in:
Accounts receivable	$	(23,512	)	$	(25,593	)	$	9,421
Prepaids and other current assets		(6,772	)		(10,899	)		4,322
Inventory		(35,286	)		(89,660	)		(26,069	)
Increase (decrease) in:
Accounts payable and accrued liabilities		14,501			47,335			(8,984	)
Deferred revenue		134			(15	)		8,839
	$	(50,935	)	$	(78,832	)	$	(12,471	)

Commitments and contingencies (Tables)

12 Months Ended

May 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Schedule of Purchase and Other Commitments Maturities

	Total		2022		2023		2024		2025		2026		Thereafter
Long-term debt repayment	$	204,108		36,623		69,925		95,181		1,438		941		—
Convertible notes, principal and interest		571,989		13,893		13,893		284,803		259,400		—		—
ABG finance liability		6,000		1,500		1,500		1,500		1,500		—		—
Material purchase obligations		26,097		21,141		4,009		854		93		—		—
Construction commitments		1,814		1,814		—		—		—		—		—
Total	$	810,008	$	74,971	$	89,327	$	382,338	$	262,431	$	941	$	—

Financial risk management and financial instruments (Tables)

12 Months Ended

May 31, 2021

Financial Risk Management And Financial Instruments [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

								May 31,
	Level 1		Level 2		Level 3			2021
Financial assets
Cash and cash equivalents	$	488,466	$	—	$	—		$	488,466
Convertible notes receivable		—		2,485		—			2,485
Long-term investments		9,251		2,934		—			12,185
Financial liabilities
Warrant liability		—		—		(78,168	)		(78,168	)
Contingent consideration		—		—		(60,657	)		(60,657	)
APHA 24 Convertible debenture		—		—		(399,444	)		(399,444	)
Total recurring fair value measurements	$	497,717	$	5,419	$	(538,269	)	$	(35,133	)

								May 31,
	Level 1		Level 2		Level 3			2020
Financial assets
Cash and cash equivalents	$	360,646	$	—	$	—		$	360,646
Convertible notes receivable		—		10,609		—			10,609
Long-term investments		11,244		8,351		—			19,595
Financial liabilities
APHA 24 Convertible debenture		—		—		(196,405	)		(196,405	)
Total recurring fair value measures	$	371,890	$	18,960	$	(196,405	)	$	194,445

Schedule of Opening Balances of Assets and Liabilities Categorized Within Level 3 of Fair Value Hierarchy Measured at Fair Value on Recurring Basis

The opening balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled to the closing balances as follows:

	APHA 24
	Convertible			Warrant			Contingent
	debenture			liability			consideration			Total
Closing balance May 31, 2020	$	(196,405	)	$	—		$	—		$	(196,405	)
Additions		—			(79,402	)		(58,959	)		(138,361	)
Disposals		—			—			—			—
Unrealized gain (loss) on fair value		(203,039	)		1,234			(1,698	)		(203,503	)
Closing balance May 31, 2021	$	(399,444	)	$	(78,168	)	$	(60,657	)	$	(538,269	)

Schedule of Estimated Fair Value of Warrant Liability

The Company estimated the fair value of the warrant liability at May 31, 2021 at $12.59 per warrant using the Black Scholes pricing model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		0.90	%
Expected volatility		70	%
Expected term	4.3 years
Expected dividend yield		—	%
Strike price	$	5.95
Fair value of common stock	$	16.67

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 3 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 4 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%

Schedule of Trade Receivables

Trade receivables included an allowance for doubtful accounts of $4,571 at May 31, 2021 (2020-$2,313), and is comprised of the following aged receivables:

	Total		0-30 days			31-60 days			61-90 days			90+ days
Trade receivables	$	87,309		70,997			8,253			1,051			7,008
				82	%		9	%		1	%		8	%

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Segment reporting (Tables)

12 Months Ended

May 31, 2021

Segment Reporting [Abstract]

Schedule of Segment Net Revenue From External Customers

Segment net revenue from external customers:

	For the year ended May 31,
	2021		2020		2019
Cannabis business	$	201,392	$	129,896	$	59,876
Distribution business		277,300		275,430		119,427
Beverage alcohol business		28,599		—		—
Wellness business		5,794		—		—
Business under development		—		—		—
Total net revenue	$	513,085	$	405,326	$	179,303

Channels of Cannabis revenue were as follows:

	For the year ended May 31,
	2021			2020			2019
Revenue from medical cannabis products	$	25,539		$	28,685		$	33,017
Revenue from adult-use cannabis products		222,930			112,207			30,236
Revenue from wholesale cannabis products		6,615			12,585			4,339
Revenue from international cannabis products		9,250			—			—
Less excise tax		(62,942	)		(23,581	)		(7,716	)
Total net cannabis revenue	$	201,392		$	129,896		$	59,876

Schedule of Geographic Net Revenue

Geographic net revenue:

	For the year ended May 31,
	2021		2020		2019
North America	$	229,120	$	129,663	$	59,629
EMEA		279,062		271,291		116,578
Latin America		4,903		4,372		3,096
Total net revenue	$	513,085	$	405,326	$	179,303

Schedule of Geographic Capital Assets

Geographic capital assets:

	May 31, 2021		May 31, 2020
North America		504,575	$	371,823
EMEA		140,838		44,348
Latin America		5,285		4,535
Total capital assets	$	650,698	$	420,706

Quarterly financial data (Unaudited) (Tables)

12 Months Ended

May 31, 2021

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Data

	For the three months ended
	August 31, 2020			November 30, 2020			February 28, 2021			May 31, 2021
Net revenue	$	117,490		$	129,459			123,900			142,236
Gross profit		34,945			35,283			30,456			22,498
Net income (loss)		(21,744	)		(89,249	)		(258,626	)		33,605
Net income (loss) attributable to Tilray shareholders		(32,958	)		(100,811	)		(280,856	)		47,204
Earnings (loss) per share - basic		(0.09	)		(0.37	)		(0.97	)		0.18
Earnings (loss) per share - fully diluted		(0.09	)		(0.37	)		(0.97	)		0.18

	For the three months ended
	August 31, 2019		November 30, 2019			February 29, 2020			May 31, 2020
Net revenue	$	94,078	$	89,967		$	107,739		$	113,542
Gross profit		20,555		21,812			25,879			27,807
Net income (loss)		1,435		(6,265	)		(11,699	)		(84,306	)
Net income (loss) attributable to Tilray shareholders		1,564		(5,996	)		(11,003	)		(87,105	)
Earnings (loss) per share - basic		0.01		(0.03	)		(0.05	)		(0.39	)
Income (loss) per share - fully diluted		0.01		(0.03	)		(0.05	)		(0.39	)

Description of Business - Additional Information (Details)	Apr. 30, 2021
Aphria Stockholders
Description Of Business [Line Items]
Stockholders ownership percentage	61.20%
Aphria Stockholders \| Class 2 Common Stock
Description Of Business [Line Items]
Share exchange rate	0.8381
Tilray Stockholders
Description Of Business [Line Items]
Stockholders ownership percentage	38.80%

Basis of Preparation - Additional Information (Details) - USD ($)	3 Months Ended								12 Months Ended
	May 31, 2021	Feb. 28, 2021	Nov. 30, 2020	Aug. 31, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2021	May 31, 2020	May 31, 2019
Basis Of Preparation [Abstract]
Consolidated net loss	$ (33,605,000)	$ 258,626,000	$ 89,249,000	$ 21,744,000	$ 84,306,000	$ 11,699,000	$ 6,265,000	$ (1,435,000)	$ 336,014,000	$ 100,833,000	$ 36,093,000
Net cash used in operating activities									(44,717,000)	(100,627,000)	(42,049,000)
Working capital	482,368,000				461,732,000				482,368,000	461,732,000
Consolidated VIEs	$ 0				$ 0				0	$ 0	$ 0
Noncontrolling Interest gain (loss) recognized									$ 0

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Basis of Preparation - List of Company's Operating Subsidiaries (Details)	12 Months Ended
	May 31, 2021
Natura Naturals Inc.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
Tilray, Inc.
Minority Interest [Line Items]
Jurisdiction of incorporation	United States
Ownership interest	100.00%
Manitoba Harvest USA LLC
Minority Interest [Line Items]
Jurisdiction of incorporation	United States
Ownership interest	100.00%
Tilray Canada, Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
Dorada Ventures, Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
FHF Holdings Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
High Park Farms Ltd
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
Tilray Deutschland GmbH
Minority Interest [Line Items]
Jurisdiction of incorporation	Germany
Ownership interest	100.00%
Pardal Holdings, Lda.
Minority Interest [Line Items]
Jurisdiction of incorporation	Portugal
Ownership interest	100.00%
Tilray Portugal Unipessoal, Lda.
Minority Interest [Line Items]
Jurisdiction of incorporation	Portugal
Ownership interest	100.00%
Tilray Australia New Zealand Pty. Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Australia
Ownership interest	100.00%
Tilray Ventures Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Ireland
Ownership interest	100.00%
Manitoba Harvest Japan K.K.
Minority Interest [Line Items]
Jurisdiction of incorporation	Japan
Ownership interest	100.00%
High Park Holdings, Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
Fresh Hemp Foods Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
Natura Naturals Holdings Inc.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
National Cannabinoid Clinics Pty Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Australia
Ownership interest	100.00%
Tilray Latin America SpA
Minority Interest [Line Items]
Jurisdiction of incorporation	Chile
Ownership interest	100.00%
Tilray Portugal II, Lda.
Minority Interest [Line Items]
Jurisdiction of incorporation	Portugal
Ownership interest	100.00%
High Park Gardens Inc.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
1197879 B.C. Ltd
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
High Park Shops Inc.
Minority Interest [Line Items]
Jurisdiction of incorporation	Canada
Ownership interest	100.00%
Privateer Evolution, LLC
Minority Interest [Line Items]
Jurisdiction of incorporation	United States
Ownership interest	100.00%
Tilray France SAS
Minority Interest [Line Items]
Jurisdiction of incorporation	France
Ownership interest	100.00%
High Park Holdings B.V.
Minority Interest [Line Items]
Jurisdiction of incorporation	Netherlands
Ownership interest	100.00%
High Park Botanicals B.V.
Minority Interest [Line Items]
Jurisdiction of incorporation	Netherlands
Ownership interest	100.00%
Broken Coast Cannabis Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	British Columbia, Canada
Ownership interest	100.00%
SweetWater Brewing Company, LLC
Minority Interest [Line Items]
Jurisdiction of incorporation	United States
Ownership interest	100.00%
SweetWater Colorado Brewing Co.
Minority Interest [Line Items]
Jurisdiction of incorporation	United States
Ownership interest	100.00%
ARA - Avanti Rx Analytics Inc.
Minority Interest [Line Items]
Jurisdiction of incorporation	Ontario, Canada
Ownership interest	100.00%
FL Group S.r.l.
Minority Interest [Line Items]
Jurisdiction of incorporation	Italy
Ownership interest	100.00%
ABP, S.A.
Minority Interest [Line Items]
Jurisdiction of incorporation	Argentina
Ownership interest	100.00%
Aphria Germany GmbH
Minority Interest [Line Items]
Jurisdiction of incorporation	Germany
Ownership interest	100.00%
Aphria RX GmbH
Minority Interest [Line Items]
Jurisdiction of incorporation	Germany
Ownership interest	100.00%
CC Pharma GmbH
Minority Interest [Line Items]
Jurisdiction of incorporation	Germany
Ownership interest	100.00%
CC Pharma Research and Development GmbH
Minority Interest [Line Items]
Jurisdiction of incorporation	Germany
Ownership interest	100.00%
Aphria Wellbeing GmbH
Minority Interest [Line Items]
Jurisdiction of incorporation	Germany
Ownership interest	100.00%
CC Pharma Luxemburg GmbH
Minority Interest [Line Items]
Jurisdiction of incorporation	Luxemburg
Ownership interest	100.00%
ASG Pharma Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Malta
Ownership interest	100.00%
ColCanna S.A.S.
Minority Interest [Line Items]
Jurisdiction of incorporation	Colombia
Ownership interest	90.00%
CC Pharma Nordic ApS
Minority Interest [Line Items]
Jurisdiction of incorporation	Denmark
Ownership interest	75.00%
1974568 Ontario Ltd.
Minority Interest [Line Items]
Jurisdiction of incorporation	Ontario, Canada
Ownership interest	51.00%

Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	May 31, 2021 Segment shares
Summary Of Significant Accounting Policies [Line Items]
Number of operating segments \| Segment	5
SARs
Summary Of Significant Accounting Policies [Line Items]
Number of shares issued \| shares	0
Maximum
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents maturity period	3 months

Significant Accounting Policies - Summary of Depreciation Calculation (Details)	12 Months Ended
	May 31, 2021
Land
Property Plant And Equipment [Line Items]
Depreciation method	Not depreciated
Depreciation term (estimated useful life)	No term
Production Facility
Property Plant And Equipment [Line Items]
Depreciation method	Straight-line
Production Facility \| Minimum
Property Plant And Equipment [Line Items]
Depreciation term (estimated useful life)	20 years
Production Facility \| Maximum
Property Plant And Equipment [Line Items]
Depreciation term (estimated useful life)	30 years
Equipment
Property Plant And Equipment [Line Items]
Depreciation method	Straight-line
Equipment \| Minimum
Property Plant And Equipment [Line Items]
Depreciation term (estimated useful life)	3 years
Equipment \| Maximum
Property Plant And Equipment [Line Items]
Depreciation term (estimated useful life)	25 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Depreciation method	Straight-line
Depreciation term (estimated useful life)	Lesser of estimated useful life or lease term
Construction in Progress
Property Plant And Equipment [Line Items]
Depreciation method	Not depreciated
Depreciation term (estimated useful life)	No term
Finance Lease Right-of-use Assets
Property Plant And Equipment [Line Items]
Depreciation method	Straight-line
Depreciation term (estimated useful life)	Lesser of the lease term and the useful life of the leased asset

Significant Accounting Policies - Summary of Estimated Useful Lives of Definite Life Intangible Assets (Details)	12 Months Ended
	May 31, 2021
Customer Relationships and Distribution Channel \| Minimum
Finite Lived Intangible Assets [Line Items]
Amortization term	14 years
Customer Relationships and Distribution Channel \| Maximum
Finite Lived Intangible Assets [Line Items]
Amortization term	16 years
Licences, Permits & Applications \| Minimum
Finite Lived Intangible Assets [Line Items]
Amortization term	90 months
Licences, Permits & Applications \| Maximum
Finite Lived Intangible Assets [Line Items]
Amortization term	indefinite
Brands, Intellectual Property and Trademarks \| Minimum
Finite Lived Intangible Assets [Line Items]
Amortization term	15 months
Brands, Intellectual Property and Trademarks \| Maximum
Finite Lived Intangible Assets [Line Items]
Amortization term	25 years
Non-compete Agreements
Finite Lived Intangible Assets [Line Items]
Amortization term	Over term of non-compete
Know How
Finite Lived Intangible Assets [Line Items]
Amortization term	5 years
Workforce
Finite Lived Intangible Assets [Line Items]
Amortization term	3 years

Prepaids and Other Current Assets - Summary of Prepaids and Other Current Assets (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepaid assets	$ 31,012	$ 13,760
Sales tax receivable	9,331	8,464
Prepaid corporate taxes		4,670
Other	8,577	5,766
Total	$ 48,920	$ 32,660

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Inventory [Line Items]
Total inventory	$ 256,429	$ 139,781
Plants
Inventory [Line Items]
Total inventory	23,083	12,288
Dried Cannabis
Inventory [Line Items]
Total inventory	118,269	59,045
Cannabis Trim
Inventory [Line Items]
Total inventory	2,931	2,796
Cannabis Derivatives
Inventory [Line Items]
Total inventory	24,158	19,496
Cannabis Vapes
Inventory [Line Items]
Total inventory	3,791	4,124
Packaging and Other Inventory Items
Inventory [Line Items]
Total inventory	31,462	16,398
Wellness Inventory
Inventory [Line Items]
Total inventory	15,171
Beverage Alcohol Inventory
Inventory [Line Items]
Total inventory	5,402
Distribution Inventory
Inventory [Line Items]
Total inventory	$ 32,162	$ 25,634

Inventory - Additional Information (Details) - USD ($)	12 Months Ended
Inventory - Additional Information (Details) - USD ($)	May 31, 2021	May 31, 2020	May 31, 2019
Cannabis
Inventory [Line Items]
Inventory write-downs	$ 19,919,000	$ 0	$ 0

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Related Party Transaction [Line Items]
Operational expenses	$ 255,353	$ 200,062	$ 182,442
Fluent and Cannfections
Related Party Transaction [Line Items]
Ownership and voting interest	50.00%	50.00%	50.00%
General and Administrative Expenses \| Docklight LLC
Related Party Transaction [Line Items]
Royalty fees	$ 125

Capital Assets - Schedule of Capital Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Property Plant And Equipment [Line Items]
Capital assets, beginning balance	$ 457,889	$ 377,650
Business acquisition	179,729
Additions	36,079	95,515
Disposals	(5,942)	(9,486)
ROU Amortization	(827)
Impairment		(4,297)
Effect of foreign exchange	60,646	(1,493)
Capital assets, ending balance	727,574	457,889
Accumulated amortization, beginning balance	37,183	12,162
Amortization	39,693	25,021
Accumulated amortization, ending balance	76,876	37,183
Capital assets, net book value	650,698	420,706	$ 365,488
Land
Property Plant And Equipment [Line Items]
Capital assets, beginning balance	24,088	24,047
Business acquisition	5,538
Additions	261
Transfers		54
Disposals	(5,237)
Impairment		(11)
Effect of foreign exchange	3,899	(2)
Capital assets, ending balance	28,549	24,088
Capital assets, net book value	28,549	24,088	24,047
Production Facility
Property Plant And Equipment [Line Items]
Capital assets, beginning balance	196,858	168,614
Business acquisition	55,916
Additions	3,236	3,342
Transfers	63,159	27,968
Impairment		(2,561)
Effect of foreign exchange	27,341	(505)
Capital assets, ending balance	346,510	196,858
Accumulated amortization, beginning balance	15,690	5,556
Amortization	14,007	10,134
Accumulated amortization, ending balance	29,697	15,690
Capital assets, net book value	316,813	181,168	163,058
Equipment
Property Plant And Equipment [Line Items]
Capital assets, beginning balance	147,068	57,755
Business acquisition	35,045
Additions	6,284	15,691
Transfers	11,189	81,112
Disposals	(513)	(5,339)
Impairment		(34)
Effect of foreign exchange	16,335	(2,117)
Capital assets, ending balance	215,408	147,068
Accumulated amortization, beginning balance	21,020	6,469
Amortization	24,996	14,551
Accumulated amortization, ending balance	46,016	21,020
Capital assets, net book value	169,392	126,048	51,286
Leasehold Improvements
Property Plant And Equipment [Line Items]
Capital assets, beginning balance	13,383	896
Business acquisition	1,560
Additions	525	925
Transfers		11,996
Disposals	(192)
Impairment		(89)
Effect of foreign exchange	1,783	(345)
Capital assets, ending balance	17,059	13,383
Accumulated amortization, beginning balance	473	137
Amortization	690	336
Accumulated amortization, ending balance	1,163	473
Capital assets, net book value	15,896	12,910	759
ROU Assets Under Finance Lease
Property Plant And Equipment [Line Items]
Business acquisition	35,519
ROU Amortization	(827)
Effect of foreign exchange	34
Capital assets, ending balance	34,726
Capital assets, net book value	34,726
Construction in Progress
Property Plant And Equipment [Line Items]
Capital assets, beginning balance	76,492	126,338
Business acquisition	46,151
Additions	25,773	75,557
Transfers	(74,348)	(121,130)
Disposals		(4,147)
Impairment		(1,602)
Effect of foreign exchange	11,254	1,476
Capital assets, ending balance	85,322	76,492
Capital assets, net book value	$ 85,322	$ 76,492	$ 126,338

Leases - Additional Information (Details)	12 Months Ended
Leases - Additional Information (Details)	May 31, 2021 USD ($)
Lessee Lease Description [Line Items]
Operating lease, existence of option to extend	true
Operating lease, existence of option to terminate	true
Finance lease, existence of option to extend	true
Finance lease, existence of option to terminate	true
Short term lease expense	$ 0
Sublease income	$ 0
Maximum
Lessee Lease Description [Line Items]
Operating lease, remaining lease term	20 years
Finance lease, remaining lease term	20 years

Leases - Summary of Lease-related Assets and Liabilities (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Assets
Operating lease, right-of- use assets	$ 18,267	$ 5,356
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List	us-gaap:OperatingLeaseRightOfUseAsset	us-gaap:OperatingLeaseRightOfUseAsset
Finance lease, right-of-use assets	$ 34,726
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List	tlry:CapitalAssets	tlry:CapitalAssets
Total right-of-use asset	$ 52,993	$ 5,356
Liabilities
Operating lease liability, current	$ 3,613	$ 954
Operating Lease Liability Current Statement Of Financial Position Extensible List	tlry:AccruedLeaseObligationCurrent	tlry:AccruedLeaseObligationCurrent
Finance lease liability, current	$ 651
Finance Lease Liability Current Statement Of Financial Position Extensible List	tlry:AccruedLeaseObligationCurrent	tlry:AccruedLeaseObligationCurrent
Operating lease liability, non-current	$ 18,465	$ 4,227
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List	tlry:AccruedLeaseObligationNoncurrent	tlry:AccruedLeaseObligationNoncurrent
Finance lease liability, non-current	$ 35,481
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List	tlry:AccruedLeaseObligationNoncurrent	tlry:AccruedLeaseObligationNoncurrent
Total lease liabilities	$ 58,210	$ 5,181

Leases - Summary of Information Related to Lease Costs for Finance and Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020
Finance lease cost:
Amortization of right-of-use assets	$ 806
Interest on lease liabilities	765
Operating lease cost	1,374	$ 1,128
Total lease cost	$ 2,945	$ 1,128

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$ 1,466	$ 994
Operating cash flows from finance leases	774
Financing cash flows from finance leases	$ 231

Leases - Summary of Future Undiscounted Payment Associated with Lease Liabilities (Details) $ in Thousands	May 31, 2021 USD ($)
Operating leases
2022	$ 7,824
2023	4,272
2024	3,925
2025	3,023
2026	2,964
Thereafter	4,102
Total minimum lease payments	26,110
Less: amounts of leases related to interest payments	(419)
Present value of minimum lease payments	25,691
Less: current accrued lease obligation	(3,613)
Obligation recognized	$ 22,078
Operating Lease Liability Statement Of Financial Position Extensible List	tlry:OperatingLeaseLiabilitiesMember
Finance leases
2022	$ 2,404
2023	7,183
2024	2,061
2025	2,122
2026	2,186
Thereafter	39,586
Total minimum lease payments	55,542
Less: amounts of leases related to interest payments	(18,759)
Present value of minimum lease payments	36,783
Less: current accrued lease obligation	(651)
Obligation recognized	$ 36,132
Finance Lease, Liability, Statement of Financial Position [Extensible List]	tlry:FinanceLeaseLiabilitiesMember

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	$ 288,197	$ 298,596
Business acquisition	1,338,796
Additions		5,850
Impairment		(14,445)
Effect of foreign exchange	31,117	(1,804)
Intangible assets, Cost	1,658,110	288,197
Intangible assets, Accumulated depreciation	24,879	14,230
Amortization	27,313	10,649
Intangible assets, Accumulated depreciation	52,192	24,879
Intangible assets, Net book value	1,605,918	263,318	$ 284,366
Customer Relationships and Distribution Channel
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	23,772	23,957
Business acquisition	214,000
Additions		84
Effect of foreign exchange	2,038	(269)
Intangible assets, Cost	239,810	23,772
Intangible assets, Accumulated depreciation	8,860	4,354
Amortization	9,442	4,506
Intangible assets, Accumulated depreciation	18,302	8,860
Intangible assets, Net book value	221,508	14,912	19,603
Licences, Permits & Applications
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	188,208	200,102
Business acquisition	202,716
Additions		2,158
Impairment		(14,445)
Effect of foreign exchange	24,006	393
Intangible assets, Cost	414,930	188,208
Intangible assets, Accumulated depreciation	754	623
Amortization	413	131
Intangible assets, Accumulated depreciation	1,167	754
Intangible assets, Net book value	413,763	187,454	199,479
Non-compete Agreements
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	2,405	2,415
Business acquisition	10,000
Effect of foreign exchange	48	(10)
Intangible assets, Cost	12,453	2,405
Intangible assets, Accumulated depreciation	2,087	1,081
Amortization	2,212	1,006
Intangible assets, Accumulated depreciation	4,299	2,087
Intangible assets, Net book value	8,154	318	1,334
Intellectual Property, Trademarks, Know How & Brands
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	73,812	72,122
Business acquisition	912,080
Additions		3,608
Effect of foreign exchange	5,025	(1,918)
Intangible assets, Cost	990,917	73,812
Intangible assets, Accumulated depreciation	13,178	8,172
Amortization	15,246	5,006
Intangible assets, Accumulated depreciation	28,424	13,178
Intangible assets, Net book value	$ 962,493	$ 60,634	$ 63,950

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Licences, Permits & Applications
Indefinite Lived Intangible Assets By Major Class [Line Items]
Indefinite lived intangible assets	$ 412,000	$ 186,000

Intangible Assets - Schedule of Estimated Amortization Expense (Details) $ in Thousands	May 31, 2021 USD ($)
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2022	$ 72,172
2023	68,409
2024	65,946
2025	65,533
2026	65,533
Thereafter	855,801
Total	$ 1,193,394

Business Acquisitions - Additional Information (Details)			3 Months Ended								12 Months Ended
	Apr. 30, 2021 USD ($)	Nov. 25, 2020 USD ($) shares	May 31, 2021 USD ($)	Feb. 28, 2021 USD ($)	Nov. 30, 2020 USD ($)	Aug. 31, 2020 USD ($)	May 31, 2020 USD ($)	Feb. 29, 2020 USD ($)	Nov. 30, 2019 USD ($)	Aug. 31, 2019 USD ($)	May 31, 2021 USD ($)	May 31, 2020 USD ($)	May 31, 2019 USD ($)
Business Acquisition And Goodwill [Line Items]
Goodwill			$ 2,832,794,000				$ 447,330,000				$ 2,832,794,000	$ 447,330,000
Business acquisition, goodwill, expected deductible for income tax purposes			0								0
Net income (loss)			$ 47,204,000	$ (280,856,000)	$ (100,811,000)	$ (32,958,000)	$ (87,105,000)	$ (11,003,000)	$ (5,996,000)	$ 1,564,000	(367,421,000)	(102,540,000)	$ (25,037,000)
Amortization											$ 27,313,000	$ 10,649,000
Discount Rate
Business Acquisition And Goodwill [Line Items]
Business combination, contingent consideration, liability, measurement input			0.05								0.05
Aphria Inc
Business Acquisition And Goodwill [Line Items]
Business acquisition, date of acquisition agreement											Apr. 30, 2021
Business acquisition, transaction costs	$ 42,000,000
Goodwill	2,221,613,000
Business acquisition, goodwill, expected deductible for income tax purposes	0
Net revenue	13,018,000
Net income (loss)	645,000
Non recurring transaction costs											$ 37,000,000
Amortization											28,000,000
Interest expense associated with senior notes											5,000,000
Contingent consideration	$ 71,297,000
S W Brewing Company L L C
Business Acquisition And Goodwill [Line Items]
Goodwill		$ 100,202,000	$ 102,202,000								102,202,000
Business combination cash consideration		255,543,000
Contingent consideration		$ 58,959,000	$ 60,657,000								$ 60,657,000
S W Brewing Company L L C \| Discount Rate
Business Acquisition And Goodwill [Line Items]
Business combination, contingent consideration, liability, measurement input			5								5
S W Brewing Company L L C \| Four Twenty Corporation \| Sweet Water
Business Acquisition And Goodwill [Line Items]
Stockholders ownership percentage		100.00%
Business combination cash consideration		$ 255,543,000
Business combination share consideration \| shares		8,232,810
Business combination fair value of shares		$ 65,889,000
Business combination fair value of contingent consideration		58,959,000
S W Brewing Company L L C \| Four Twenty Corporation \| Sweet Water \| Maximum
Business Acquisition And Goodwill [Line Items]
Business combination additional cash consideration		$ 66,000,000

Business Acquisitions - Schedule of Fair Value of Purchase Price (Details) - Aphria Inc $ / shares in Units, $ in Thousands	1 Months Ended
	Apr. 30, 2021 USD ($) $ / shares shares
Business Acquisition [Line Items]
Conversion ratio	0.8381
Tilray common shares issued at closing \| shares	214,337,159
Market share price of Aphria converted stock units \| $ / shares	$ 14.62
Fair value of Tilray common stock transferred to Aphria shareholders	$ 3,133,609
Consideration related to stock-based compensation	71,297
Total fair value of consideration transferred	$ 3,204,906
Common Stock
Business Acquisition [Line Items]
Number of Tilray common shares outstanding at acquisition date \| shares	179,635,973

Business Acquisitions - Schedule of Fair Value of Purchase Price (Parenthetical) (Details) - Aphria Inc $ in Thousands	May 03, 2021 USD ($) shares
Restricted Stock Units (RSUs)
Business Acquisition [Line Items]
Stock issued \| shares	1,207,010
Pre-combination fair value \| $	$ 17,646
Equity Option
Business Acquisition [Line Items]
Stock issued \| shares	4,782,132
Pre-combination fair value \| $	$ 53,650

Business Acquisitions - Summary of Preliminary Estimated Fair Value of Assets Acquired and Liabilities Assumed at Effective Acquisition Date (Details) - USD ($) $ in Thousands	Nov. 25, 2020	May 31, 2021	Apr. 30, 2021	May 31, 2020
Assets
Goodwill		$ 2,832,794		$ 447,330
Aphria Inc
Consideration
Contingent consideration			$ 71,297
Assets
Cash and cash equivalents			375,673
Accounts receivable			28,054
Inventory			76,547
Prepaids and other current assets			8,960
Capital assets			136,637
Right-of-use assets, operating leases			12,606
Goodwill			2,221,613
Other assets			22,879
Total assets			3,961,969
Liabilities
Accounts payable			62,292
Accrued expenses and other current liabilities			85,120
Accrued lease obligations			21,962
Warrant liability			79,402
Deferred tax liability			236,391
Convertible notes			267,862
Other liabilities			4,034
Total liabilities			757,063
Net assets acquired			3,204,906
S W Brewing Company L L C
Consideration
Cash	$ 255,543
Shares	65,889
Contingent consideration	58,959	60,657
Total consideration	380,391
Assets
Cash and cash equivalents	6,988
Accounts receivable	3,810
Inventory	4,815
Prepaids and other current assets	528
Capital assets	43,093
Goodwill	100,202	$ 102,202
Total assets	416,436
Liabilities
Accrued lease obligations	434
Accounts payable and accrued liabilities	5,289
Lease liabilities	30,322
Total liabilities	36,045
Net assets acquired	380,391
Licenses \| Aphria Inc
Assets
Business combination indefinite lived intangible assets			200,000
Distribution Channel \| Aphria Inc
Assets
Business combination intangibles			404,000
Customer Relationships \| Aphria Inc
Assets
Business combination intangibles			59,000
Customer Relationships \| S W Brewing Company L L C
Assets
Business combination intangibles	155,000
Know How \| Aphria Inc
Assets
Business combination intangibles			115,000
Brands \| Aphria Inc
Assets
Business combination intangibles			$ 301,000
Intellectual Property, Trademarks & Brands \| S W Brewing Company L L C
Assets
Business combination intangibles	92,000
Non-compete Agreements \| S W Brewing Company L L C
Assets
Business combination intangibles	$ 10,000

Business Acquisitions - Summary of Preliminary Estimated Fair Value of Assets Acquired and Liabilities Assumed at Effective Acquisition Date (Parenthetical) (Details)		12 Months Ended
	Apr. 30, 2021	May 31, 2021
Know How
Business Acquisition [Line Items]
Estimated useful life of intangible assets		5 years
Aphria Inc \| Distribution Channel
Business Acquisition [Line Items]
Estimated useful life of intangible assets	15 years
Aphria Inc \| Customer Relationships
Business Acquisition [Line Items]
Estimated useful life of intangible assets	15 years
Aphria Inc \| Know How
Business Acquisition [Line Items]
Estimated useful life of intangible assets	5 years
Aphria Inc \| Brands \| Minimum
Business Acquisition [Line Items]
Estimated useful life of intangible assets	10 years
Aphria Inc \| Brands \| Maximum
Business Acquisition [Line Items]
Estimated useful life of intangible assets	25 years

Business Acquisitions - Schedule of Goodwill (Details) - USD ($) $ in Thousands	May 31, 2021	Apr. 30, 2021	May 31, 2020
Business Combination Segment Allocation [Line Items]
Goodwill related to Tilray	$ 2,832,794		$ 447,330
Aphria Inc
Business Combination Segment Allocation [Line Items]
Goodwill related to Tilray		$ 2,221,613
Aphria Inc \| Cannabis
Business Combination Segment Allocation [Line Items]
Goodwill related to Tilray		2,144,143
Aphria Inc \| Wellness
Business Combination Segment Allocation [Line Items]
Goodwill related to Tilray		$ 77,470

Business Acquisitions - Schedule of Supplemental Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020
Aphria Inc
Business Acquisition [Line Items]
Revenue	$ 692,270	$ 624,950
Net loss	$ (795,251)	$ (649,276)
Net loss per share - basic and diluted	$ (1,770)	$ (1,710)
S W Brewing Company L L C
Business Acquisition [Line Items]
Revenue	$ 542,000	$ 470,000
Net loss	$ (328,000)	$ (80,000)
Net loss per share - basic and diluted	$ (0.73)	$ (0.37)

Goodwill - Additional Information (Details) $ in Thousands	12 Months Ended
Goodwill - Additional Information (Details) $ in Thousands	May 31, 2021 USD ($)	May 31, 2020 USD ($)	May 31, 2020 CAD ($)
Goodwill [Line Items]
Business acquisition, goodwill, expected deductible for income tax purposes	$ 0
CannInvest Africa Ltd. \| COVID-19
Goodwill [Line Items]
Goodwill, impairment charges	$ 0	$ 3,581,000	$ 4,800
Goodwill impairment discount rate		38.50%	38.50%
ABP, S.A. \| COVID-19
Goodwill [Line Items]
Goodwill, impairment charges		$ 3,730,000	$ 5,000
Goodwill impairment discount rate		23.30%	23.30%
Marigold \| COVID-19
Goodwill [Line Items]
Goodwill, impairment charges		$ 14,301,000	$ 19,171
Goodwill impairment discount rate		38.50%	38.50%
ColCanna S.A.S. \| COVID-19
Goodwill [Line Items]
Goodwill, impairment charges		$ 29,067,000	$ 35,000
Goodwill impairment discount rate		40.00%	40.00%

Goodwill - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020
Goodwill [Line Items]
Effect of foreign exchange	$ 63,713	$ 64
Goodwill	2,832,794	447,330
Broken Coast Cannabis Ltd. \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	105,963	105,963
Nuuvera Corp. \| Business Under Development
Goodwill [Line Items]
Goodwill, acquired during period	273,606	273,606
LATAM Holdings Inc. \| Business Under Development
Goodwill [Line Items]
Goodwill, acquired during period	63,239	63,239
CC Pharma GmbH \| Distribution Business
Goodwill [Line Items]
Goodwill, acquired during period	4,458	$ 4,458
Sweet Water \| Beverage Alcohol Business
Goodwill [Line Items]
Goodwill, acquired during period	100,202
Tilray \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	2,144,143
Tilray \| Hemp Business
Goodwill [Line Items]
Goodwill, acquired during period	$ 77,470

Convertible Notes Receivable - Additional Information (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Apr. 10, 2019 CAD ($) shares	Dec. 28, 2018 CAD ($) $ / shares	May 31, 2021 USD ($)	May 31, 2021 CAD ($)	May 31, 2020 USD ($)	May 31, 2020 CAD ($)	May 31, 2019 USD ($)	May 31, 2021 CAD ($)	Apr. 11, 2021 CAD ($)	May 31, 2020 CAD ($)	Aug. 14, 2017 CAD ($) $ / shares
Convertible Notes Receivable [Line Items]
Unrealized loss on convertible notes receivables			$ (3,824,000)		$ (5,476,000)		$ (2,570,000)
Repayment of convertible notes receivable			$ 5,752,000		19,396,000		$ 6,466,000
Secured Convertible Debentures \| High Tide Inc
Convertible Notes Receivable [Line Items]
Debt instrument, face amount									$ 2,000
Debt instrument interest rate percentage									9.00%
Debt instrument maturity date			Apr. 21, 2023	Apr. 21, 2023
Secured Convertible Debentures \| Aphria Inc \| HydRx Farms Ltd.
Convertible Notes Receivable [Line Items]
Debentures purchased											$ 11,500
Debt instrument interest rate percentage											8.00%
Debt instrument frequency of periodic payment			semi-annually	semi-annually
Debt instrument, maturity date			two years	two years
Debt instrument conversion price per share \| $ / shares											$ 2.75
Repayment of convertible notes receivable			$ 4,032,000	$ 5,000
Secured Convertible Debentures \| Aphria Inc \| Starbuds
Convertible Notes Receivable [Line Items]
Debentures purchased		$ 5,000
Debt instrument interest rate percentage		8.50%
Debt instrument conversion price per share \| $ / shares		$ 0.50
Debt instrument maturity date		Dec. 28, 2020
Fair value of convertible debentures			828,000		3,429,000			$ 1,000		$ 4,728
Accrued Interest			$ 385,000	$ 465	157,000	$ 216
Secured Convertible Debentures \| Aphria Inc \| High Tide Inc
Convertible Notes Receivable [Line Items]
Debentures purchased	$ 4,500
Debt instrument interest rate percentage	10.00%
Debt instrument frequency of periodic payment			annually	annually
Debt instrument maturity date	Apr. 10, 2021
Warrants received \| shares	6,000,000
Convertible Notes Receivable
Convertible Notes Receivable [Line Items]
Debt instrument, face amount			$ 0
Unrealized loss on convertible notes receivables			3,824,000		$ 5,476,000
Proceeds from issuance of debt			1,251,000
Gain (loss) on available-for-sale securities			$ 5,277,000
Convertible Notes Receivable \| Risk-Free Interest Rate
Convertible Notes Receivable [Line Items]
Debt instrument measurement input			0.0125					0.0125
Convertible Notes Receivable \| Expected Volatility
Convertible Notes Receivable [Line Items]
Debt instrument measurement input			0.70					0.70

Convertible Notes Receivable - Summary of Convertible Notes Receivable (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Convertible notes receivable, fair value	$ 2,485	$ 10,609
Total convertible notes receivable, non current portion	667,624	196,405
Convertible Notes Receivable
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Deduct - current portion	(2,485)	(10,609)
Convertible Notes Receivable \| HydRx Farms Ltd.
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Convertible notes receivable, fair value		4,352
Convertible Notes Receivable \| Starbuds
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Convertible notes receivable, fair value	828	3,429
Convertible Notes Receivable \| High Tide Inc
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Convertible notes receivable, fair value	$ 1,657	$ 2,828

Interest in Equity Investees - Additional Information (Details)	May 31, 2021 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Investment in joint venture under the equity method	$ 8,106,000
Anheuser-Busch InBev
Schedule Of Available For Sale Securities [Line Items]
Percentage of ownership	50.00%
Percentage of voting interest	50.00%
Cannfections
Schedule Of Available For Sale Securities [Line Items]
Percentage of ownership	50.00%
Investment in joint venture under the equity method	$ 4,200,000
Cannfections \| Joint Venture
Schedule Of Available For Sale Securities [Line Items]
Percentage of ownership	50.00%
Percentage of voting interest	50.00%
Investment in joint venture under the equity method	$ 0

Interest in Equity Investees - Summary of Ownership Interests in Equity Method Investments (Details) $ in Thousands	12 Months Ended
	May 31, 2021 USD ($)
Schedule Of Equity Method Investments [Line Items]
Carrying value	$ 8,106
Loss from equity method investments	$ (458)
Fluent
Schedule Of Equity Method Investments [Line Items]
Approximate ownership %	50.00%
Carrying value	$ 3,906
Loss from equity method investments	$ (416)
Cannfections
Schedule Of Equity Method Investments [Line Items]
Approximate ownership %	50.00%
Carrying value	$ 4,200
Loss from equity method investments	$ (42)

Long-term Investments - Schedule of Long-term Investments (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Investments Debt And Equity Securities [Abstract]
Equity investments measured at fair value	$ 12,185	$ 19,595
Equity investments under measurement alternative	5,500
Total other investments	$ 17,685	$ 19,595

Long-term Investments - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Investments Debt And Equity Securities [Abstract]
Proceeds on sale of investments	$ 8,430	$ 19,570	$ 83,343
Unrealized losses on change in fair value of investments	$ 1,567	$ 23,057	$ 8,122

Income Taxes and Deferred Income Taxes - Summary of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Canada	$ (323,964)	$ (88,930)	$ (30,733)
(Loss) income before income taxes	(344,986)	(109,185)	(38,138)
United States
Other countries	(7,814)
Other Countries
Other countries	$ (13,208)	$ (20,255)	$ (7,405)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes and Deferred Income Taxes - Summary of (Recoveries) Expense for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Current:
Canada	$ 15,227	$ 5,294	$ 3,296
Other countries	697	375	407
Current	15,924	5,669	3,703
Deferred:
United States	1,517
Canada	(30,111)	(9,226)	(3,281)
Other countries	3,698	(4,795)	(2,467)
Deferred	(24,896)	(14,021)	(5,748)
Income tax benefits, net	$ (8,972)	$ (8,352)	$ (2,045)

Income Taxes and Deferred Income Taxes - Summary of Reconciliation of Income Taxes at Statutory Rate with Reported Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Income Tax Disclosure [Abstract]
Loss before net income taxes:	$ (344,986)	$ (109,185)	$ (38,138)
Income tax benefits at statutory rate	(72,408)	(22,929)	(8,009)
Tax impact of foreign operations	(19,016)	(6,310)	(2,504)
Foreign exchange and other	1,011	(63)	(491)
Non-deductible expenses	(1,347)	2,474	5,731
Non-deductible (taxable) losses	45,230	2,152	(11,724)
Changes in enacted rates	135
Change in fair value of warrant liability	(259)
Stock based and other compensation	2,902	4,105	14,655
Change in valuation allowance	46,007	1,066	297
Non deductible dividend	(755)
Non deductible impairment		11,153
Effect of transaction	(10,472)
Income tax benefits, net	$ (8,972)	$ (8,352)	$ (2,045)

Income Taxes and Deferred Income Taxes - Summary of Components of Deferred Tax (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020	May 31, 2019
Deferred assets
Operating loss carryforwards - Canada	$ 152,382	$ 20,512	$ 9,535
Capital loss carryforwards	1,350	1,854	7,028
Intangible assets	86,541
Property and equipment	17,107
Currently nondeductible interest	9,491
Partnership interests	34,108
Deferred financing costs	4,237	5,022
Investment tax credits and related pool balance	526
Other	26,716	1,704	1,101
Total Deferred tax assets	397,579	38,129	22,743
Less valuation allowance	(265,940)	(4,583)	(4,583)
Net deferred tax assets	131,639	33,546	18,160
Deferred tax liabilities
Property and equipment	(15,997)	(8,356)	(1,995)
Intangible assets	(376,228)	(69,580)	(73,454)
Convertible Senior Notes Due 2023	(4,977)	(4,056)	(4,739)
Total deferred tax liabilities	(397,202)	(81,992)	(80,188)
Net deferred tax liability	(265,563)	(48,446)	(62,028)
United States
Deferred assets
Operating loss carryforwards	57,320
Other Countries
Deferred assets
Operating loss carryforwards	$ 7,801	$ 9,037	$ 5,079

Income Taxes and Deferred Income Taxes - Additional Information (Details) - USD ($) $ in Thousands			12 Months Ended
	Mar. 27, 2020	Dec. 22, 2017	May 31, 2021	May 31, 2020	May 31, 2019
Operating Loss Carryforwards [Line Items]
Adjustable taxable income deductible net interest percentage	30.00%		50.00%
U.S. statutory federal corporate tax rate		35.00%	21.00%
Operating loss carry-forwards			$ 510,456
Net operating loss carry-forward expiration year			2028
Net operating loss carry-forward expiration period			20 years
Unrecognized tax benefits			$ 0	$ 0	$ 0
Interest and penalty expenses related to uncertain tax positions			0	0	$ 0
Accrued interest and penalties on unrecognized tax positions			$ 0	0
Earliest Tax Year \| Canada
Operating Loss Carryforwards [Line Items]
Open tax year			2016
Earliest Tax Year \| Germany
Operating Loss Carryforwards [Line Items]
Open tax year			2016
Earliest Tax Year \| Australia
Operating Loss Carryforwards [Line Items]
Open tax year			2017
Earliest Tax Year \| United States
Operating Loss Carryforwards [Line Items]
Open tax year			2018
Deferred Tax Asset, Valuation Allowance
Operating Loss Carryforwards [Line Items]
Increase in deferred tax valuation allowance			$ 261,357	$ 0
United States
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards offset percentage of taxable income	100.00%		80.00%
Operating loss carry-forwards			$ 224,795
Portugal \| Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Open tax year			2017

Bank Indebtedness - Additional Information (Details)	12 Months Ended
Bank Indebtedness - Additional Information (Details)	May 31, 2021 CAD ($) Lineofcredit	May 31, 2021 EUR (€) Lineofcredit	May 31, 2021 USD ($)	May 31, 2021 CAD ($)	May 31, 2021 EUR (€)
Line Of Credit Facility [Line Items]
Operating line of credit	$ 1,000
Line of credit			$ 0
CC Pharma
Line Of Credit Facility [Line Items]
Line of credit				$ 8,717,000	€ 7,000
Number of operating lines of credit \| Lineofcredit	2	2
Available credit amount \| €		€ 8,500
Four Twenty Corporation (“420”) \| Revolving Credit Facility
Line Of Credit Facility [Line Items]
Line of credit			$ 0
Operating Lines of Credit One \| CC Pharma
Line Of Credit Facility [Line Items]
Operating line of credit \| €		5,000
Operating Lines of Credit Two \| CC Pharma
Line Of Credit Facility [Line Items]
Operating line of credit \| €		€ 3,500
Prime Rate
Line Of Credit Facility [Line Items]
Interest rate	7.50%	7.50%
Euro Over Night Index Average Plus \| Operating Lines of Credit One \| CC Pharma
Line Of Credit Facility [Line Items]
Interest rate			1.79%	1.79%	1.79%
Euro Interbank Offered Rate Plus \| Operating Lines of Credit Two \| CC Pharma
Line Of Credit Facility [Line Items]
Interest rate			3.682%	3.682%	3.682%
EURIBOR \| Four Twenty Corporation (“420”) \| Revolving Credit Facility
Line Of Credit Facility [Line Items]
Line of credit			$ 20,000,000

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Accounts Payable And Accrued Liabilities Current And Noncurrent [Abstract]
Trade payables	$ 57,706	$ 41,159
Accrued liabilities	112,594	48,105
Accrued payroll and employment related taxes	19,390
Income taxes payable	14,764	4,651
Accrued interest	148
Accrued legal settlement		18,496
Other accruals	8,211
Total accounts payable and accrued liabilities	$ 212,813	$ 112,411

Accounts Payable and Accrued Liabilities - Additional Information (Details) - ABG Prince Agreement	12 Months Ended
	May 31, 2021 USD ($)
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Royalty payment, terms	on a quarterly basis until the maturity date of December 31, 2025
Royalty payment, maturity date	Dec. 31, 2025
Minimum
Accounts Payable Accrued Liabilities And Other Current Liabilities [Line Items]
Guaranteed royalty payment	$ 375,000

Long-term Debt - Schedule of Net Carrying Amount of Long-term Debt Instruments (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Debt Instrument [Line Items]
Long-term debt, gross	$ 206,169	$ 100,646
Deduct - unamortized financing fees	(2,061)	(477)
- principal portion included in current liabilities	(36,622)	(6,141)
Long-term debt	167,486	94,028
Credit Facility Due in November 2022
Debt Instrument [Line Items]
Long-term debt, gross	62,964	58,026
Term Loan Due in July 2023
Debt Instrument [Line Items]
Long-term debt, gross	14,335	13,231
Term Loan Due in April 2022
Debt Instrument [Line Items]
Long-term debt, gross	17,117	15,939
Term Loan Due in July 2021
Debt Instrument [Line Items]
Long-term debt, gross	587	602
Mortgage Payable due in July 2021
Debt Instrument [Line Items]
Long-term debt, gross	2,562	2,349
Vendor-Take-Back Mortgage Due in June 2021
Debt Instrument [Line Items]
Long-term debt, gross	92	508
Term Loan Due in December 2023 \| Euro Interbank Offered Rate + 1.79%
Debt Instrument [Line Items]
Long-term debt, gross	3,356	4,163
Term Loan Due in December 2023 \| Euro Interbank Offered Rate + 2.68%
Debt Instrument [Line Items]
Long-term debt, gross	3,356	4,163
Term Loan Due in April 2025 \| Euro Interbank Offered Rate + 2.00%
Debt Instrument [Line Items]
Long-term debt, gross	1,831	$ 1,665
Term Loan Due in June 2025 \| Euro Interbank Offered Rate + 2.00%
Debt Instrument [Line Items]
Long-term debt, gross	1,831
Term Loan Due in March 2024 \| EURIBOR
Debt Instrument [Line Items]
Long-term debt, gross	$ 98,138

Long-term Debt - Schedule of Net Carrying Amount of Long-term Debt Instruments (Parenthetical) (Details) € in Thousands, $ in Thousands, $ in Thousands	12 Months Ended
	May 31, 2021 USD ($)	May 31, 2021 EUR (€)	May 31, 2021 CAD ($)	May 31, 2021 EUR (€)
Credit Facility Due in November 2022 \| Canadian Prime Interest Rate
Debt Instrument [Line Items]
Debt instrument, face amount			$ 80,000
Debt instrument term	3 years	3 years
Debt instrument amortization period	10 years	10 years
Term Loan Due in July 2023 \| Canadian Five Year Bond Interest Rate Plus 2.73
Debt Instrument [Line Items]
Debt instrument, face amount			$ 25,000
Debt instrument term	5 years	5 years
Debt instrument amortization period	15 years	15 years
Debt instrument interest rate percentage	2.73%		2.73%	2.73%
Term Loan Due in July 2023 \| Canadian Five Year Bond Interest Rate Plus 2.73 \| Minimum
Debt Instrument [Line Items]
Debt instrument interest rate percentage	4.50%		4.50%	4.50%
Term Loan Due in April 2022
Debt Instrument [Line Items]
Debt instrument, face amount			$ 25,000
Debt instrument term	5 years	5 years
Debt instrument amortization period	15 years	15 years
Debt instrument interest rate percentage	3.95%		3.95%	3.95%
Repayment of instalments including interest	$ 188
Term Loan Due in July 2021
Debt Instrument [Line Items]
Debt instrument, face amount			$ 1,250
Debt instrument term	5 years	5 years
Debt instrument amortization period	10 years	10 years
Debt instrument interest rate percentage	3.99%		3.99%	3.99%
Repayment of instalments including interest	$ 13
Mortgage Payable due in July 2021
Debt Instrument [Line Items]
Debt instrument, face amount			$ 3,750
Debt instrument term	5 years	5 years
Debt instrument amortization period	20 years	20 years
Debt instrument interest rate percentage	3.95%		3.95%	3.95%
Repayment of instalments including interest	$ 23
Vendor-Take-Back Mortgage Due in June 2021
Debt Instrument [Line Items]
Debt instrument, face amount			$ 2,850
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	6.75%		6.75%	6.75%
Repayment of instalments including interest	$ 56
Term Loan Due in December 2023 \| Euro Interbank Offered Rate + 1.79%
Debt Instrument [Line Items]
Debt instrument, face amount \| €				€ 5,000
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	1.79%		1.79%	1.79%
Repayment of instalments including interest \| €		€ 250
Term Loan Due in December 2023 \| Euro Interbank Offered Rate + 2.68%
Debt Instrument [Line Items]
Debt instrument, face amount \| €				€ 5,000
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.68%		2.68%	2.68%
Repayment of instalments including interest \| €		€ 250
Term Loan Due in April 2025 \| Euro Interbank Offered Rate + 2.00%
Debt Instrument [Line Items]
Debt instrument, face amount \| €				€ 1,500
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.00%		2.00%	2.00%
Repayment of instalments including interest \| €		€ 98
Term Loan Due in June 2025 \| Euro Interbank Offered Rate + 2.00%
Debt Instrument [Line Items]
Debt instrument, face amount \| €				€ 1,500
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.00%		2.00%	2.00%
Repayment of instalments including interest \| €		€ 98
Term Loan Due in March 2024 \| EURIBOR
Debt Instrument [Line Items]
Debt instrument, face amount	$ 100,000
Debt instrument term	3 years	3 years
Long-term debt, repayments of principal in next rolling twelve months	$ 7,500
Long-term debt, repayments of principal in rolling year two	10,000
Long-term debt, repayments of principal in rolling year three	$ 10,000

Long-term Debt - Additional Information (Details) € in Thousands, $ in Thousands, $ in Thousands	12 Months Ended
	May 31, 2021 USD ($)	May 31, 2021 CAD ($)	May 31, 2021 EUR (€)	May 31, 2020 USD ($)	May 31, 2020 CAD ($)
Debt Instrument [Line Items]
Long-term debt, gross	$ 206,169			$ 100,646
Credit Facility Due in November 2022
Debt Instrument [Line Items]
Long-term debt, gross	62,964			58,026
Credit Facility Due in November 2022 \| Secured Debt \| Aphria Diamond \| First Mortgage
Debt Instrument [Line Items]
Long-term debt, gross	$ 66,278	$ 80,000
Debt instrument, issuance date	Nov. 29, 2019
Ownership interest	51.00%	51.00%	51.00%
Term Loan Due in July 2023
Debt Instrument [Line Items]
Long-term debt, gross	$ 14,335			13,231
Term Loan Due in July 2023 \| Secured Debt \| First Mortgage
Debt Instrument [Line Items]
Long-term debt, gross	$ 20,712	$ 25,000
Debt instrument, issuance date	Jul. 27, 2018
Debt instrument, effective interest rate	4.68%	4.68%	4.68%
Term Loan Due in April 2022
Debt Instrument [Line Items]
Long-term debt, gross	$ 17,117			15,939
Term Loan Due in April 2022 \| Secured Debt \| First Mortgage
Debt Instrument [Line Items]
Long-term debt, gross	$ 20,712	$ 25,000
Debt instrument, issuance date	May 09, 2017
Mortgage Payable due in July 2021
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,562			2,349
Mortgage Payable due in July 2021 \| Secured Debt \| First Mortgage
Debt Instrument [Line Items]
Long-term debt, gross				3,108	$ 3,750
Debt instrument, issuance date	Jul. 22, 2016
Term Loan Due in July 2021
Debt Instrument [Line Items]
Long-term debt, gross	$ 587			602
Term Loan Due in July 2021 \| Secured Debt \| First Mortgage
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,036	1,250
Debt instrument, issuance date	Jul. 22, 2016
Vendor-Take-Back Mortgage Due in June 2021
Debt Instrument [Line Items]
Long-term debt, gross	$ 92			$ 508
Vendor-Take-Back Mortgage Due in June 2021 \| Secured Debt \| Second Mortgage
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,361	$ 2,850
Debt instrument, issuance date	Jun. 30, 2016
Term Loan Due in April 2025 \| Secured Debt \| CC Pharma
Debt Instrument [Line Items]
Long-term debt, gross	$ 13,955		€ 9,500
Term Loan Due in December 2023 \| Secured Debt \| CC Pharma
Debt Instrument [Line Items]
Long-term debt, gross	2,210		€ 1,500
Term Loan Due in March 2024 \| Secured Debt \| Four Twenty Corporation
Debt Instrument [Line Items]
Long-term debt, gross	$ 100,000

Convertible Debentures - Additional Information (Details)	1 Months Ended	12 Months Ended
	Apr. 30, 2019 USD ($) $ / shares	May 31, 2021 USD ($) shares Tradingday $ / shares	May 31, 2020 USD ($)
5.00% Convertible Notes ("TLRY 23")
Debt Instrument [Line Items]
Debt instrument face amount		$ 277,856,000	$ 0
Debt instrument term		5 years
Debt instrument interest rate percentage		5.00%
Debt instrument frequency of periodic payment		The TLRY 23 bears interest at a rate of 5.00% per annum, payable semi-annually in arrears on April 1 and October 1 of each year.
Debt instrument maturity date		Oct. 01, 2023
Initial conversion rate of debt instrument		5.9735
Debt instrument conversion price per share \| $ / shares		$ 167.41
Debt instrument, convertible, value of embedded conversion option		$ 277,857,000
Debt instrument, periodic payment of principal amount		$ 0
Debt instrument, default condition		To the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after such event of default, consist exclusively of the right to receive additional interest on the notes. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election (the “cash conversion option”).
Debt instrument, convertible, number of common stock \| shares		1,659,737
Debt instrument, face amount		$ 277,856,000	0
5.00% Convertible Notes ("TLRY 23") \| Convertible Debt
Debt Instrument [Line Items]
Debt instrument, convertible, remaining term of accretion of convertible notes		28 months
Total interest expense		$ 1,585,000
Contractual interest coupon		1,158,000
Amortization of discount		$ 427,000
5.25% Convertible Notes ("APHA 24")
Debt Instrument [Line Items]
Debt instrument face amount	$ 350,000,000
Debt instrument term	5 years
Debt instrument interest rate percentage	5.25%
Debt instrument frequency of periodic payment		The APHA 24 bears interest at a rate of 5.25% per annum, payable semi-annually in arrears on June 1 and December 1 of each year.
Debt instrument maturity date	Jun. 01, 2024
Debt instrument conversion price per share \| $ / shares	$ 11.20
Debt instrument convertible description		Holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time between December 1, 2023 to the maturity date.
Debt instrument, convertible, terms of conversion feature		(a) the last reported sales price of the common shares for at least 20 trading days during a period of 30 consecutive trading days immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (b) during the five-business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1 principal amount of the APHA 24 for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company’s common shares and the conversion rate on each such trading day; (c) the Company calls any or all of the APHA 24 for redemption or; (d) upon occurrence of specified corporate event.
Debt instrument, convertible, minimum trading days \| Tradingday		20
Debt instrument, convertible, consecutive trading days \| Tradingday		30
Debt instrument, convertible, threshold percentage of stock price trigger		130.00%
Debt instrument, convertible, minimum threshold percentage during measurement period		98.00%
Percentage of redemption value on principal plus accrued and unpaid interest		100.00%
Fair value increase (decrease) of debt instrument		$ 170,453,000	(43,094,000)
Foreign exchange impact		32,586,000
Debt instrument contractual interest		13,600,000	17,979,000
Debt instrument principal outstanding		$ 259,400,000	$ 259,400,000
Debt instrument, face amount	$ 350,000,000
5.25% Convertible Notes ("APHA 24") \| Tilray \| Common Stock
Debt Instrument [Line Items]
Initial conversion rate of debt instrument	89.31162364
Common stock par value per share \| $ / shares	$ 0.0001

Convertible Notes - Schedule of Components of Net Carrying Amount of Convertible Debentures (Detail) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020	May 31, 2019
Debt Instrument [Line Items]
Total convertible notes receivable, non current portion	$ 667,624	$ 196,405
5.25% Convertible Notes ("APHA 24")
Debt Instrument [Line Items]
Total convertible notes receivable, non current portion	399,444	$ 196,405	$ 305,626
5.00% Convertible Notes ("TLRY 23")
Debt Instrument [Line Items]
Total convertible notes receivable, non current portion	$ 268,180

Convertible Debentures - Schedule of Convertible Debentures - APHA 24 (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020
Debt Instrument [Line Items]
Opening balance	$ 196,405
Closing balance	667,624	$ 196,405
5.25% Convertible Notes ("APHA 24")
Debt Instrument [Line Items]
Opening balance	196,405	305,626
Debt settlement		(66,127)
Fair value adjustment	203,039	(43,094)
Closing balance	$ 399,444	$ 196,405

Convertible Debentures - Schedule of Convertible Debentures - TLRY 23 (Details) $ in Thousands	12 Months Ended
	May 31, 2021 USD ($)
Debt Instrument [Line Items]
Opening balance	$ 196,405
Closing balance	667,624
5.00% Convertible Notes ("TLRY 23")
Debt Instrument [Line Items]
Principal amount issued	277,856
Unamortized discount	(9,676)
Closing balance	$ 268,180

Warrants - Schedule of Warrant Details (Details) - $ / shares	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Class Of Warrant Or Right [Line Items]
Number of warrants	12,203,651	5,994,651	1,903,024
Weighted average price	$ 7.41	$ 8.91	$ 12.01
Warrant Expiring September 26, 2021
Class Of Warrant Or Right [Line Items]
Type of warrant	Warrant
Classification	Equity
Warrant expiry date	Sep. 26, 2021
Number of warrants	166,000
Weighted average price	$ 3.14
Warrant Expiring January 30, 2022
Class Of Warrant Or Right [Line Items]
Type of warrant	Warrant
Classification	Equity
Warrant expiry date	Jan. 30, 2022
Number of warrants	5,828,651
Weighted average price	$ 9.26
Warrant Expiring March 17, 2025
Class Of Warrant Or Right [Line Items]
Type of warrant	Warrant
Classification	Liability
Warrant expiry date	Mar. 17, 2025
Number of warrants	6,209,000
Weighted average price	$ 5.95

Warrants - Additional Information (Details) - $ / shares	12 Months Ended
	May 31, 2021	May 31, 2020
Class Of Warrant Or Right [Line Items]
Warrants issued	6,209,000	5,828,652
Daily cash penalty	1.00%
Level 3 [Member]
Class Of Warrant Or Right [Line Items]
Estimated fair value of warrant liability per warrant	$ 12.59
2016 Aphria Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued	200,000
Warrant expiry date	Sep. 26, 2021
Warrants replacement	166,000
2016 Aphria Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued	7,022,472
Warrant expiry date	Jan. 30, 2022
Warrants received	5,828,651

Warrants - Schedule of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	May 31, 2021	May 31, 2020
Warrants And Rights Note Disclosure [Abstract]
Outstanding, beginning of the year, Number of warrants	5,994,651	1,903,024
Exercised during the year, Number of warrants		(636,089)
Issued during the year,Number of warrants	6,209,000	5,828,652
Expired during the year,Number of warrants		(1,100,936)
Outstanding, end of the year, Number of warrants	12,203,651	5,994,651
Outstanding, beginning of the year, weighted average price	$ 8.91	$ 12.01
Exercised during the year, weighted average price		1.47
Issued during the year, weighted average price	5.95	9.08
Expired during the year, weighted average price		19.46
Outstanding, end of the year, weighted average price	$ 7.41	$ 8.91

Warrants - Schedule of Estimated Fair Value of Warrant Liability (Details)	May 31, 2021 USD ($) yr
Risk-Free Interest Rate \| Warrant [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk-free interest rate	0.0090
Expected Volatility \| Warrant [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk-free interest rate	0.70
Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk-free interest rate \| yr	4
Expected Term \| Warrant [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk-free interest rate \| yr	4.3
Strike Price \| Warrant [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk-free interest rate \| $	5.95
Fair Value of Common Stock \| Warrant [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk-free interest rate \| $	16.67

Stock-Based Compensation - Additional Information (Details) - USD ($)	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019	Apr. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share-based compensation expenses	$ 17,351,000	$ 18,079,000	$ 21,951,000
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation, number of other than options issued	0
Tilray 2018 Equity Incentive Plan and Original Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock granted value share based compensation	$ 500,000,000
Stock granted fair value share based compensation	$ 1,000,000
Stock options granted	0
Risk-free interest rate		2.10%	2.92%
Expected stock option life		8 years 11 months 19 days	5 years 9 months 14 days
Expected volatility		61.33%	58.54%
Tilray 2018 Equity Incentive Plan and Original Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance				9,806,851
Common shares reserved for issuance, annual automatic increase percentage	4.00%
Tilray 2018 Equity Incentive Plan and Original Plan \| Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation, number of other than options issued	0
Predecessor Plan \| Aphria
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.39%
Expected stock option life	5 years	5 years
Expected volatility	70.00%	70.00%	70.00%
Forfeiture rate	35.00%	20.00%	0.00%
Predecessor Plan \| Time-based Stock Options \| Aphria
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	41,500
Weighted-average exercise price, Granted	$ 5.88
Weighted average remaining contractual term (years), exercisable	2 years 2 months 12 days
Weighted average fair values of stock options granted, per share	$ 2.18	$ 3.54	$ 7.32
Intrinsic values of stock options exercised	$ 4,679,758,000	$ 4,869,447,000	$ 28,025,979,000
Fair values of stock option vested	3,054,257,000	9,592,767,000	14,983,131,000
Unrecognized compensation expenses	$ 3,058,733,000	$ 8,209,817,000	$ 17,110,533,000
Unrecognized stock-based compensation expense to be recognized in period, years	1 year 21 days	1 year 6 months 10 days	1 year 6 months 7 days
Predecessor Plan \| Time-based Stock Options \| Aphria \| Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	41,500
Weighted-average exercise price, Granted	$ 5.88
Weighted average remaining contractual term (years), exercisable	5 years
Predecessor Plan \| Performance Based Stock Option \| Aphria
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic values of stock options exercised	$ 746,743,000	$ 326,033,000	$ 1,864,100,000
Fair values of stock option vested	395,138,000	222,721,000	461,188,000
Unrecognized compensation expenses		$ 1,074,701,000	$ 1,206,415,000
Unrecognized stock-based compensation expense to be recognized in period, years		6 months 29 days	9 months 3 days
Predecessor Plan \| Time-based and Performance-based RSU \| Aphria
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic values of stock options exercised	10,905,991,000	$ 5,123,883,000	$ 775,962,000
Fair values of stock option vested	8,777,963,000	4,507,883,000	2,044,952,000
Unrecognized compensation expenses	$ 16,273,457,000	$ 10,240,001,000	$ 1,392,478,000
Unrecognized stock-based compensation expense to be recognized in period, years	1 year 10 days	1 year 5 months 8 days	6 months 14 days
Maximum \| Tilray 2018 Equity Incentive Plan and Original Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common stock reserved for issuance, term	10 years
Maximum \| Tilray 2018 Equity Incentive Plan and Original Plan \| Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation, grant term	10 years
Maximum \| Tilray 2018 Equity Incentive Plan and Original Plan \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Maximum \| Predecessor Plan \| Aphria
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate		1.56%	2.38%
Expected stock option life			5 years
Minimum \| Tilray 2018 Equity Incentive Plan and Original Plan \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
Minimum \| Predecessor Plan \| Aphria
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate		1.20%	1.66%
Expected stock option life			3 years

Stock-Based Compensation - Schedule of Stock-Based Activity Under EIP and Original Plan (Details) - USD ($)	12 Months Ended
	May 31, 2021	May 31, 2020
EIP Time-based Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	3,182,547
Shares, Exercised	(1,665)
Shares, Forfeited	(188)
Shares, Cancelled	(468)
Stock Options, Ending Balance	3,180,226	3,182,547
Weighted-average exercise price, Beginning Balance	$ 14.19
Weighted-average exercise price, Exercised	7.76
Weighted-average exercise price, Forfeited	7.76
Weighted-average exercise price, Cancelled	65.20
Weighted-average exercise price, Ending Balance	$ 14.19	$ 14.19
Weighted average remaining contractual term (years)	1 year 8 months 12 days	1 year 3 months 18 days
Aggregate intrinsic value	$ 25,171,187	$ 30,331,823
Original Plan Time-based Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	946,948
Shares, Exercised	(29,403)
Stock Options, Ending Balance	917,545	946,948
Weighted-average exercise price, Beginning Balance	$ 3.99
Weighted-average exercise price, Exercised	4.71
Weighted-average exercise price, Ending Balance	$ 3.97	$ 3.99
Weighted average remaining contractual term (years)	1 year 8 months 12 days	2 years
Aggregate intrinsic value	$ 11,885,699	$ 13,777,571
Time-based RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	1,285,134
Stock options granted	198,521
Shares, Vested	(112,508)
Shares, Forfeited	(165,904)
Stock Options, Ending Balance	1,205,243	1,285,134
Weighted-average grant date fair value per share, Beginning Balance	$ 15.70
Weighted-average grant date fair value per share, Granted	7.76
Weighted-average grant date fair value per share, Vested	12.99
Weighted-average grant date fair value per share, Forfeited	11.97
Weighted-average grant date fair value per share, Ending Balance	$ 15.16	$ 15.70
Aggregate intrinsic value	$ 20,091,286

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - Predecessor Plan - Aphria - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Time-based Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	4,484,051
Shares, Exercised	(1,073,986)
Shares, Granted	41,500
Shares, Forfeited	(884,320)
Shares, Expired	(68,060)
Stock Options, Ending Balance	2,499,185	4,484,051
Shares, Vested and exercisable	1,846,090
Weighted-average exercise price, Beginning Balance	$ 12.04
Weighted average exercise price, Exercised	8.70
Weighted average exercise price, Granted	5.88
Weighted average exercise price, Forfeited	14.06
Weighted average exercise price, Expired	18.72
Weighted-average exercise price, Ending Balance	12.48	$ 12.04
Weighted average exercise price, Vested and exercisable	13.53
Weighted-average grant date fair value per share, Beginning Balance	6.24
Weighted average grant date fair value, Exercised	4.38
Weighted-average grant date fair value per share, Granted	2.18	3.54	$ 7.32
Weighted-average grant date fair value per share, Forfeited	7.46
Weighted average grant date fair value, Expired	8.80
Weighted-average grant date fair value per share, Ending Balance	6.51	$ 6.24
Weighted average grant date fair value, Vested and exercisable	$ 7.16
Weighted average remaining contractual term (years)	2 years 4 months 24 days	2 years 10 months 24 days
Weighted average remaining contractual term (years), Vested and exercisable	2 years 2 months 12 days
Aggregate Intrinsic Amount	$ 10,472	$ (32,781)
Aggregate Intrinsic Amount, Vested and exercisable	$ 5,797
Performance Based Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	398,400
Shares, Exercised	(166,000)
Shares, Forfeited	(232,400)
Stock Options, Ending Balance		398,400
Weighted-average exercise price, Beginning Balance	$ 8.11
Weighted average exercise price, Exercised	5.15
Weighted average exercise price, Forfeited	10.23
Weighted-average exercise price, Ending Balance		$ 8.11
Weighted-average grant date fair value per share, Beginning Balance	3.80
Weighted average grant date fair value, Exercised	2.38
Weighted-average grant date fair value per share, Forfeited	$ 4.81
Weighted-average grant date fair value per share, Ending Balance		$ 3.80
Weighted average remaining contractual term (years)		7 months 6 days
Aggregate Intrinsic Amount		$ (1,347)

Stock-Based Compensation - Schedule of Time-based and Performance-based RSU Activity (Details) - Predecessor Plan - Aphria	12 Months Ended
	May 31, 2021 $ / shares shares
Time-based RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested, beginning of the year \| shares	1,588,743
Granted during the year \| shares	2,370,862
Vested during the year \| shares	(1,006,222)
Forfeited during the year \| shares	(158,411)
Non-vested, end of the year \| shares	2,794,972
Weighted average grant - date fair value per share, Beginning Balance \| $ / shares	$ 7.71
Weighted average grant - date fair value per share, Granted \| $ / shares	6.24
Weighted average grant - date fair value per share, Vested \| $ / shares	(6.83)
Weighted average grant - date fair value per share, Forfeited \| $ / shares	(6.68)
Weighted average grant - date fair value per share, Ending Balance \| $ / shares	$ 6.88
Performance-based RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested, beginning of the year \| shares	19,335
Forfeited during the year \| shares	(19,335)
Weighted average grant - date fair value per share, Beginning Balance \| $ / shares	$ 6.01
Weighted average grant - date fair value per share, Forfeited \| $ / shares	$ (6.01)

Accumulated Other Comprehensive Loss- Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ (5,434)	$ 900	$ 2,954
Other comprehensive income (loss)	152,825	(6,334)	(2,660)
Elimination of CTA on disposal of equity investee			606
Settlement of convertible notes receivable	5,277
Ending balance	152,668	(5,434)	900
Foreign Currency Translation (Loss) Gain [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(232)	626	110
Other comprehensive income (loss)	156,649	(858)	(90)
Elimination of CTA on disposal of equity investee			606
Ending balance	156,417	(232)	626
Unrealized Loss on Convertible Notes Receivables [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(5,202)	274	2,844
Other comprehensive income (loss)	(3,824)	(5,476)	(2,570)
Settlement of convertible notes receivable	5,277
Ending balance	$ (3,749)	$ (5,202)	$ 274

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

Non-controlling Interests - Summary of Information Relating to Company's Subsidiaries (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	May 31, 2021	Feb. 28, 2021	Nov. 30, 2020	Aug. 31, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2021	May 31, 2020	May 31, 2019
Minority Interest [Line Items]
Current assets	$ 883,609				$ 581,627				$ 883,609	$ 581,627
Current liabilities	(401,241)				(119,895)				(401,241)	(119,895)
Revenue	142,236	$ 123,900	$ 129,459	$ 117,490	113,542	$ 107,739	$ 89,967	$ 94,078	513,085	405,326	$ 179,303
Shareholders of Tilray Inc.	47,204	$ (280,856)	$ (100,811)	$ (32,958)	(87,105)	$ (11,003)	$ (5,996)	$ 1,564	(367,421)	(102,540)	(25,037)
Other comprehensive income (loss)									152,825	(6,334)	(2,660)
Shareholders of Tilray Inc.									(214,596)	(108,874)	(27,697)
Non-controlling Interests
Minority Interest [Line Items]
Current assets	20,765				26,504				20,765	26,504
Non-current assets	300,386				240,108				300,386	240,108
Current liabilities	(29,529)				(11,611)				(29,529)	(11,611)
Non-current liabilities	(76,344)				(152,502)				(76,344)	(152,502)
Net assets	215,278				102,499				215,278	102,499
Revenue									132,208	24,182	174
Total expenses (recovery)									(68,911)	(699)	(24,220)
Shareholders of Tilray Inc.									63,297	23,483	(24,046)
Shareholders of Tilray Inc.									63,297	23,483	(24,046)
Non-controlling Interests \| CC Pharma Nordic ApS
Minority Interest [Line Items]
Current assets	919								919
Non-current assets	103								103
Current liabilities	(956)								(956)
Non-current liabilities	(406)								(406)
Net assets	(340)								(340)
Revenue									827
Total expenses (recovery)									(958)
Shareholders of Tilray Inc.									(131)
Shareholders of Tilray Inc.									(131)
Non-controlling Interests \| Aphria Diamond
Minority Interest [Line Items]
Current assets	19,531				25,957				19,531	25,957
Non-current assets	153,696				156,251				153,696	156,251
Current liabilities	(28,511)				(11,337)				(28,511)	(11,337)
Non-current liabilities	(69,332)				(128,031)				(69,332)	(128,031)
Net assets	75,384				42,840				75,384	42,840
Revenue									131,381	24,142
Total expenses (recovery)									(67,030)	(25,141)	(21,273)
Shareholders of Tilray Inc.									64,351	(999)	(21,273)
Shareholders of Tilray Inc.									64,351	(999)	(21,273)
Non-controlling Interests \| Marigold
Minority Interest [Line Items]
Revenue										40
Total expenses (recovery)										4,995	(572)
Shareholders of Tilray Inc.										5,035	(572)
Shareholders of Tilray Inc.										5,035	(572)
Non-controlling Interests \| ColCanna S.A.S.
Minority Interest [Line Items]
Current assets	315				547				315	547
Non-current assets	146,587				83,857				146,587	83,857
Current liabilities	(62)				(274)				(62)	(274)
Non-current liabilities	(6,606)				(24,471)				(6,606)	(24,471)
Net assets	$ 140,234				$ 59,659				140,234	59,659
Total expenses (recovery)									(923)	19,447	(942)
Shareholders of Tilray Inc.									(923)	19,447	(942)
Shareholders of Tilray Inc.									$ (923)	$ 19,447	(942)
Non-controlling Interests \| CannInvest Africa Ltd.
Minority Interest [Line Items]
Total expenses (recovery)											(8)
Shareholders of Tilray Inc.											(8)
Shareholders of Tilray Inc.											(8)
Non-controlling Interests \| Verve Dynamics
Minority Interest [Line Items]
Total expenses (recovery)											(634)
Shareholders of Tilray Inc.											(634)
Shareholders of Tilray Inc.											(634)
Non-controlling Interests \| Nuuvera Malta Ltd.
Minority Interest [Line Items]
Revenue											174
Total expenses (recovery)											(791)
Shareholders of Tilray Inc.											(617)
Shareholders of Tilray Inc.											$ (617)

Net Revenue - Summary of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	May 31, 2021	Feb. 28, 2021	Nov. 30, 2020	Aug. 31, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2021	May 31, 2020	May 31, 2019
Net revenue	$ 142,236	$ 123,900	$ 129,459	$ 117,490	$ 113,542	$ 107,739	$ 89,967	$ 94,078	$ 513,085	$ 405,326	$ 179,303
Cannabis Revenue
Net revenue									264,334	153,477	67,592
Cannabis Excise Taxes
Net revenue									(62,942)	(23,581)	(7,716)
Net Cannabis Revenue
Net revenue									201,392	129,896	59,876
Beverage Alcohol Revenue
Net revenue									29,661
Beverage Alcohol Excise Taxes
Net revenue									(1,062)
Net Beverage Alcohol Revenue
Net revenue									28,599
Distribution Revenue
Net revenue									277,300	$ 275,430	$ 119,427
Wellness Revenue
Net revenue									$ 5,794

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Cost of Goods Sold - Summary of Cost of Goods Sold (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Cost Of Goods And Services Sold [Abstract]
Cannabis costs	$ 130,511	$ 68,551	$ 31,341
Beverage alcohol costs	12,687
Distribution costs	242,472	240,722	104,451
Wellness costs	4,233
Total	$ 389,903	$ 309,273	$ 135,792

General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
General And Administrative Expense [Abstract]
Executive compensation	$ 8,645	$ 6,777	$ 4,402
Consulting fees	6,633	9,272	4,928
Office and general	19,503	12,351	12,486
Professional fees	5,146	4,918	8,916
Salaries and wages	37,126	28,252	14,842
Stock-based compensation	17,351	18,079	21,951
Insurance	12,257	9,370	4,050
Travel and accommodation	2,711	2,798	2,356
Rent	2,203	1,972	1,910
General and administrative expense	$ 111,575	$ 93,789	$ 75,841

Finance Income (Expense), Net - Summary of Finance Income (Expense), Net (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Finance Income Expense Net [Abstract]
Interest income	$ 2,926	$ 6,273	$ 11,138
Interest expense	(30,903)	(25,644)	(5,879)
Finance income (expense), net	$ (27,977)	$ (19,371)	$ 5,259

Non-operating (expense) income - Schedule of Non-Operating (Expense) Income (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Nonoperating Income Expense [Abstract]
Foreign exchange (loss) gain	$ (22,347)	$ 6,145	$ 692
Loss on marketable securities		(252)	(135)
Gain (loss) on sale of capital assets	1,523	(8,075)	42
(Loss) gain from equity investees	(458)		44,191
Deferred gain on sale of intellectual property			257
Loss on promissory notes receivable		(9,698)
(Loss) gain on long-term investments	(2,352)	(24,295)	14,860
Unrealized (loss) gain on convertible debentures	(170,453)	44,322	36,630
Realized gain on settlement of convertible debentures		9,289
Legal settlement		(3,241)
Unrealized loss on financial liabilities			(1,003)
Change in fair value of warrant liability	1,234
Other non-operating items, net	8,015
Non operating (expense) income	$ (184,838)	$ 14,195	$ 95,534

Change in Non-cash Working Capital - Summary of Change in Non-cash Working Capital (Detail) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Change In Non Cash Working Capital [Abstract]
Accounts receivable	$ (23,512)	$ (25,593)	$ 9,421
Prepaids and other current assets	(6,772)	(10,899)	4,322
Inventory	(35,286)	(89,660)	(26,069)
Accounts payable and accrued liabilities	14,501	47,335	(8,984)
Deferred revenue	134	(15)	8,839
Total	$ (50,935)	$ (78,832)	$ (12,471)

Commitments and Contingencies - Schedule of Purchase and Other Commitments Maturities (Details) $ in Thousands	May 31, 2021 USD ($)
Other Commitments [Line Items]
Total	$ 810,008
2022	74,971
2023	89,327
2024	382,338
2025	262,431
2026	941
Long-term Debt Repayment
Other Commitments [Line Items]
Total	204,108
2022	36,623
2023	69,925
2024	95,181
2025	1,438
2026	941
Convertible Notes, Principal and Interest
Other Commitments [Line Items]
Total	571,989
2022	13,893
2023	13,893
2024	284,803
2025	259,400
ABG Finance Liability
Other Commitments [Line Items]
Total	6,000
2022	1,500
2023	1,500
2024	1,500
2025	1,500
Material Purchase Obligations
Other Commitments [Line Items]
Total	26,097
2022	21,141
2023	4,009
2024	854
2025	93
Construction Commitments
Other Commitments [Line Items]
Total	1,814
2022	$ 1,814

Financial Risk Management and Financial Instruments - Additional Information (Details) $ in Thousands	12 Months Ended
	May 31, 2021 USD ($)	May 31, 2020 USD ($)	May 31, 2019 USD ($)
Financial Risk Management And Financial Instruments [Line Items]
Long-term debt, subject to fixed interest rates	$ 20,358	$ 19,398
Cash and cash equivalents	488,466	360,646
Unrealized gain or loss due to change in foreign exchange rate	$ (49,342)	451	$ 194
Hypothetical decrease in fair value of investments	10.00%
Estimated decrease in fair values of investments upon hypothetical decrease of 10% in the prices	$ 1,769
Hypothetical increase in common stock	10.00%
Estimated increase in fair values of warrant liability upon hypothetical increase of 10% in the price of common stock	$ 9,800
Allowance for doubtful accounts	$ 4,571	$ 2,313
Discount Rate
Financial Risk Management And Financial Instruments [Line Items]
Business combination, contingent consideration, liability, measurement input	0.05
Level 3 [Member] \| Discount Rate
Financial Risk Management And Financial Instruments [Line Items]
Business combination, contingent consideration, liability, measurement input	0.05

Financial Risk Management and Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Financial assets
Convertible notes receivable	$ 2,485	$ 10,609
Financial liabilities
Contingent consideration	(60,657)
Convertible debenture	(667,624)	(196,405)
Fair Value, Measurements, Recurring
Financial assets
Cash and cash equivalents	488,466	360,646
Convertible notes receivable	2,485	10,609
Long-term investments	12,185	19,595
Financial liabilities
Warrant liability	(78,168)
Contingent consideration	(60,657)
Total recurring fair value measurements	(35,133)	194,445
Fair Value, Measurements, Recurring \| APHA 24 Convertible Debenture
Financial liabilities
Convertible debenture	(399,444)	(196,405)
Level 1 \| Fair Value, Measurements, Recurring
Financial assets
Cash and cash equivalents	488,466	360,646
Long-term investments	9,251	11,244
Financial liabilities
Total recurring fair value measurements	497,717	371,890
Level 2 \| Fair Value, Measurements, Recurring
Financial assets
Convertible notes receivable	2,485	10,609
Long-term investments	2,934	8,351
Financial liabilities
Total recurring fair value measurements	5,419	18,960
Level 3 [Member] \| Fair Value, Measurements, Recurring
Financial liabilities
Warrant liability	(78,168)
Contingent consideration	(60,657)
Total recurring fair value measurements	(538,269)	(196,405)
Level 3 [Member] \| Fair Value, Measurements, Recurring \| APHA 24 Convertible Debenture
Financial liabilities
Convertible debenture	$ (399,444)	$ (196,405)

Financial Risk Management and Financial Instruments - Schedule of Opening Balances of Assets and Liabilities Categorized Within Level 3 of Fair Value Hierarchy Measured at Fair Value on Recurring Basis (Details) - Level 3 [Member] - Fair Value, Measurements, Recurring $ in Thousands	12 Months Ended
	May 31, 2021 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	$ (196,405)
Additions	(138,361)
Unrealized gain (loss) on fair value	(203,503)
Ending balance	(538,269)
APHA 24 Convertible Debenture
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	(196,405)
Unrealized gain (loss) on fair value	(203,039)
Ending balance	(399,444)
Contingent Consideration
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Additions	(58,959)
Unrealized gain (loss) on fair value	(1,698)
Ending balance	(60,657)
Warrant Liability
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Additions	(79,402)
Unrealized gain (loss) on fair value	1,234
Ending balance	$ (78,168)

Financial Risk Management and Financial Instruments - Schedule of Financial Assets and Liabilities Measurement Inputs and Valuation Techniques (Details)	May 31, 2021 yr
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt Instrument, Valuation Technique [Extensible List]	tlry:ValuationTechniqueBlackScholesMember
Warrants and Rights Outstanding, Valuation Technique [Extensible List]	tlry:ValuationTechniqueBlackScholesMember
Business Combination, Contingent Consideration, Liability, Valuation Technique [Extensible List]	us-gaap:ValuationTechniqueDiscountedCashFlowMember
Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument measurement input	0.70
Risk-free interest rate	0.70
Expected Term
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument measurement input	3
Risk-free interest rate	4
Discount Rate
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent consideration measurement input	0.05
Achievement [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent consideration measurement input	1.00

Financial Risk Management and Financial Instruments - Schedule of Trade Receivables (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Financing Receivable Recorded Investment Past Due [Line Items]
Accounts receivable, net	$ 87,309	$ 37,931
0-30 Days
Financing Receivable Recorded Investment Past Due [Line Items]
Accounts receivable, net	$ 70,997
Financing receivable, Percentage	82.00%
31-60 Days
Financing Receivable Recorded Investment Past Due [Line Items]
Accounts receivable, net	$ 8,253
Financing receivable, Percentage	9.00%
61-90 Days
Financing Receivable Recorded Investment Past Due [Line Items]
Accounts receivable, net	$ 1,051
Financing receivable, Percentage	1.00%
90+ Days
Financing Receivable Recorded Investment Past Due [Line Items]
Accounts receivable, net	$ 7,008
Financing receivable, Percentage	8.00%

Segment Reporting - Additional Information (Details)	12 Months Ended
Segment Reporting - Additional Information (Details)	May 31, 2021 Segment Customer	May 31, 2020 Customer	May 31, 2019 Customer
Segment Reporting Information [Line Items]
Number of operating segments \| Segment	5
Number of major customers \| Customer	0	0	0
Customer Concentration Risk \| Revenue
Segment Reporting Information [Line Items]
Concentration risk, percentage	10.00%	10.00%	10.00%

Segment Reporting - Schedule of Segment Net Revenue From External Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Segment Reporting Information [Line Items]
Revenue from external customers	$ 513,085	$ 405,326	$ 179,303
Cannabis Business
Segment Reporting Information [Line Items]
Revenue from external customers	201,392	129,896	59,876
Distribution Business
Segment Reporting Information [Line Items]
Revenue from external customers	277,300	$ 275,430	$ 119,427
Beverage Alcohol Business
Segment Reporting Information [Line Items]
Revenue from external customers	28,599
Wellness Business
Segment Reporting Information [Line Items]
Revenue from external customers	$ 5,794

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Segment Reporting - Summary of Channels of Cannabis Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	May 31, 2021	Feb. 28, 2021	Nov. 30, 2020	Aug. 31, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2021	May 31, 2020	May 31, 2019
Segment Reporting Information [Line Items]
Net revenue	$ 142,236	$ 123,900	$ 129,459	$ 117,490	$ 113,542	$ 107,739	$ 89,967	$ 94,078	$ 513,085	$ 405,326	$ 179,303
Total net cannabis revenue									513,085	405,326	179,303
Cannabis
Segment Reporting Information [Line Items]
Less excise tax									(62,942)	(23,581)	(7,716)
Total net cannabis revenue									201,392	129,896	59,876
Cannabis \| Revenue from Medical Cannabis Products
Segment Reporting Information [Line Items]
Net revenue									25,539	28,685	33,017
Cannabis \| Revenue from Adult-use Cannabis Products
Segment Reporting Information [Line Items]
Net revenue									222,930	112,207	30,236
Cannabis \| Revenue from Wholesale Cannabis Products
Segment Reporting Information [Line Items]
Net revenue									6,615	$ 12,585	$ 4,339
Cannabis \| Revenue from International Cannabis Products
Segment Reporting Information [Line Items]
Net revenue									$ 9,250

Segment Reporting - Schedule of Geographic Net Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	May 31, 2021	May 31, 2020	May 31, 2019
Segment Reporting Information [Line Items]
Total net revenue	$ 513,085	$ 405,326	$ 179,303
North America
Segment Reporting Information [Line Items]
Total net revenue	229,120	129,663	59,629
EMEA
Segment Reporting Information [Line Items]
Total net revenue	279,062	271,291	116,578
Latin America
Segment Reporting Information [Line Items]
Total net revenue	$ 4,903	$ 4,372	$ 3,096

- Definition

+ References

+ Details

Segment Reporting - Schedule of Geographic Capital Assets (Details) - USD ($) $ in Thousands	May 31, 2021	May 31, 2020
Segment Reporting Information [Line Items]
Capital assets	$ 650,698	$ 420,706
North America
Segment Reporting Information [Line Items]
Capital assets	504,575	371,823
EMEA
Segment Reporting Information [Line Items]
Capital assets	140,838	44,348
Latin America
Segment Reporting Information [Line Items]
Capital assets	$ 5,285	$ 4,535

Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	May 31, 2021	Feb. 28, 2021	Nov. 30, 2020	Aug. 31, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2021	May 31, 2020	May 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 142,236	$ 123,900	$ 129,459	$ 117,490	$ 113,542	$ 107,739	$ 89,967	$ 94,078	$ 513,085	$ 405,326	$ 179,303
Gross profit	22,498	30,456	35,283	34,945	27,807	25,879	21,812	20,555	123,182	96,053	43,511
Net (loss) income for the year	33,605	(258,626)	(89,249)	(21,744)	(84,306)	(11,699)	(6,265)	1,435	(336,014)	(100,833)	(36,093)
Net income (loss) attributable to Tilray shareholders	$ 47,204	$ (280,856)	$ (100,811)	$ (32,958)	$ (87,105)	$ (11,003)	$ (5,996)	$ 1,564	$ (367,421)	$ (102,540)	$ (25,037)
Earnings (loss) per share - basic	$ 0.18	$ (0.97)	$ (0.37)	$ (0.09)	$ (0.39)	$ (0.05)	$ (0.03)	$ 0.01	$ (1.25)	$ (0.47)	$ (0.18)
Earnings (loss) per share - fully diluted	$ 0.18	$ (0.97)	$ (0.37)	$ (0.09)	$ (0.39)	$ (0.05)	$ (0.03)	$ 0.01	$ (1.25)	$ (0.47)	$ (0.18)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.